Professional Documents
Culture Documents
Page
PROFESSIONAL INFORMATION
A.
B
C.
D.
E.
F.
G.
BIOGRAPHY ...........................................................................................................................3-6
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
PERSONAL STATEMENT.........................................................................................5
EXPANDED RESEARCH ..........................................................................................5
PRESS RELEASE - HEPATITIS B FOUNDATION ....................................................6
FACULTY APPOINTMENTS ..................................................................................7-8
EMPLOYMENT AND STAFF POSITIONS ............................................................8-10
STATE OF CALIFORNIA CONSULTANT POSITIONS............................................ 10
CONSULTANT POSITIONS ....................................................................................11
BUSINESS POSITIONS ..........................................................................................11
RESEARCH SUPPORT......................................................................................12-30
UCSD RESEARCH / ADVISORY .......................................................................31-32
COINVESTIGATOR: GASTROINTESTINAL TRIALS .........................................32-33
............................................................................................................................................ Page
OTHER
CME PRESENTATIONS AND PUBLICATIONS...............................................................113-119
FEDERAL AND STATE HEARINGS .......................................................................................120
EDUCATIONAL EVENTS .......................................................................................................121
SPECIAL COURSES ATTENDED ...................................................................................121-122
COMMUNITY SERVICE and MEDIA APPEARANCES ....................................................123-132
INTERNATIONAL COMMUNITY PROGRAMS ....................................................................... 133
INTERNET SITES AND PUBLICATIONS ...............................................................................134
INVITED LECTURES: NATIONAL AND INTERNATIONAL.............................................. 135-145
INVITED LECTURES: REGIONAL...................................................................................146-198
AWARDS, CERTIFICATES, AND HONORS ....................................................................199-200
CONSULTANT: ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES ...... 201-220
HISTORICAL PRACTICE ADDRESSES AND OUTREACH SITES ................................. 221-222
RESEARCH SUMMARY ..................................................................................................223-224
FORMER PRACTICE LEADERSHIP ......................................................................................225
DISCLOSURES ......................................................................................................................226
PHARMACEUTICAL COMPANY RELATIONSHIPS ............................................................... 226
SPEAKERS BUREAU .............................................................................................................226
ii
Curriculum Vitae
LICENSURE
State of California, G-045632
State of Nevada, 772112
State of Arizona, 48551
BOARD CERTIFICATION
1984
1987
2007
Curriculum Vitae
EDUCATION
9/1/1973 6/15/1977
Pharmaceutical Sciences
University of Kansas
Lawrence, Kansas
9/1/1977 6/15/1980
Medical Doctor
University of Kansas School of Medicine
Kansas City, Kansas
POSTGRADUATE EDUCATION
6/1/1980 5/30/1981
6/1/1981 6/30/1983
7/1/1984 5/30/1988
NATIONAL HONORS
SOCIETY MEMBERSHIPS
American Association for the Study of Liver Disease
American Gastroenterological Association
American Society of Transplant Physicians
American College of Physicians
Asia Pacific Association for the Study of the Liver
California Medical Association
European Association for the Study of the Liver
International Liver Cancer Association
American Liver Foundation
American Transplant Society
International Coalition of Hepatology Educators
LANGUAGES
English
Spanish
Vietnamese
French
Curriculum Vitae
BIOGRAPHY
Dr. Robert G. Gish began his medical training in 1974 when he was enrolled into the Pharmacy
School at the University of Kansas. He transferred to the University of Kansas Medical School in
1977 and finished his MD degree in 1980.
Dr. Gish went on to complete a 3 year Internal Medicine residency at the University of California, San Diego and a 4 year Gastroenterology and Hepatology fellowship at the University of
California Los Angeles during which time he was awarded the NIH Physician Scientist Award to
study calcium signaling in liver cells.
After completing his training, Dr. Gish moved to San Francisco and took a position at the
California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital). He became
the Co- Medical Director of the Liver Transplant Program in 1988 and then the Medical Director
of the Liver Transplant Program in 1994. In that role he developed an outreach program that
eventually served over 35,000 patients in the Northern California and Nevada regions, and
made the CPMC a leading liver transplant center.
Dr. Gish has had and continues to have an active research program in viral hepatitis, liver
transplant, bio artificial liver, and public policy especially related to liver cancer, liver transplantation and viral hepatitis. Although his primary research focus is clinical research, he frequently
collaborates with basic scientists in his research activities. He has published more than 500
original articles, review articles, abstracts and book chapters.
Dr. Gish is also actively involved in numerous professional societies, and is a long-term member
of the American Association for the Study of Liver Disease, European Association for the Study
of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society
of Transplant Physicians.
He is a fellow of both the American College of Physicians and a long-term member of the
American Association for the Study of Liver Disease. Dr. Gish has served on the editorial
boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases
and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of
Viral Hepatitis. He has co-authored a public health policy for liver health in Vietnam and is also
assisting with the development of health care policies in Armenia and the Philippines.
In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical
Professor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for
Hepatobiliary Disease and Abdominal Transplantation (C.H.A.T.).
In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. Gish
Consultants LLC to provide consultative support to Hepatology Centers and Liver Transplant
Programs who wish to start or grow their programs through pathways of quality and optimal
patient care that is integrated with research and education. In September of 2013, Dr Gish
joined Dr Manch at St Josephs Hospital and Medical Center to start a liver and liver transplant
center which continues to be an ogoing venture. On April 1, 2014, Dr Gish joined the Stanford
Curriculum Vitae
BIOGRAPHY: Continued
Department of Medicine, Division of Gastroenterology and Hepatology and Liver Transplant
Service Line as a Staff Physician with major roles in inreach and outreach as well as program
development. Over the years of 2012 to 2014, Dr Gish has been and continues to be very active
with the National Viral Hepatitis Round Table (NVHR) a patient and community advocacy nonprofit organization. In February of 2014, Dr Gish joined the Hepatitis B Foundation, (HBF) as their
medical director to lend his policy, advocacy and clinical science skills to their amametaium.
Today, Dr. Gish is a Clinical Professor of Medicine (Adjunct) at the University of Nevada in Las
Vegas where he continues to teach and is a senior consultant at St Josephs Medical Center in
Phoenix. And Clinical Professor of Medicine at Stanford University (Consultant).
LIVER CENTERS AND LIVER TRANSPLANT PROGRAMS
Dr. Gish became the Co-Medical Director of the Liver Transplant Program at the California
Pacific Medical Center in 1988. He developed an outreach program that now serves over
35,000 patients in Northern California and Nevada, making CPMC a leading liver transplant
center. Dr. Gish joined the faculty of University of California San Diego in several capacities,
including Director of the Center for Hepatobiliary Disease and Abdominal Transplantation. He
also became Director of Clinical Hepatology at UCSD in 2010. His research on Regional Review
Boards may also change public policies on liver transplants in the United States. This research
supports the replacement of the current RRB system with a national review board that uses
clinical expertise to assign priorities. The goal of this system is to allocate organs equitably while
improving compliance with the HHS Final Rule. His appointment with the Liver Transplant
Program and Department of Medicine at Stanford University began on April 30, 2014.
RESEARCH
Dr. Gishs pharmaceutical research includes a 2011 Phase III study on the effects of BI
201335, pegylated interferon-a and ribavirin on patients infected with genotype 1 chronic
hepatitis C. He is also the principle investigator in an ongoing study on screening for viral
hepatitis and its economic effects on healthcare. Another study currently being conducted by Dr.
Gish involves the analysis of liver patients at UCSD.
Dr. Gish was the principle investigator in a study that was started in 2012 to investigate the
effects of PSI-352938, PSE-7977 and Ribavirin in patients with Chronic HCV. He is also
currently investigating the challenges of educating Asians in San Diego County on Hepatitis B in
a study that began in 2012.
Dr. Gish was an investigator in studies that led to the development of tests for HBV and HCV
and most recently a 2005 study on DNA HBV genotyping and molecular profiling in newly
recruited, HBV and HCV patients. He was also an investigator in a 2006 study that used
molecular signatures to predict interferon response in patients infected with Hepatitis C.
Dr Gishs research now includes co-leading a research program with Arrowhead Pharmaceuticals on iRNA treatment of HBV infection.
Curriculum Vitae
BIOGRAPHY: Continued
HEALTH POLICY AND PATIENT ADVOCACY
Dr. Gish has been involved with patient care and patient advocacy groups dating back to 1988
when he became involved with the American Liver Foundation. Since that time, he has been
active with a number of organizations including the National Viral Hepatitis Roundtable, Viral
Hepatitis Action Coalition, the Fair Foundation, Center for Eradication of Viral Hepatitis/Asia
Pacific Organization, HEP- DART, World Health Organization, Centers for Disease Control,
Hepatitis B Free (San Francisco and San Diego), Hepatitis B Foundation, Hepatitis C Caring
Ambassadors, Viral Hepatitis Foundation, and Hepatitis Foundation for Vietnam.
Dr. Gishs international advocacy career focuses on public policy in Vietnam, Philippines, and
Armenia. His team wrote a white paper on Health Care and Liver Health in Vietnam that was
published in a peer-reviewed publication. Additional projects in Vietnam and the Philippines
include protocols that advance screening for viral hepatitis and link- age to care, as well as
global liver health issues including obesity, fatty liver, and alcohol induced liver disease. The
newest addition to Dr. Gishs global health policy work is in Armenia, where he is developing a
white paper for that countrys 5-year Liver Health Policy.
PERSONAL STATEMENT
My clinical research and studies focus on viral hepatitis, liver transplant, bioartificial liver, public
policy especially related to liver transplantation and viral hepatitis. Clinical trials for a variety of
antiviral therapies and new bioartificial livers systems will continue to be a major focus of my
practice. We will use databases to help uncover associations between liver cancer and certain
cancer biomarkers. In addition we will be building a multidisciplinary liver cancer program and
will integrate models of HCC signaling into our program. My background includes training in viral
hepatitis clinical trials and liver cancer trials. I plan to have a focus on biomarkers for liver
cancer to help guide treatment decisions and therapies. I have 25 years of experience as a
clinician and clinical investigator in the realm of liver disease, liver transplant and liver cancer. I
do a variety of educational programs for Pharma including promotional talks that are highly
regulated by the FDA and the Pharma Code: these funds are all recycled into research,
education, policy, philanthropy and supporting international health care.
EXPANDED RESEARCH
Dr. Gishs work focuses on the epidemiology of liver disease, biomarkers for liver disease and
multi-targeted therapies for liver cancer such as protein kinase inhibitors, fibroblast growth
factors and iRNA technologies to treat viral hepatitis. His research also includes the diagnosis
and treatment of liver failure, liver transplantation, and viral hepatitis, both B and C variants.
Recent clinical studies have focused on the Hepatitis B Virus within the Asian population at
large as well as exosomes, liver failure, bioartifical livers and international health policy.
Curriculum Vitae
BIOGRAPHY: Continued
PRESS RELEASE February 2014
Hepatitis B Foundation Welcomes Dr. Robert Gish as Medical Director
Renowned leader in the field of liver disease takes on new role leading advocacy and research
DOYLESTOWN, Pa. (February 2014) The Hepatitis B Foundation (www.hepb.org), the only
national nonprofit organization solely dedicated to finding a cure for hepatitis B, is pleased to
announce that Robert G. Gish, M.D., became the foundations medical director on Jan. 30,
2014. An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has
made invaluable contributions to the understanding and treatment of hepatitis B, which is the
worlds leading cause of liver cancer. A longtime supporter of the foundations mission and a
member of the Scientific Advisory Board, Dr. Gishs new role will further strengthen its research
and advocacy efforts worldwide. We are delighted to welcome Dr. Gish to our board, said Dr.
W. Thomas London, senior member emeritus of Fox Chase Cancer Center and vice president
of the board of directors of the Hepatitis B Foundation. He has long been a leader in the field
and has extensive experience in the conduct of clinical trials of new drugs to combat chronic
hepatitis B. His leadership as medical director will help us advance the treatment and prevent
the severe consequences of this potentially deadly disease. After receiving his medical degree
in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on
investigation of viral hepatitis B and C. He went on to become medical director of the liver
transplant program at California Pacific Medical Center in 1994, developing an outreach
program that eventually served more than 35,000 patients in northern California and Nevada
and made the medical center a leading liver transplant center. Over the course of his career, Dr.
Gish has published more than 600 original articles, abstracts and book chapters and more than
120 peer-reviewed publications. Today, he is a clinical professor of Medicine at the University of
Nevada in Las Vegas, where he continues to teach, and is a senior consultant at St. Josephs
Medical Center in Phoenix. In 2013, he formed Robert G. Gish Consultants LLC to support liver
health and transplant programs with operations, outreach, compliance, financial planning and
program development in the U.S. and Asia. Dr. Gishs background is a perfect fit for the work
we do here at the Foundation and our Baruch S. Blumberg Institute, said Dr. Timothy Block,
president of the Hepatitis B Foundation and also a professor of Microbiology at Drexel University. We are honored that Dr. Gish has agreed to become our medical director and look forward
to many years of collaboration so we can finally put an end to this serious liver infection. To
learn more about Dr. Robert Gish, visit his website.
Curriculum Vitae
FACULTY APPOINTMENTS
* Please note: The following dates are best estimates due to lack of evidenced documentation:
7/1/1983 6/30/1984
6/1/1985 5/30/1988
Research Associate
Division of Gastroenterology
University of California, Los Angeles
Los Angeles, California
9/11988 6/1/1993
Research Associate
Medical Research Institute
California Pacific Medical Center
University of the Pacific
San Francisco, California
9/1/1991 7/2/1996
7/1/1991 6/30/1996
7/1/1993 6/30/1998
7/1/1994 6/30/1998
7/1/1998 6/30/2005
7/1/2005 6/30/2006
8/1/1995 1/1/2010
9/1/1996 6/1/1999
Curriculum Vitae
9/1/2010 8/30/2013
1/1/2014 Present
Clinical Professor,
Department of Internal Medicine, Adjucnt
University of Nevada School of Medicine,
Las Vegas, Nevada
1975 1977
Research Associate
McCollum Laboratories
University of Kansas
Lawrence, Kansas
1982 1983
1982 1983
1982 1983
1983 1984
1983 1984
Curriculum Vitae
1984 1986
1986 1988
Consultant
Sherman Oaks Community Hospital
Sherman Oaks, California
1987
Consultant
Phillip Edelman, M.D.
Occupational Medicine
Orange, California
1987
Consultant
Washington Medical Center
Culver City, California
1987 1988
Consultant
Valley Presbyterian
Van Nuys, California
1988
Staff Physician
Oliveview Medical Center
Sylmar, California
1988
Consultant
West Hills Medical Center
Conoga Park, California
1988 1989
Consultant
Mt. Zion Medical Center
San Francisco, California
1990 1991
Consultant
Seton Medical Center
Daly City, California
1990 1995
Consultant
Valley Children's Hospital
Fresno, California
1993 2006
Consultant
Enloe Hospital,
Chico, California
2002 2009
Consultant
Sunrise Hospital
Las Vegas, NV
Curriculum Vitae
10
1988 2010
Staff Physician
California Pacific Medical Center
San Francisco, California
2009 2010
Physician
St. Lukes Hospital
San Francisco, California
1991 2010
Consultant
Highland Hospital
Oakland, California
1996 2010
Consultant
Medical Staff, Department of Medicine
John Muir Medical Center
Walnut Creek, California
1997 2006
Consultant
Alta Bates Medical Center
Medicine and Family Practice
Berkeley, California
2003 2010
Physician
Saint Marys Medical Center
San Francisco, California
2010 2013
2014 Present
State of California
Department of Corrections
Infectious Disease Advisory Board
Curriculum Vitae
11
CONSULTANT POSITIONS
2010 Present
Founding Member
CEVHAP (Coalition to Eradicate Viral Hepatitis in Asia Pacific).
Singapore
2012 2014
2013 2014
BUSINESS POSITIONS
1999 2000
1999 2001
2000 2005
President
Pacific Hepatology and Gastroenterology Medical Group, P.C.
San Francisco, California
2009 Present
1988 2010
Office address:
California Pacific Medical Center
2340 Clay Street
San Francisco, California 94115
2010 2013
8/31/2013
Present
Robert G. Gish MD
Robert G. Gish Consultants, LLC
Business address:
6022 La Jolla Mesa Drive
San Diego, CA 92037
Cell phone: 1 858 229 9865
Email: rgish@robertgish.com
Website: robertgish.com
Curriculum Vitae
12
RESEARCH SUPPORT
1975 1977
1985 1988
1993 1995
Co-Investigator: Amgen grant. A Phase III, Randomized, DoubleBlind Controlled Trial of Recombinant Methionyl Interferon
Consensus (r-tetIFN-Con1) in Patients with Chronic Hepatitis C
Virus (HCV) Infection. California Pacific Medical Center.
Grant award: $187,604.
1993 1994
1993 1998
1994
1994
Principle Investigator: Schering Corporation grant. Interferon alfa2b: Dose Escalation and Taper for the Treatment of Hepatitis C.
Grant award: $15,000.
1995
1995
1995 1997
1995 1997
Co-investigator: GlaxoWellcome grant. Study P110-008Tucaresol Dose Escalation Drug Study for Hepatitis B.
Grant award: $35,000.
1996 1997
Curriculum Vitae
13
1996 1997
1996 1997
Co-Investigator: GlaxoWellcome grant. Study NUCA3005Lamivudine Open Label Program for Treatment of Patients with
Hepatitis B Viral Infection Post-Liver Transplantation.
Grant award: $20,000.
1996 1997
1996 2001
1996 1997
1996 1997
1996 1998
1996 1997
1996 1999
Principle Investigator: GlaxoWellcome grant. Study NUCA3021Lamivudine Compassionate Use Treatment Program for Subjects
of Three Life-Threatening Forms of Hepatitis B Infection.
1997 2000
Curriculum Vitae
14
1997 2002
1997 2002
1998 2000
1998 2001
1998 1999
1999 2000
1998 1999
1997 1998
1998 Present
1998 2000
Principle Investigator: Schering-Plough grant. Study C98-169Comparison of Intron A Induction Therapy + Rebetol vs. Intron
A + Rebetol for the Treatment of Adult Naive Subjects with
Chronic Hepatitis C Infected with HCV Genotypes 1, 2, 3, or 2/3.
Grant award: $59,000.
Curriculum Vitae
15
1998 2001
1997 2001
Principle Investigator: Schering-Plough grant. Study C96-318Treatment of Relapse in Patients with Chronic Hepatitis C
Comparing Intron A Monotherapy vs. IntronA + Ribavirin.
Grant award: $20,000.
1998 2001
1997 1999
Principle Investigator: Schering-Plough grant. Study C97-010Comparison of Peg-interferon vs. Intron A for Treatment of Adult
Subjects with Chronic Hepatitis C not Previously Treated with
Interferon: Dose-finding study. Grant award: $105,000.
1999 2002
1999 2002
Principle Investigator: Hoffmann-LaRoche grant. Study NR15994A randomized, open-label, multicenter, efficacy and safety Study
of Pegasys plus Ribavirin, Pegasys plus CellCept,
Pegasys plus Amantadine, or Pegasys plus Amantadine plus
Ribavirin in Patients with Chronic HCV Infection who have not
Responded to at least 12 Weeks of Treatment with Rebetron.
Grant award: $75,000.
1999 2002
Principle Investigator: Gilead grant. Study GS98-437- A doubleblind, randomized, placebo-controlled Study of Adefovir Dipivoxil
for the Treatment of Patients with HBeAg+ Chronic Hepatitis B Virus Infection. Grant award: $106,000.
Curriculum Vitae
16
1999 2006
2000 2001
2000
2000 2005
2000 2005
2000 2005
2000 2005
2000 2005
2001
Principle Investigator: GlaxoSmithKline grant. Study Nuc2094 Lamivudine and Adefovir Combination for the Treatment of
Chronic HBV Infection.
Curriculum Vitae
17
2001 2002
2001 2002
2001 2002
2001 2002
Principle Investigator: Bristol-Meyers Squibb grant. Study 014020- Entecavir vs. Lamivudine (52 weeks therapy) in Adult
Patients with Chronic Hepatitis B who are Positive for Hepatitis B
e-Antigen and Nave to Previous Therapy.
2001 2002
Principle Investigator: Roceh Pharmaceuticals: 8 weeks of PegInterferon +/- Ribavirin vs. Roferon 3 MU TIW + Ribavirin for
Patients with Chronic Hepatitis C Co-infected with HIV, Nave to
Interferon Therapy.
2001 2002
2001 2002
2001 2006
2001 2008
Curriculum Vitae
18
2001 2005
2001 2006
2001 2005
Principle Investigator: Schering-Plough grant. Comparison of peginterferon plus ribavirin given as a fixed dose or on a weight
optimized basis for treatment of chronic hepatitis C in previously
untreated adult subjects. Grant award: $41,950.
2002 2004
2002
2002
2002 2003
2002
Principle Investigator: Chiron grant. Randomized, placebocontrolled study of the safety and efficacy of HBV/MF59 (vaccine)
alone or in combination with lamivudine.
2002 2003
Curriculum Vitae
19
2002 2005
2002 2005
2002 2005
2002 2003
2002 2003
2002 2004
2002 2003
2002 2003
2002 2005
2002 2005
Curriculum Vitae
20
2002 2009
2003 2004
Principle Investigator: Bristol-Meyers Squibb. Entecavir vs. Lamivudine (52 weeks therapy) in Adult patients with Chronic Hepatitis
B who have had an Incomplete Response to Lamivudine Therapy:
Rollover study.
2003
2003
2003
Sub-investigator: Two-week randomized, double-blind, placebocontrolled study of PRN, BID and fixed dosing regimens of
alosetron in female subjects with severe diarrhea-predominant
irritable bowel syndrome who have failed conventional therapy.
2003
2003
2003
2003
2003 2004
Curriculum Vitae
21
2003 2006
Sub-Investigator: Hoffman-LaRoche grant. Rrandomized, multicenter, open-label, phase IV study evaluating efficacy and safety
of 16 week vs. 24 week treatment with Pegasys in combination
with Copegus in interferon-nave patients with chronic hepatitis C
genotype 2 or 3 virus infection. Grant award: $136,513.
2003 2006
2003 2005
Principle Investigator: XTL Pharmaceuticals grant. Phase II, multicenter, randomized, open-label, dose ranging, parallel group study
of the antiviral effects, pharmacokinetics and safety of HepeX-B
as compared to hepatitis B immune globulin in patients who have
received hepatic allografts for hepatitis B virus infection.
Grant award: $7,400.
2004
2004
2004
2004
2004 2005
2004 2005
Curriculum Vitae
22
2004 2006
2004 2006
2004 2006
2004 2007
2004 2007
2004 2009
2005 2007
2005 2007
2005 2008
2005 2007
Curriculum Vitae
23
2005
2005
2007 2008
2008 2010
PROTOCOL GS-US-174-0108 A Phase II, Double-Blind, MultiCenter, Randomized Study Comparing Tenofovir Disoproxil
Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and
Entecavir In The Treatment Of Chronic Hepatitis B Subjects With
Decompensated Liver Disease And In The Prevention Of Hepatitis
B Recurrence Post-Transplantation. Budget $26,642
2010
2010
2010
Sub-Investigator: A Randomized, Placebo-Controlled, DoseEscalation Study to Assess the Safety and Effect of Cidofovir in
Renal Transplant Recipients with BK Virus Nephropathy
(CASG209).
2010
2010
Sub-Investigator: A Phase III randomized, double-blind, placebocontrolled study of sorafenib as adjuvant treatment for
hepatocellular carcinoma after surgical resection or local ablation.
Curriculum Vitae
24
2010
Sub-Investigator: A Phase II randomized, double-blind, placebocontrolled study of Sorafenib or Placebo in combination with
transarterial chemoembolization (TACE) performed with DC bead
and doxorubicin for intermediate stage hepatocellular carcimoma
(HCC).
2010
2010
Sub-Investigator: A Phase I, Open-Label, Multi-center, Doseescalation Study of the Safety, Tolerability, and Pharmacokinetics
of GC33 in Combination with Sorafenib (Nexavar) in Patients with
Advanced or Metastic Hepatocellular Carcinoma (HCC).
2010
2010
2010
2010
2010
2010
Curriculum Vitae
25
2010
2010
2010
2010
2010
2010
2010
2010
2010
Curriculum Vitae
26
2010
2010
2010
4/2010 8/2013
Co-Primary Investigator: NV20536. A Roche Study: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding
Study to Evaluate the Sustained Virologic Response of the HCV
Polymerase Inhibitor Prodrug (RO5024048) in Combination with
Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients
with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. Grant
Award: $214,336.60.
11/2010 8/2013
4/2011 8/2013
2011
Co-Primary Investigator: WV21913C. A Roche Study: A Randomized, Open-Label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir
Boosted with Low Dose Ritonavir (DNV/r) and Copegus, in Combination with the HCV Polymerase Inhibitor Prodrug RO 5024048
and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients who
have Failed a Previous Course of Peginterferon Alfa Plus Ribavirin Combination Therapy. Grant Award: $141,986.
Curriculum Vitae
27
6/2011 8/2013
9/2011 8/2013
2011 8/2013
2011 8/2013
2011 8/2013
2011 8/2013
2011 8/2013
Curriculum Vitae
28
2011 8/2013
Primary Investigator: P2938-0721. A Gilead Sciences / Pharmasett, Inc. Study: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics
and Pharmacodynamics following Administration of Regimens
Containing PSI-352938, PSI-7977, and Ribavirin in Patients with
Chronic HCV Infection. Grant Award: $273,564.
2012 8/2013
2012 8/2013
2012 8/2013
Co-Primary Investigator: P7977-2025. A Gilead Sciences / Pharmasett, Inc. Study: An Open-Label Study to Explore the Clinical
Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in
Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant.
Grant Award: $80,722.
2012 8/2013
2012 8/2013
2012 8/2013
Curriculum Vitae
29
2012 8/2013
Primary Investigator: P7977-1231, A Gilead Sciences / Pharmasett, Inc. Study: A Phase 3, Multicenter, Randomized, ActiveControlled Study to Investigate the Safety and Efficacy of PSI7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Nave Patients with
Chronic Genotype 2 or 3 HCV Infection. Grant Award: $43,041.
2012 8/2013
2012
2012
2012
2012
Curriculum Vitae
30
2013
2013
Co-Primary Investigator: GS M14-002. An AbbVie Study: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy
and Safety of the Combination of ABT-450/Ritonavir/ABT-267
(ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin
(RBV) in Treatment-Nave Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV). Grant Award:
$126,539.00. 3/1/13 8/2013.
2013
2013
GS-US-342-0102, A Gilead Sciences, Inc. Study: A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety
and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in TreatmentNave Subjects with Chronic HCV Infection . Grant Award:
$46,551. 5/1/13 8/2013.
Curriculum Vitae
31
2012
2013
2012
Principal Investigator: Retrospective Analysis of UCSD Liver Patient Population, UCSD Medical Center, 5-Year Study. UCSD
Liver Center.
2011
2011
2011 2013
2012
2012 2013
2012 2013
2013 Present
Curriculum Vitae
32
2012 Present
8/31/2013
Present
Robert G. Gish MD
Robert G. Gish Consultants, LLC
Business address:
6022 La Jolla Mesa Drive
San Diego, CA 92037
Cell phone: 1 858 229 9865
Email: rgish@robertgish.com
Website: robertgish.com
2002
2002
A phase III, double-blind, multicenter, randomized, placebocontrolled study of the effects of a somatostatin analogue lanreotide as an adjuvant to endoscopic band ligation of patients
with acute bleeding from oesophageal varies secondary to
cirrhosis and portal hypertension (Biomeasure).
2002
2002
2002
2002
2002
A pilot Phase II, muliticenter, randomized, double-blind, placebocontrolled, dose escalation study of the safety and efficacy of
human HCV-antibody (HCV-Ab XTL 68) for prevention of hepatitis
C disease recurrence in patients who have received hepatic
allografts for treatment of end-stage liver disease due to hepatitis
C virus infection.
Curriculum Vitae
33
2010
2010
2011
2011
2011
2011
2011
2011
2011
Focus will be all Asian data results vs. USA - performance needs
and discussion around country-level differences (possible
publication in special supplement of ONCOLOGY, tbc).
2011
2012
2013
2011 2013
Curriculum Vitae
34
TEACHING ACTIVITIES
19871988
Consult Attending
Gastroenterology and Liver Services
Wadsworth Veterans Hospital
Los Angeles, California
19871988
Clinical Toxicology
UCLA School of Medicine
Los Angeles, California
19891991
19911995
1994
Visiting Professor
University of Florida
Gainesville, Florida
1996
Visiting Professor
University of Iowa
Iowa
Visiting Professor
University of California, Los Angeles
Los Angeles, CA
2003
Visiting Professor
University of Colorado
Denver, Colorado
2006
Visiting Professor
University of Southern California
Los Angeles, California
Gastroenterology Teaching Service
Highland General Hospital, Alameda County Medical Center
Oakland, California
1988 2010
1988 2010
1993 1999
Curriculum Vitae
35
1996 2010
Department of Medicine
University of California, San Francisco
San Francisco, California
OSCE 1995-2002
Medicine Teaching Service at CPMC
Housestaff Teaching Service at Highland Hospital
50 hours per year of teaching service (minimum)
2008 2010
Department of Medicine
University of California, San Francisco
San Francisco, California
Medicine Teaching Service
(a total of 88 hours of preceptorship)
2010 2013
Department of Medicine
University of California, San Diego
San Diego, California
2013
2013
June 2013
August 20 2014:
Curriculum Vitae
36
COMMITTEES
1989 1992
1989 1992
1990 1992
1990 1992
1991 1993
1992 1993
1992 1993
1993
1993 1996
1994 1997
1996
1997 1998
Curriculum Vitae
37
COMMITTEES: Continued
1997 2001
1999
Secretary
Hepatitis Resource Network
1999 2000
1999 2013
1999 2001
2001 2002
2001 2002
2002 2004
2003
Chair
AASLD Topic Forum
2003
Faculty Member
AASLD Expert Consensus Conference
2003
2003 2006
2004
2004
Curriculum Vitae
38
COMMITTEES: Continued
2004 2006
2005 2007
2004 2010
2006 Present
1994 2007
1995 2007
1996 1998
1997 2000
1997 2003
1997
1998 2010
2004 2005
2007
2007
Abstract Reviewer
American Transplant Congress
2007 2008
2007 2010
Curriculum Vitae
39
COMMITTEES: Continued
2008 2010
2008 2010
Advisor, LASH
Local Area Support for Hepatitis, Inc. (L.A.S.H.)
2008 Present
2008 Present
2009
Program of comprehensive research actions: Hepatocellular carcinoma. French National Cancer Institute. Grant Review. 2009
2009 2010
2009 Present
Board Member
Hepatitis C Oversight Partnership (HepCop)
2009 Present
2010 Present
2010
Abstract Reviewer
Asian Pacific Association for the Study of Liver Disease
(ASPASL), Beijing, China
2009 2013
2010
Nomination Committee
San Francisco Medical Society
2010 Present
2011 Present
LI-RADS
(Liver Imaging Reporting and Data System)
2011
2011 Present
2011 Present
Curriculum Vitae
40
COMMITTEES: Continued
2012 2013
2012 Present
2012
2012 2013
2012 2015
2012 Present
Faculty Interviewer Committee, Internal Medicine Residency Applicants, University of California, San Diego Department of Internal
Medicine.
2013
2013
2011 2013
2013
2013
2013 Present
2010
2013
2014
Curriculum Vitae
41
COMMITTEES: Continued
2014 Present
Medical Director
Hepatitis B Foundation, Doylestown, PA
2014 Present
Member
Global Hepatitis Community, www.hepcomm.com
2014 Present
2014 Present
2014 Present
2014 Present
September 2014
Curriculum Vitae
42
BOARD ACTIVITIES
1999 2002
1999 2002
2001 2003
2002 2010
2002 2006
2003 2004
1999 Present
2007
2003 2006
2004 Present
2005 Present
2007 Present
2009 Present
2009
2011
Curriculum Vitae
43
1992
1992 1994
1999 2002
1999 2000
Editorial Board
The Practical Hepatitis Newsletter (PHN)
2011 Present
2011
2012 Present
2012 Present
2012
2013
2013 Present
2013 Present
2013 Present
2013 Present
2013 Present
2013 Present
Curriculum Vitae
44
2013
2013
2013
2014 2015
Curriculum Vitae
45
EDITORIAL ACTIVITIES
Curriculum Vitae
46
MENTEE LIST
NAME
ETHNICITY
MENTOR RELATIONSHIP
(Dates, How mentored)
POSITION NOW
Debbie Hana-Yi
Korean
2008-2010 research
associate
NYU Residency
Michael Mangahas
Filipino
2008-2010 research
associate
Sumbella F. Baqai,
MD
Pakistani
2008-2010 research
associate
Javaheri Shahram
Persian
1999-2000: GI Fellow
Fellowship mentor
Aris Mendiola
Pilipino
2000-2001: GI Fellow
Fellowship mentor
Sheila Savur
Indonesian
2001-2001: GI Fellow
Fellowship mentor
Tammy Daugherty
Caucasian
2000-2003: GI Fellow
Fellowship mentor
Linda Nguyen
Vietnamese
2000-2003: GI Fellow
Fellowship mentor
Daniel Rengstorff
Caucasian
2001-2004: GI Fellow
Fellowship mentor
Ann Chen
Chinese
2003-2004: GI Fellow
Fellowship mentor
Christine Pizzute
Caucasian
2004-2005: GI Fellow
Fellowship mentor
Jessie Liu
Chinese
2005-2006: GI Fellow
Fellowship mentor
Katerina Shetler
Fellowship mentor
Mimi Lin
Chinese
2006-2007: GI Fellow
Fellowship mentor
Liz Clark
Chinese/Hawaiian
2007-2008: GI Fellow
Fellowship mentor
Michele Tana
Chinese
2008-2009: GI Fellow
Fellowship mentor
Cathy Cabansag
Filapina
2008-2009: GI Fellow
Fellowship mentor
Edward Holt
Caucasian
2009-2010: GI Fellow
Fellowship mentor
Curriculum Vitae
47
ETHNICITY
MENTOR RELATIONSHIP
(Dates, How mentored)
POSITION NOW
Caucasian
Iris Ma
Chinese
Arlene Vazquez
Hispanic
Patricia Zheng
Chinese
Steve Kane
Caucasian
2010-2013
Premed student,
research associate
Margaret Clark
Caucasian
2010-2013
Premed student,
research associate
Erica Boettcher
Caucasian
2010 2013
GI Fellow
Brigid Boland
Caucasian
2010 2013
GI Fellow
Imad Elkhatib
Middle Eastern
2010 2013
GI Fellow
Wilson Kwong
Asian
2011 2013
GI Fellow
Michael McTigue
Caucasian
2011 2013
GI Fellow
Mazen Nourredin
Caucasian
2010 2013
GI Fellow
Suresh Pola
Asian Indian
2010 2013
GI Fellow
Ashish Shah
Asian Indian
2011 2013
GI Fellow
Amir Zarrinpar
Persian
2011 2013
GI Fellow
Ingrid Gonzalez
Hispanic
2011 2013
GI Fellow
Thuy Anh Le
Asian
2010 2013
GI Fellow
Julio Guttierrez
Hispanic
2010 2013
GI Fellow
Fred Park
Asian
2011 2013
GI Fellow
Toritsesan Boyo
(Tosan)
Nigerian
2011-2013
Business Resident
Irene Vodkin
Curriculum Vitae
48
ETHNICITY
MENTOR RELATIONSHIP
(Dates, How mentored)
POSITION NOW
Lilly Nguyen
Vietnamese
2013 2013
Pharmacy Student
Thuy Nguyen
Vietnamese
2013
Pharmacy Student
Xuan Phan
Vietnamese
2013
Pharmacy Student
Laura Stinton
Caucasian
June 2013
My Traing
Vietnamee
August 2014
Fellowship mentor
Pharmacy Student
.
CLINICAL EXAM SESSIONS
Participant / Proctor, GI Focused clinical exam session, UCSD, November 2011
Participant, Clinical Exam Sessions, University of California, San Diego School of Internal
Medicine, November 21, 2011.
Curriculum Vitae
49
Stella VJ, Gish RG. Ionization kinetics of the carbon acid phenindione. J Pharm Sci.
August 1979; 68(8):1042-1047.
2.
Stella VJ, Gish RG. Kinetics and mechanism of ionization of the carbon acids 4substituted 2-phenyl-1, 3-indanediones. J Pharm Sci. August 1979; 68(8):1047-1049.
3.
Gish RG, Garcia C, Reedy T, Kaplowitz N, Langer GA. Calcium compartmentation and
exchange rates in primary hepatocyte culture. Anal Biochem. May 1990; 187(1):187196.
4.
Zeldis JB, Depner TA, Kuramoto RK, Gish RG, Holland PV. The prevalence of hepatitis
C virus antibodies among hemodialysis patients. Ann Intern Med. Jun 1990;112(12):958960.
5.
Linton MF, Gish RG, Hubl ST, Butler E, Esquivel CO, Boyles JK, Wardell MR, Young
SG. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J
Clin Invest. Jul 1991;88(1):270-281.
6.
7.
Gish RG, Warmerdam M, Zeldis J, Keeffe EB, Nakazato P, Lim J, Cox K, Kuramoto IK,
Fry KE, Yarbough P, Moeckli R, Yun-cho K, Reyes G. Variation in antibody reactivity to
the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. Viral
Immunology. Spring 1993;6(1):49-54.
8.
Gish RG, Lee AH, Keeffe EB, Rome H, Concepcion W, Esquivel CO. Liver transplantation for patients with alcoholism and end-stage liver disease. Am J Gastroenterol. Sep
1993;88(9):1337-1342.
9.
Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Tsukiyama-Kohara K, Kohara M,
Mondelli MU, Lesniewski R, Phillips MI, Mizokami M, et al. Optimization for the detection
of viral hepatitis C (HCV) antigens in liver. J Hepatology. Jan 1994;20(1):143-147.
10.
1995
11.
Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Gish RG, Cox K, So S,
Esquivel CO, Krams SM. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc. Feb 1995;27(1):1211-1212.
12.
Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic Tlymphocyte (CTL) differentiation factor in allograft recipients. Transplant Proceed. Feb
1995;27(1):459-460.
Curriculum Vitae
50
13.
Lau JY, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, Perrill RP, Lindsay
KL, Gish RG, Qian KP, Kohara M, Simmonds P, and Urdea MS. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United
States. J Inf Dis. Feb 1995;171(2):281-289.
14.
Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation
for chronic hepatitis B using reduced immunosuppression. J Hepatol. Mar
1995;22(3):257-262.
15.
Gonzalez-Peralta RP, Fang JW, Davis GL, Gish RG, Kohara M, Mondelli MU, Urdea
MS, Mizokami M, Lau JY. Significance of hepatic expression of hepatitis C viral (HCV)
antigens in chronic hepatitis C. Dig Dis Sci. Dec 1995;40(12):2595-2601.
1996
16.
Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, Garcia-Kennedy R,
Esquivel CO, Keeffe EB. Ganciclovir treatment of hepatitis B virus infection in liver
transplant recipients. Hepatology. Jan 1996;23(1):1-7.
17.
Lau GK, Davis GL, Wu SP, Gish RG, Balart LA, Lau JY. Hepatic expression of hepatitis
C virus RNA in chronic hepatitis C: a study by in situ reverse-transcription polymerase
chain reaction. Hepatology. Jun 1996;23(6):1318-1323.
18.
Cacciarelli T, Martinez OM, Gish RG, Villaneuva JC, Krams SM. Immunoregulatory
cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology. Jul 1996;24(1):6-9.
19.
Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M, Simmonds P; Hepatitis Interventional Therapy Group (Gish RG). Distribution of hepatitis C
virus genotypes determined by line probe assay in patients with chronic hepatitis C seen
at tertiary referral centers in the United States. Ann Intern Med. May 1996;124(10):868876.
1997
20.
Gish RG, Qian KP, Quan S, Xu YL, Pike I, Polito A, DiNello R, Lau JY. Concordance
between hepatitis C virus serotyping assays. J Viral Hepat. 1997;4(6):421-422.
21.
Ku NO, Wright TL, Terrault NA, Gish RG, Omary MB. Mutation of human keratin 18 in
association with cryptogenic cirrhosis. J Clin Invest. Jan 1997;99(1):19-23.
22.
Gish RG. Hepatitis C virus: Seven years old. Viral Hepatitis Reviews. 1997;3(1):1737.Gish RG, Lau JYN. Hepatitis C Virus: Eight Years Old. Viral Hepatitis Reviews. Mar
1997;3(1):17-37.
23.
Gish RG and Olden K. Alcohol and liver disease should transplantation be offered? Practical Gastroenterology. December 1997.
Curriculum Vitae
51
24.
Lucey MR, Brown KA, Everson GT, Fung JJ, Gish RG, Keeffe EB, Kneteman NM, Lake
JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American
Association for the Study of Liver Diseases. Liver Transpl Surg. Nov 1997;3(6):628-637.
25.
Gish RG. Review of computer program "A simplified approach to the management of
patients with chronic hepatitis B and C infections." Gastroenterology. Dec1997.
1998
26.
Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B
virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. Jan 1998;27(1):213-222.
27.
Xiang J, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish RG, Stapleton JT.
Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid
and expression of sequences upstream of the E1 protein. J Virol. Apr 1998;72(4):27382744.
28.
Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake
JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement
of adults on the liver transplant waiting list: a report of a national conference organized
by the American Society of Transplant Physicians and the American Association for the
Study of Liver Diseases. Transplantation. Oct 1998;66(7):956-962.
29.
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML,
Zeuzem S, Craxi A, Ling MH, Albrecht J; International Hepatitis Interventional Therapy
Group (Gish RG). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. Nov 1998;339(21):1493-1499
30.
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman
ZD, Ling MH, Cort S, Albrecht JK; Hepatitis Interventional Therapy Group (Gish RG). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. Nov 1998;339(21):1485-1492.
31.
1999
32.
Poordad FF, Gish RG. Evolving therapies for the treatment of viral hepatitis. Expert
Opinion on Emerging Drugs. Jan 1999;4(1):15-34.
33.
Curriculum Vitae
52
34.
Gish RG, Qian K, Brooks L, Leung J, Xu Y, Pike I, Lau JY. Characterization of antihepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. J Gastroenterol Hepatol. Apr 1999;14(4):339-344.
35.
36.
Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Laffler T,
Traylor D, Hunt G, Rosenthal P. GB virus C (GBV-C/HGV) and E2 antibodies in children
preliver and postliver transplant. Pediatr Res. Jun 1999;45(6):795-798.
37.
Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, Kowdley KV.
Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver
Transpl Surg. Sep 1999;5(5):369-374.
38.
Ware JE Jr., Bayliss MS, Mannocchia M, Davis GL; The Interventional Therapy Group
(Gish RG). Health-related quality of life in chronic hepatitis C: impact of disease and
treatment response. Hepatology. Aug 1999;30(2):550-555.
39.
Nalbandian G, Van de Water J, Gish R, Manns M, Coppel RL, Rudich SM, Prindiville T,
Gershwin ME. Is there a serological difference between men and women with primary
biliary cirrhosis? Am J Gastroenterol. Sep 1999;94(9):2482-2486.
40.
Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB, Ansari A, Gershwin
ME. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J
Hepatol. Oct 1999;31(4):664-671.
41.
Tanaka A, Lindor K, Gish R, Batts K, Shiratori Y, Omata M, Omata M, Nelson JL, Ansari
A, Coppel R, Newsome M, Gershwin ME. Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology. Oct 1999;30(4):833-38.
42.
Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish
RG. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis
against hepatitis B recurrence after liver transplantation. Liver Transpl and Surg. Nov
1999;5(6):491-496.
43.
Gish, RG, Wakil AE. Combination interferon-alfa 2B plus ribavirin for treatment of
chronic hepatitis C. Current Practice of Medicine. 1999;2(4-10).
2000
44.
McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T,
Yao R, Albrecht; International Hepatitis Interventional Therapy Group (Gish RG). The
Impact of Interferon Plus Ribavirin on Response to Therapy in Black Patients With
Chronic Hepatitis C. Gastroenterology. Nov 2000;119(5):1317-1323.
Curriculum Vitae
53
2001
45.
Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish RG, Martin P, Dienstag J, Adams
P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N; Lamivudine North American
Transplant Group. A multicenter United States-Canadian trial to assess lamivudine
monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology.
Feb 2001;33(2):424-432.
46.
Ku NO, Gish R., Omary M, Wright TL. Keratin 8 mutations in patients with cryptogenic
liver disease. N Engl J Med. May 2001;344(21):1580-1587.
47.
Gish RG, Lee A, Brooks L, Leung J, Lau JY, Moore DH. Long-term follow-up of patients
diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver
transplantation. Liver Transpl. Jul 2001;7(7):581-87.
48.
Hadlock KG, Gish RG, Rowe J, Rajyaguru SS, Newsom M, Warford A, Foung SK.
Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second
envelope glycoprotein (E2). J Med Virol. Sep 2001;65(1):23-29.
49.
2002
50.
51.
Kato H, Orito E, Gish RG, et al. Characteristics of hepatitis B virus isolates of genotype
G and their phylogenetic differences from the other six genotypes (A through F). Journal
of Virology. Jun 2002;76(12):6313-6137.
52.
Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH,
Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis
B virus infection. Antimicrob Agents Chemother. Jun 2002;46(6):1734-40.
53.
54.
Mao TK, Kimura Y, Kenny TP, Branchi A, Gish RG, Van de Water J, Kung HJ, Friedman
SL, Gershwin ME. Elevated expression of tyrosine kinase DDR2 in primary biliary cirrhosis. Autoimmunity. Dec 2002;35(8):521-529.
55.
Curriculum Vitae
54
2003
56.
Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G,
Gardner SD, Brown N, Griffiths D; United States Lamivudine Compassionate Use Study
Group (Gish RG). A United States compassionate use study of lamivudine treatment in
nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
Liver Transpl. Jan 2003;9(1):49-56.
57.
Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Shiffman, M, Jeffers L, Goodman Z,
Wulfsohn MS, Xion S, Fry J, Brosgart C, for the Adefovir Dipivoxil 437 Study Group
(Gish RG). Adefovir Dipivoxil for the treatment of hepatitis B e antigen-positive chronic
hepatitis B. N Engl J Med. Feb 2003;348(9):808-816.
58.
59.
60.
61.
62.
Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry
J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. Jul
2003;125(1):107-116.
63.
Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain
KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J,
Flamm S, Blei A, Befeler AS; Liver Cancer Network. Hepatitis C-related hepatocellular
carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, Sep
2003;98(9):2060-2063.
64.
Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. De novo nonalcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant.
Nov 2003;3(11):1413-1417.
Curriculum Vitae
55
2004
65.
Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG,
Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J
Gen Virol. Apr 2004;85(Pt 4):811-820.
66.
67.
Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T,
Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group (Gish RG). Epoetin
alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. May 2004;126(5):1302-1311.
68.
Kato H, Gish RG, Bzowej N, Newsom M, Sugauchi F, Tanaka Y, Kato T, Orito E, Usuda
S, Ueda R, Miyakawa Y, Mizokami M. Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. J Med Virol. Aug 2004;73(4):516-21.
69.
Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI,
Zweiban B, Podda M, Gershwin ME. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. Aug
2004;127(2):485-92.
70.
Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A,
Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M. A case-control
study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and
Ae) and D. Hepatology. Sep 2004;40(3):747-55.
71.
Jazayeri M, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, Carman WF. HBV
core sequence: definition of genotype-specific variability and correlation with geographical origin. J Viral Hepat. Nov 2004;11(6):488-501.
2005
72.
Aora S, Xu C, Teng A, Peterson J, Yeh LT, Gish R, Lau D, Rossi S, Lin CC. Ascending
multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects
with compensated hepatitis C infection. J Clin Pharmacol. Mar 2005;45(3):275-285.
73.
74.
Curriculum Vitae
56
75.
Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J,
Mondou E, Snow A, Sorbel J, Rousseau F, Corey L. Safety and antiviral activity of
emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J
Hepatol. Jul 2005;43(1):60-66..
76.
Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana
RJ, McCashland T, Cotler SJ, Bacon BR, Keeffe EB, Gordon F, Polissar N; National
Hemochromatosis Transplant Registry. Survival after liver transplantation in patients with
hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. Aug 2005;129(2):494-503.
77.
78.
Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G,
Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes
RG; BEHoLD Study Group. A dose-ranging study of the efficacy and tolerability of
entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. Oct
2005;129(4):1198-1209.
79.
80.
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM,
Vierling JM; USA PBC Epidemiology Group (Gish RG). Risk factors and comorbidities in
primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology.
Nov 2005;42(5):1194-1202.
81.
82.
83.
Gores G, Gish R, Sudan D. MELD Exception Guidelines for Candidates with Cholangiocarcinoma. www.unos.org November 21, 2005.
84.
85.
Ham J, Gish R, Mullen K. MELD Exception Guidelines for Candidates with Hepatic
Encephalopathy. www.unos.org November 21, 2005.
86.
87.
Mulligan DC, Gish RG, Krowka MJ. MELD Exception Guidelines for Candidates with
Hepato-pulmonary Syndrome. www.unos.org November 21, 2005.
Curriculum Vitae
57
88.
Garcia-Tsao G, Gish RG, Punch J. MELD Exception Guidelines for Candidates with
Hereditary Hemorrhagic Telangiectasia. www.unos.org November 21, 2005
89.
Horslen S, Gish RG, McDonald R. MELD Exception Guidelines for Candidates with
Primary Hyperoxaluria. www.unos.org November 21, 2005.
90.
Arrazola L, Gish RG, Everson GT. MELD Exception Guidelines for Candidates with
Polycystic Liver Disease. www.unos.org November 21, 2005.
91.
Mulligan DC, Gish R, Krowka MJ. MELD Exception Guidelines for Candidates with
Portopulmonary Hypertension. www.unos.org November 21, 2005.
92.
Washburn WK, Gish R. MELD Exception Guidelines for Candidates with Severe
Pruritus. www.unos.org November 21, 2005.
93.
Gores G, Gish R, Roshan Shrestha, MELD Exception Guidelines for Candidates with
Recurrent Bacterial Cholangitis associated with Structural Biliary Disease. www.unos.org November 21, 2005.
94.
Sheiner P, Gish R, Sunyal A. MELD Exception Guidelines for Candidates with Portal
Hypertensive GI Bleeding. www.unos.org November 21, 2005.
95.
Sheiner P, Gish R, Miller C. MELD Exception Guidelines for Candidates with Small for
Size Syndrome after Liver Transplantation. www.unos.org November 21, 2005.
96.
Punch J, Gish R.MELD Exception Guidelines for Candidates with Uncommon Hepatic
Tumors. www.unos.org November 21, 2005.
97.
2006
98.
99.
Perrillo RP, Gish RG, Peters M, Keeffe EB, Alberti A, Buti M, Cooksley WG, Fried MW,
Hadziyannis SJ, Liaw YF, Naoumov NV, Schiff ER, Thio CL, Tsai N, Schalm S. Chronic
hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol
Hepatol. Feb 2006;4(2):233-248.
100.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH,
Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD
AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive
chronic hepatitis B. N Engl J Med. Mar 2006;354(10):1001-1010.
101.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber
R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group (Gish
RG). Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med. Mar 2006;354(10):1011-1020.
Curriculum Vitae
58
102.
Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM,
Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM.
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol. Oct 2006;78(10):1296-1303.
103.
Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A,
Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus
genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology. Oct 2006;44(4):915-924.
104.
Arrazola L, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD)
exception for polycystic liver disease. Liver Transpl 2006; 12 Suppl 3:S110-S111.
105.
Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for end-stage liver disease
(MELD) exception for ascites. Liver Transpl 2006; 12 Suppl 3:S88-S90.
106.
Freeman RB, Jr., Gish RG, Harper A, Davis GL, Vierling J, Lieblein L et al. Model for
end-stage liver disease (MELD) exception guidelines: Results and recommendations
from the MELD exception study group and conference (MESSAGE) for the approval of
patients who need liver transplantation with diseases not considered by the standard
MELD formula. Liver Transpl 2006; 12 Suppl 3:S128-S136.
107.
Garcia-Tsao G, Gish RG, Punch J. Model for end-stage liver disease (MELD) exception
for hereditary hemorrhagic telangiectasia. Liver Transpl 2006; 12 Suppl 3:S108-S109.
108.
Gores GJ, Gish RG, Shrestha R, Wiesner RH. Model for end-stage liver disease
(MELD) exception for bacterial cholangitis. Liver Transpl 2006; 12 Suppl 3:S91-S92.
109.
Gores GJ, Gish RG, Sudan D, Rosen CB. Model for end-stage liver disease (MELD)
exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl 2006; 12 Suppl
3:S95-S97.
110.
Ham J, Gish RG, Mullen K. Model for end-stage liver disease (MELD) exception for
hepatic encephalopathy. Liver Transpl 2006; 12 Suppl 3:S102-S104.
111.
Horslen S, Sweet S, Gish RG, Shepherd R. Model for end-stage liver disease (MELD)
exception for cystic fibrosis. Liver Transpl 2006; 12 Suppl 3:S98-S99.
112.
Horslen S, Gish RG, McDonald R. Model for end-stage liver disease (MELD) exception
for primary hyperoxaluria. Liver Transpl 2006; 12 Suppl 3:S117-S118.
113.
Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for end-stage liver disease
(MELD) exception for portopulmonary hypertension. Liver Transpl 2006; 12 Suppl
3:S114-S116.
114.
McDiarmid S, Gish RG, Horslen S, Mazariegos GV. Model for end-stage liver disease
(MELD) exception for unusual metabolic liver diseases. Liver Transpl 2006; 12 Suppl
3:S124-S127.
Curriculum Vitae
59
115.
Pomfret E, Gish RG, Brandhagen D. Model for end-stage liver disease (MELD)
exception for familial amyloidotic polyneuropathy. Liver Transpl 2006; 12 Suppl 3:S100S101.
116.
Punch J, Gish RG. Model for end-stage liver disease (MELD) exception for uncommon
hepatic tumors. Liver Transpl 2006; 12 Suppl 3:S122-S123.
117.
Sheiner P, Gish RG, Sanyal A. Model for end-stage liver disease (MELD) exception for
portal hypertensive gastrointestinal bleeding. Liver Transpl 2006; 12 Suppl 3:S112-S113.
118.
Sheiner P, Belghiti J, Gish RG, Miller C. Model for end-stage liver disease (MELD)
exception small-for-size syndrome. Liver Transpl 2006; 12 Suppl 3:S120-S121.
119.
Washburn WK, Gish RG, Kamath PS. Model for end-stage liver disease (MELD)
exception for Budd-Chiari syndrome. Liver Transpl 2006; 12 Suppl 3:S93-S94.
120.
Washburn WK, Gish RG. Model for end-stage liver disease (MELD) exception for
severe pruritus. Liver Transpl 2006; 12 Suppl 3:S119.
121.
Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD)
exception guidelines. Liver Transpl 2006; 12 Suppl 3:S85-S87.
2007
122.
Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV,
Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in
HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25(11):963-977.
123.
Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR,
Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S. Final results of a
double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in
chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology. Mar
2007;45(3):569-578.
124.
Gish RG. Do we need to MEND the MELD? Liver Transpl. Apr 2007;13(4):486-487.
125.
126.
Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M.
Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to
standard immunosuppressive therapy. Clin Gastroenterol Hepatol. Jul 2007;5(7):799802.
127.
Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral
drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a costeffectiveness analysis. Aliment Pharmacol Ther. 2008; Epub 2007 Mar 27.
Curriculum Vitae
60
128.
Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J,
Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of
patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. Jul 2007;25(21):3069-3075.
129.
Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic
hepatitis C. Hepatology. Aug 2007;46(2):324-329.
130.
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee
SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in
patients with HBeAg-positive chronic hepatitis B. Gastroenterology. Nov
2007;133(5):1437-1444. Epub 2007 Aug 14.
131.
132.
Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ,
McCashland TM, Han SH, Gordon FD, Schilsky ML, Kowdley KV. Prevalence of hepatic
iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int. Dec
2007;27(10):1394-1401.
133.
Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon
alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol. Dec 2007;102(12):2718-23. Epub 2007 Jul 27.
134.
Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P,
Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I; USA PBC Epidemiology
Group (Gish RG). Quality of life and everyday activities in patients with primary biliary
cirrhosis. Hepatology. 2007 Dec;46(6):1836-43.
135.
Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH.
The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities
from Infected and Uninfected Persons. Value Health. 2007; Epub 2007 Dec 17.
2008
136.
Gish RG, Jacobson I, Pockros P. Improving HBV Treatment: Early Screening and
Sustained Control for Improved Outcomes. Clinical Roundtable Monograph. Gastroenterology and Hepatology. January 2008.
137.
Gish RG. Comment: Entecavir therapy provides long-term benefit for chronic hepatitis B.
Contemporary Dental Assisting. Reuters Health, 2008.
138.
Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the
American Association for the Study of Liver Disease (Gish RG). Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. Apr
2008;47(4):1363-1370.
Curriculum Vitae
61
139.
Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH.
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from
infected and uninfected persons. Value Health. May-Jun 2008;11(3):527-38.
140.
Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral
drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a costeffectiveness analysis. Aliment Pharmacol Ther. Jun 2008;27(12):1240-1252.
2009
141.
142.
Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of
thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int. Sept 2009; 3(3):480-489.
143.
Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, Cheinquer H,
Bessone F, Brett-Smith H, Tamez R. Results of up to 2 years of entecavir vs lamivudine
therapy in nucleoside-nave HBeAg-positive patients with chronic hepatitis B. J Viral
Hepat. Nov 2009;16(11):784-789.
144.
Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E et al. Safety and efficacy
of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapynaive hepatitis C patients. J Hepatol 2009.
2010
145.
Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H,
Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-nave HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. Jan
2010;17(1):16-22.
146.
147.
Gish RG, Cooper SL. Hepatitis B in the greater San Francisco bay area: an integrated
program to respond to a diverse local epidemic. Aug. 2010: J Viral Hep.
148.
2011
149.
Gish RG, Satishchandran C, Young M, Pachuk C. RNA Interference and its Potential
Applications to Chronic HBV Treatment: Results Of A Phase 1 Safety And Tolerability
Study. Antivir Ther. 2011;16(4):547-554.
Curriculum Vitae
62
150.
151.
152.
153.
Gish RG, Cooper SL, Hepatitis B in the Greater San Francisco Bay Area: An Integrated
Programme to Respond to a Diverse Local Epidemic, Journal of Viral Hepa Apr; 18(4):
e40-51, April 2011.
154.
Han SH, Reddy KR, Keefe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok
A and the NIH HBV OLT study group. Clinical Outcomes Of Liver Transplantation For
Hbv-Related Hepatocellular Carcinoma: Data From The NIH HBV OLT Study. Clin
Transplant. 2011 Mar-Apr;25(2):E152-E162.
155.
156.
Cohen C, Holmberg SD, McMahon Bi, Block JM, Brosgart CL, Gish RG, London WT,
Block TM, Is Chronic Hepatitis B Being Undertreated in the United States?, Journal of
Viral Hepatitis, Jun;18(6):377-83. June 18, 2011.
157.
Cachey ER, Wyles DL, Goiceochea M, Torriani FJ, Ballard C, Colwell B, Gish RG,
Mathews WC. Reliability And Predictive Validity Of A Hepatitis-Related Symptom Inventory In HIV-Infected Individuals Referred for Hepatitis C Treatment. AIDS Res & Ther.
2011 Aug 10;8:29.
158.
Gish, RG, Kaveh H. HBV screening in asians and pacific islanders: interim costeffectiveness analysis of a single-enter San Francisco program; Journal of Epide and
Com Health. 2011 Sept (1).
2012
159.
160.
161.
Kuo A, Gish R. Chronic Hepatitis B Infection. Clin Liver Dis. 2012 May;16(2):347-369.
Curriculum Vitae
63
162.
Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar Risk of Renal
Events among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B. Clin
Gastroenterol Hepatol. 2012 Aug; 10(8):941-946.
2013
163. Gish RG, Chang, Lai CL, Ade Man R. Quantitative Hepatitis B surface antigen analysis i
Hepatitis B E-antigen in positive, nucleoside-nave patients treated with encantavir, antiviral therapy, AVT-12-OA-2806.R1, 2013 Mar(6):
164. Gish RG, Hana YD, Kane S, Clark M, Mangahas M, Baqai S, Winters M, Proudfoot, J,
Glenn JS,. Coinfection with Hepatitis B and D: epidemiology, prevalence and disease in
patients in northern California.
165. Gish RG, et al, One-Step Real-Time PCR Assay for Detection and Quantitation of
Hepatitis D Virus RNA"; Journal of Virological Methods, # VIRMET-D-13-00111R1
2014
166. Kim S, Syed G, Khan M , Chiu W, Sohail M, Gish R, Siddiqui A, "Hepatitis C Virus
Triggers Mitochondrial Fission and Attenuates Apoptosis to Promote Viral Persistence
Proc Natl Acad Sc,#:2013-21114RR 19Mar-2014.
166. Wong RJ, Gish RG; Implementing Best Practices When Initiating Hepatitis B Virus
Therapy, Clin in Liv Dis, Apr-2014.
167. Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, Locarnini S,
Hammond R, Bowden S; A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation, Journal of Viral Hep,
doi:10.1111/jvh.12257, accepted for publication, 15 March 2014.
168. Wong RJ, Gish, RG, Aijaz, A; Hepatic Encephalopathy is Associated with Significantly
Increased Mortality Among Patients Awaiting Liver Transplantation, Journal of Liver
Transplant, accepted for publication, 8 June 2014.
169. Ahn J, Gish, RG., Hepatitis D in 2014- a Call to Screening, accepted for publication,
Gastroenterology Hepatology, accepted for publication, 8 June, 2014.
170. Gish RG, Kono Y, Kartik J, Loomba R, Patton H , Alexander K, Mendler M; Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the United States,
Digestive Disease Science Journal, manuscript ID# DDSJ-D-14-00596R, accepted for
publication, 14June 2014.
171. Gish RG, Lands L, et al; Immunosuppression in Patients with Chronic Hepatitis B,
Current Hepatology Reports, Article 238, DOI: 10.1007/s11901-014-0238-2, Editorial
manuscript number: HEPS-D-14-00018.0, accepted for publication, 11 June 2014.
Curriculum Vitae
64
172. Seetharam A, Perillo RP, Gish RG; Immunosuppression in Patients with Chronic
Hepatitis B, DOI 10.1007/s11901-014-0238-2; Curr Hepatology Rep; 21 June 2014.
173. Perillo RP, Gish RG, Seetharam A, Lands L; Medical Interventions Associated with
HBV Reactivation: Common and Less Common, Clinical Liver Disease, Manuscript ID
CLD-14-0060, 10 July 2014 Perillo RP, Gish RG, FalckYtter YT; American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis
B Reactivation during Immunosuppressive Drug Therapy; Gastroenterology Press, 2014.
174. Donald G. Mitchell DG, Bruix J, Sherman M, Sirlin CB; LI-RADS (Liver Imaging Reporting and Data System): Summary, Discussion, and Consensus of the LI-RADS Management Working Group and Future Directions; Manuscript ID HEP-14-0736.R1.27304;
Heptalology 18July, 2014; co-author via the study consortium and acknowledgements.
175. Wong RJ, Gish RG; Implementing Best Practices When Initiating Hepatitis B Virus
Therapy, Critical Issues in HBV, Volume I Number I, Aug 2014. Also available through
VINDICO medical education, OpenCME.org and the Healio.com/InfectiousDisease/Education-Lab.
Curriculum Vitae
65
1.
Gish RG. Successful domino liver transplantation from a patient with methylmalonic
acidemia: first ever report. American Association for the Study of Liver Dis
ease, Liver Transplantation, Manuscript ID LT-12-522.R1; 2013 Mar(6):
2.
3.
Gish, RG, Mendler M, Kono Y, Joshi K, Loomba R, Kuo A, Patton H. HCC Surveillance: An Inquiry into Current Practices in the United States: National Survey of HCC
Surveillance Practices. Am Journ of Gastrentrol; Dec 2013. Submitted for publication.
4.
5.
Wong RF, Gish RG, Aijza, A: Hepatic Encephalopathy is Associated with Significantly
Increased Mortality Among Patients Awaiting Liver Transplantation, 5 Mar-2014. submitted for publication.
6.
Baqai SF, Hana D, Zeng L, Gish RG. Entecavir Effective for Both TreatmentExperienced and Treatment-Nave Chronic Hepatitis B Patients in Real Life Settings,
Lark Scientific, Mar-2014.
7.
Mitchell, DG, Bruix, J, Sherman, M, Sirlin, CB. Gish, RG. RADS (Liver Imaging Reporting and Data System): Summary, Discussion, Consensus of the LI-RADS Management
Working Group and Future Directions. Journ of Hep: 30 Mar-2014.
8.
Gish RG, Wong, et al., Etiology of Underlying Liver Disease Impacts Post-Liver Transplantation Survival among Patients with Hepatocellular Carcinoma, Hepatology, Manuscript ID HEP-14-1069, 7 May 2014.
9.
Baqai S, Proudfoot J, Yi D, Mangahas M, Gish RG, High rate of core promoter and
precore mutations in patients with chronic hepatitis B and their impact on the liver disease, submitted for publication, Hepatology International, 25 May 2014.
10.
Gish RG, Brosgart CL, Clary R, Block JM, Block TM, Lelt, Knowdley KV; The CDC
Underestimates the Prevalence of Chronic Hepatitis B in the U.S., advocacy letter submitted for publication, Hepatology, 11 June 2014.
11.
Gish RG, Brosgart CL, Clary R, Block JM, Block TM, Lelt, Knowdley KV; The CDC
Underestimates the Prevalence of Chronic Hepatitis c in the U.S., advocacy letter submitted for publication, American Association for the Study of Liver Disease (AASLD), 11
June 2014.
Curriculum Vitae
66
12.
Gish RG, Wong, et al., Etiology of Underlying Liver Disease Impacts Post-Liver Transplantation Survival among Patients with Hepatocellular Carcinoma, American Association for the Study of Liver Disease, manuscript ID# LT-14-348, submitted for publication,
24 June 2014.
13.
Wong RJ, Gish, RG, Aijaz, A., Hepatic Encephalopathy is Associated with Significantly
Increased Mortality Among Patients Awaiting Liver Transplantation" American Association for the Study of Liver Disease, manuscript ID# LT-14-198.R3, submitted for publication, 26 June 2014.
14.
Reddy KR, Beavers KL, Hammond SP, Lim JK, Lim, Falck-Ytter YT, et al., American
Gastroenterological Association Institute Guideline on the Prevention and Treatment of
Hepatitis B Reactivation During Immunosuppressive Drug Therapy, Gastroenterology,
submitted for publication, 26 June 2014.
15.
Wong RJ, Gish RG, Implementing Best Practices When Initiating Hepatitis B Virus
Therapy, Vindico Medical Education; http://www.vindicomeded.com, monograph submitted for publication; 11 July 2014.
16.
Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, De Man RA, Llamoso
C, Tang H; Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA in
Chronic Hepatitis B, submitted for publication, World Journal of Gastroenterology,
1Aug2014.
17.
Yu K, Tran B, Gish RG; Expanding Hepatitis B Screening in Asian and Pacific Islander
Americans in San Diego County: Needs Assessment and Linkage to Care, Abstract
Poster presented for California Pharmacists Association, San Diego, 10April, 2015.
18.
19.
Nguyen CT, Tran B, Fontanesi J, Gish RG, Point-of-care testing for hepatitis C screening at Community-Based-Organizations facilitates disease control, submitted for publication, Amer Journ Pub Health, Oct2014.
20.
Phan X, Tran B, Tang G, Fontanesi J, Gish RG, Targeting populations at risk for
hepatitis B: Demographic Considerations, submitted for publication, Amer Journ Pub
Health, Oct2014.
21.
22.
Tran B, Nguyen K, Adler D, Gish RG, Pearls gained from hepatitis B screening in the
Community setting, submitted for publication, Amer Journ Pub Health, Oct2014.
Curriculum Vitae
67
1.
Glassman P, Wong C, Gish R. A review of liver transplantation for the dentist and
guidelines for dental management. Spec Care Dentist. Mar-Apr 1993;13(2):74-80. Review.
2.
Gish RG, Ascher NL. Transmission of hepatitis B virus through allotransplantation. Liver
Transpl Surg. Mar 1996;2(2):161-164.
3.
Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis. 1999;19 Supl
1:35-47. Review.
4.
Gish RG. Future directions in the treatment of patients with chronic hepatitis C virus
infection. Can J Gastroenterol. Jan-Feb 1999;13(1):57-62. Review.
5.
Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Curr
Gastroenterol Rep. Feb-Mar 1999;1(1):20-26. Review.
6.
Gish RG, Mason A. Autoimmune liver disease. Current standards, future directions. Clin
Liver Dis. May 2001;5(2):287-314. Review.
7.
Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. Mar
2004;33(1 Suppl):S1-9.
8.
Gish RG. Clinical trial results of new therapies for HBV: implications for treatment
guidelines. Semin Liver Dis. 2005;25 Suppl 1:29-39. Review.
9.
Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in
special populations: patient and treatment considerations. Clin Gastroenterol Hepatol.
Apr 2005;3(4):311-8. Review.
10.
Gish RG. Current treatment and future directions in the management of chronic hepatitis
B viral infection. Clin Liver Dis. Nov 2005;9(4):541-65, v. Review.
11.
Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J
Antimicrob Chemother. Jan 2006;57(1):8-13. Epub 2005 Nov 17. Review.
12.
Pawlotsky JM, Gish RG. Future therapies for hepatitis C. Antivir Ther. 2006;11(4):397408. Review.
13.
14.
Chang TT, Gish R, de Man R, Gadano A, Sollano J, Han KH, et al. Management of
chronic hepatitis B virus infection: Current perspectives for the nurse practitioner. Journal of the American Academy of Nurse Practitioners. May 2006;18(5):203-215. Review.
15.
16.
Gish RG. Setting Up an Outreach Clinic and Tertiary-Quaternary Medical Care Program.
Gastroenterology and Hepatology. May 2006;2(5): 384-385. Review.
Curriculum Vitae
68
17.
Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol. Jun 2006;4(6):666-676. Review.
18.
Gish RG. Current developments in the treatment of hepatitis and hepatobiliary disease.
Clin Adv Hematol Oncol. Jul 2006;4(7):511-512.
19.
Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl. Nov
2006;12(11 Suppl 2):S54-64. Review.
20.
Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and
implications for management. J Viral Hepat. Dec 2006;13(12):787-798. Review.
21.
Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol
Rep. Mar 2007;9(1):14-22. Review.
22.
Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res. Jul
2007;37(s1):S67-78.
23.
Gish RG, Perrillo RP, Jacobson IM. Customizing the management of chronic hepatitis B
virus infection. Semin Liver Dis. Aug 2007;27 Suppl 1:9-17. Review.
24.
Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin
Liver Dis. Nov 200711(4):761-95, viii. Review.
25.
Gish RG, Baron A. Hepatocellular carcinoma (HCC): Current and evolving therapies.
IDrugs. Mar 2008;11(3):198-203.
26.
Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The
degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.
27.
Gish RG, Hisatake G. Improving clinical trial design for hepatocellular carcinoma
treatments. Oncology Reviews. May 2007;1(1):45-52.
28.
Gish R, Marrero JB, Tong MJ. Medical therapies to extend survival in hepatocellular
carcinoma. Clin Adv Hematol Oncol. Aug 2008;6(8):1-14.
29.
Gish RG, Miyashita L. Sorafenib offers a new treatment for liver cancer new
medication shown to improve survival in clinical trials. Liver and GI Review. Winter
2008, No.24.
30.
Gish RG. Diagnosis of chronic hepatitis B and the implications of viral variants and
mutations. Am J Med. Dec 2008;121(12 Suppl):S12-21.
31.
Gish RG, Benson AB, Sherman M, Morgan BS. Cases in point: risk factors, surveillance
strategies and treatment options for HCC. Gastroenterol Hepatol. Jan 2009;5(1)Suppl
3:1-16.
32.
Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J
Med. May 2009;76(Suppl 3):S14-19.
Curriculum Vitae
69
33.
Gish RG, Gholam PM. Monotherapy vs multiple-drug therapy: the experts debate. Cleve
Clin J Med. May 2009;76(Suppl3):S20-24.
34.
Gish RG. Therapy for hepatitis B: la nouvelle vague. Can J Gastroenterol. June
2009;23(6):407-409.
35.
Frenette CT, Gish RG. To be or not to be that is the question. Am Gastroenterol. Aug
2009;104(8):1948-1952.
36.
Drug Effectiveness Review Project (DERP) team, Oregon Health & Science University,
Grant Funding from Attorney General Consumer, Prescriber Grant Program, and Consumer Reports. Consumer Reports Best Buy Drugs. Consumer Reports. 2010.
37.
Gish RG, Marrero JA, Benson AB. A multidisciplinary to the management of hepatocellular carcinoma. Gastroenterol Hepatol 2010 Mar:6(3 Suppl 6):1-16. Clinical Roundtable
Monograph
38.
Gish RG, Abou-Alfa GK, Tong MG. Integrating recent data in managing adverse events
in the treatment of hepatocellular carcinoma. Clin Adv Hematol Oncol. 2010 Sep;8(9):2p
preceding 4-15. Clinical Roundtable Monograph
39.
Frenette C, Gish RG. Hepatocellular Carcinoma: Molecular and Genomic Guide for the
Clinician.Clin Liv Dis. 2011 May;15(2):307-321. Review
40.
Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers?
Clin Liv Dis. 2011 Aug;15(3):627-639. Review
41.
42.
Frenette CT, Frederick RT, Gish RG. Clinical Management and Case Reports for the
Treatment of Hepatocellular Carcinoma with Sorafenib. J Clin Gastroenterol. 2011
Sept;45(8):733-737 Case report
43.
44.
Gish RG, Society of interventional radiology critique and commentary on the cochrane
report on transarterial (chemo)embolization. American Association for the Study of Liver
Disease, Hepatology, HEP-12-0552; March 22, 2012.
45.
Gish RG, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with
high barrier to resistance. Lancet Infect Dis. 2012 Apr;12(4):341-353. Review
46.
Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoms. Expert Rev
Gastroenterol Hepatol. 2012 Apr;6(2):173-185. Review.
Curriculum Vitae
70
47.
Gish, RG, Marrero, J., Finn R. Extending survival with the use of targeted therapy for the
treatment of hepatocellular carcinoma. CAHO/G&H roundtable monograph, Clinical Advances in Hematol/Oncol, Millennium Medical Publishing, Inc. 2013 Feb;4: page numbers. Review.
48.
Gish RG. Strategies for hepatocellular carcinoma surveillance and diagnosis. Gastroenterol Hepatol. 2013 Apr;V9(4): page numbers. Review.
49.
1.
Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, Trinh HN; International
Group for Liver Health in Viet Nam. Liver Disease In Viet Nam: Screening, Surveillance,
Management And Education: A 5-Year Plan And Call To Action. J Gastroenterol Hepatol. 2012 Feb;27(2):238-247.
Curriculum Vitae
71
NEWSLETTERS
1.
Gish RG, Osorio R. New Techniques and Devices are Revolutionizing Liver Transplantation and Therapy. Pacific Currents, May 2000. Available at:
http://www.cpmc.org/professionals/research/currents/2000LiverTX.html.
2.
Gish RG. The Future of Western Treatment for Hepatitis C. HCV Advocate Medical
Writers Circle. March 2002. Available at: http://www.hcvadvocate.org/hcsp/board.asp.
3.
Gish RG. Overview of Treatment of Hepatitis B. HCV Advocate Medical Writers Circle.
April 2003. Available at: http://www.hcvadvocate.org/hcsp/board.asp.
4.
Gish RG. Minimizing the Impact of Neuropsychiatric Effects During Chronic HCV
Disease and Treatment. HCV Advocate Medical Writers Circle. April 2004. Available
at: http://www.hcvadvocate.org/hcsp/board.asp.
5.
6.
Gish RG, comment in: LoBuono C. New drug marks advance in treatment of hepatitis
B. Drug Topics: The News Magazines for Pharmacists. May 2, 2005.
7.
Gish RG. Future Therapies for Hepatits C. HCV Advocate Medical Writers Circle. Feb
2006. Available at: http://www.hcvadvocate.org/hcsp/board.asp.
8.
9.
Gish RG. Multimodality Approach to the Treatment of HCC: The Emerging Paradigm.
Newsletter from 58th Annual AASLD, Boston, MA, November 2007.
Gish RG. Ischemic and Congestive Liver Disease. In: Gitnick, G, ed. Principles and
Practice of Gastroenterology and Hepatology. New York: Elsevier Science Publishing
Co., 1988: 1346-1352.
2.
Gish RG. Ischemic and Congestive Liver Disease. In: Gitnick, G, ed. Principles and
Practice of Gastroenterology and Hepatology. New York: Elsevier Science Publishing
Co., 1988: 1346-1352.
3.
Gish RG, Keeffe EB. The Short Bowel Syndrome. In: Snape, W, ed. Consultations in
Gastroenterology. Cambridge, Mass: W.B. Saunders Company, 1995.
4.
Gish RG, Keeffe EB. The Short Bowel Syndrome. In: Snape, W, ed. Consultations in
Gastroenterology. Cambridge, Mass: W.B. Saunders Company, 1995.
5.
Gish RG, Keeffe EB. Recent developments in the treatment of chronic hepatitis B virus
infection. Expert Opinion on Investigational Drugs. Feb 1995;4(2):95-115.
Curriculum Vitae
72
Gish RG, Keeffe EB. Recent developments in the treatment of chronic hepatitis B virus
infection. Expert Opinion on Investigational Drugs. Feb 1995;4(2):95-115.
7.
Gish RG. Evolving therapies for the treatment of viral hepatitis. Ed. W. C. Bowman, J.
D. Fitzgerald and J. B. Taylor. Emerging Drugs: The prospect for improved medicines
annual executive briefing. Vol 1. London: Ashley Publications Ltd, 1996.
8.
Gish RG, Cox KL, Mizokami M, Ohno T, Lau JY. Vertical transmission of hepatitis C.
(letter) J Pediatr Gastroenterol Nutrition. Jan 1996;22(1):118-119.
9.
Gish RG. Evolving therapies for the treatment of viral hepatitis. Ed. W. C. Bowman, J.
D. Fitzgerald and J. B. Taylor. Emerging Drugs: The prospect for improved medicines
annual executive briefing. Vol 1. London: Ashley Publications Ltd, 1996.
10.
Gish RG. Hepatitis C virus: Seven years old. Viral Hepatitis Reviews. 1997;3(1):17-37.
11.
Gish RG, Lau JYN. Hepatitis C Virus: Eight Years Old. Viral Hepatitis Reviews. Mar
1997;3(1):17-37.
12.
Gish RG. Liver physiology and pathology. Chapter 20, "Liver." Gastroenterology
Nursing: A Core Curriculum. 2nd ed. St.Louis, Missouri: Mosby-Year Book, Inc., Apr
1997.
13.
Gish RG. Liver physiology and pathology. Chapter 20, "Liver." Gastroenterology
Nursing: A Core Curriculum. 2nd ed. St.Louis, Missouri: Mosby-Year Book, Inc., April
1997.
14.
Gish RG and Olden K. Alcohol and liver disease should transplantation be offered? Practical Gastroenterology. Dec1997.
15.
Gish RG. Review of computer program "A simplified approach to the management of
patients with chronic hepatitis B and C infections." Gastroenterology. Dec 1997.
16.
Gish RG, Locarnini S. Chronic Hepatitis B Viral Infection. In: Yamada and Alpers, eds.
Textbook of Gastroenterology. Vol. 2.;107:2309-2327. Lippincott Williams & Wilkins,
1998.
17.
Gish RG, Locarnini S. Chronic Hepatitis B Viral Infection. In: Yamada and Alpers, eds.
Textbook of Gastroenterology. Vol. 2.;107:2309-2327. Lippincott Williams & Wilkins,
1998.
18.
19.
Gish, RG, Wakil AE. Combination interferon-alfa 2B plus ribavirin for treatment of
chronic hepatitis C. Current Practice of Medicine. 1999;2(4-10).
20.
Gish RG, Baker EL. Imaging Before and After Liver Transplantation. Imaging in
Hepatobiliary and Pancreatic Disease, 1999.
Curriculum Vitae
73
Gish RG, Baker EL. Imaging Before and After Liver Transplantation. Imaging in
Hepatobiliary and Pancreatic Disease, 1999.
22.
23.
Gish RG. Counseling the Patient with Chronic Hepatitis C. Practical Hepatitis Update,
1999.
24.
Poordad FF, Gish RG. Development in hepatitis C during 1997 1999. Expert Opinion
on Therapeutic Patents. Sep 1999;9(9):1249-1262.
25.
Cohen MR, Gish RG and Doner K. The hepatitis C help book: a groundbreaking
treatment program combining Western and Eastern medicine for maximum wellness and
healing. 1st ed. New York: St. Martins Press, 2000.
26.
27.
Gish RG. Treatment of Chronic HBV in Transplant recipients. In: Stuart Gordon, MD,
ed. Management of Chronic Viral Hepatitis. Marcel Dekker, 2001.
28.
Gish RG. HCV: Molecular Tools for Measuring Treatment Responses. In: American
College of Gastroenterology Clinical Guidelines. ACG, 2001.
29.
Gish RG. Prevention and treatment of hepatitis B in liver transplant recipients. In:
Arroyo, Bosch, Bruix, Gines, Navasa, and Rodes, eds. Therapy in Hepatology. Barcelona: Ars Medica, 2001:183-191.
30.
Lok AS, Heathcote EJ, Hoofnagle JH, Gish RG (subauthor). Management of hepatitis B:
2000 summary of a workshop. Gastroenterology. Jun 2001;120(7):1828-1853.
31.
Gish RG. Approach to the Patient With Hepatomegaly. In: David Rossman, MD, ed.
Best Practice of Medicine. Praxis Press, 2002.
32.
Lau G, Gish R, Liang R. Hepatitis B Infection and Immunosuppression. Chapter 12. In:
Locarnini S and Lai L, eds. Hepatitis B Virus Guide. London: International Medical
Press, 2002.
33.
Gish RG, Wakil A. Hepatitis B in liver transplant recipients as a special model of antiviral
drug development. Methods Mol Med, Hepatitis B and D Protocols II. 2004;96:319-341.
34.
Gish RG, Locarnini S. Studying the treatment of chronic hepatitis B viral infection in
special populations. Methods Mol Med, Hepatitis B and D Protocols III. 2004;96:465498.
35.
Gish RG, Lau J, Fang J, Mizokam M, Wright T. Hepatitis C. In: J. Larry Jameson, ed.
Principles of Molecular Medicine. Humana Press, March 2004.
36.
Gish RG. Maximizing the benefits of antiviral therapy for HCV: the advantages of
treating side effects. [editorial] Gastroenterol Clin North Am. Mar 2004;33(1 Suppl):xxiiixxiv.
Curriculum Vitae
74
Gish RG. Overview of Hepatitis C. St. John and Sandt, eds. Hepatitis C Choices. 3rd
Edition. Hepatitis C Caring Ambassadors Program, 2004:1-6.
38.
Gish RG. Future of Allopathic Hepatitis C Treatment. St. John and Sandt, eds.
Hepatitis C Choices. 3rd Edition. Hepatitis C Caring Ambassadors Program, 2004:125134.
39.
Gish RG. Flamm S, Fried M, Pockros P. Supporting Patients With Chronic Hepattis C
During Therapy. Special Report. January 1, 2005.
40.
41.
Gish RG. Hepatitis C: Current Standards of Care and Future Perspectives. HCV
Advocate Medical Writers Circle. May 2006. Available at:
http://www.hcvadvocate.org/hcsp/board.asp.
42.
Gish RG. Principles of Molecular Medicine. 2nd Ed. Totowa, NJ: Humana Press,
2006. ISBN: 1-58829-202-9.
43.
Gish RG. Risk Factors and Treatment for Hepatocellular Carcinoma. Advances in
Hepatology. Gastroenterology & Hepatology. Volumne 2, Issue 7. July 2006.
44.
Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The
degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.
45.
Gish RG, Locarnini S. Chronic hepatitis B viral infection. Chapter 81. In: Yamada T,
Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW. (Eds) Textbook of Gastroenterology. Oxford, England. Blackwell Publishing, 2009: 2112-2138.
46.
47.
48.
Gish RG, Tam D. Bui MD, PhD, Chuc T.K. Nguyen, Pharm PhD, Duc T. Nguyen, MS,
PhD, Huy V. Tran, MD, PhD, Diem M.T. Tran, Huy N. Trinh, MD, AGAF, International
Group for Liver Health in Vietnam (ILFVN), Liver Disease in Viet Nam: Screening, Surveillance, Management and Education A Five Year Plan and Call To Action, September, 2011.
49.
Gish, RG, HBV Screening in Asians and Pacific Islanders: Interim Cost-effectiveness
Analysis of a Single-center San Francisco Program, Journal of Epidemiology & Community Health, January 2012.
Curriculum Vitae
75
1.
Huibregtse K, Gish RG, Tytgat GN. A frightening event during endoscopic papillotomy.
[letter] Gastrointes Endosc. Jan-Feb 1988;34(1):67-68.
2.
Gish RG, Cox KL, Mizokami M, Ohno T, Lau JY. Vertical transmission of hepatitis C.
(letter) J Pediatr Gastroenterol Nutrition. Jan 1996;22(1):118-119.
3.
4.
Gish RG. Do we need to MEND the MELD? [comment] Liver Transpl. Apr
2007;13(4):486-487.
Curriculum Vitae
76
1.
Gish RG. Section Editor, Hepatitis B: Epidemiology, Natural History, Treatment, and
Transplantation. Current Hepatitis Reports. May 2003;2(2):49-59, 63-87.
2.
Schreibman IR, Schiff ER. Entecavir: A Novel Treatment for Chronic Hepatitis B
Infection. Gish RG, ed. Future Virology. Sep 2006;1(5):541-552.
3.
4.
5.
6.
Gish RG, Section Editor. Treatment and Antiviral Drug Resistance. Current Hepatitis B
Reports. Aug 2007;1(1).
7.
Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK,
Schalm SW, Naoumov NV. Genetic characteristics of hepatitis B virus genotypes as a
factor for interferon-induced HBeAg clearance. Gish RG, journal editor. J Med Virol. Aug
2007;79(8):1055-63.
8.
Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin
Liver Dis 2007; 11(4):761-95, viii.
9.
Gish RG, Reviewer/Editor. Gankang Granula Therapy showed Potent Antiviral Activity
in Chronic Hepatitis B. 2007.
10.
Gish RG, Reviewer/Editor. The treatment of chronic hepatitis B focus on adefovir like
antivirals. 2007.
11.
12.
13.
Ting-Tsung Chang, You-Chen Chao, Vladimir V. Gorbakov, Kwang-hyub Han, Gish RG,
Robert de Man, Hugo Cheinquer, Fernando Bessone, Helena Brett-Smith, Ricardo
Tamez. Summary of an International Study of Entecavir for the Management of Nucleoside-Nave HBeAg-positive Patients With Chronic Hepatitis B. Manuscript AJG-081370. American Journal of Gastroenterology. Submitted August 2008.
14.
Gish, RG, Expert Reviewer, French National Cancer Institute, "Program of comprehensive research actions: Hepatocellular Carcinoma." 2008.
15.
Gish, RG, Expert Reviewer. Wong, WS and Chan, Henry LY, HCC: Prevention and
Control in Low and Middle Income Countries, October 2011.
Curriculum Vitae
77
Gish, RG, Reviewer. Higher baseline transaminases predict cirrhosis while longer time
of adherence to antiretroviral therapy is linked to favorable virological outcome in HIVHBV-co-infected patients. Manuscript for HIV Clincal Trials. 2008.
17.
James Fung, Ching-Lung Lai, Yasuhito Tanaka, Masashi Mizokami, John Yuen, Danny
Wong, Ting-Kin Cheung, Man-Fung Yuen. The duration of lamivudine therapy for chronic hepatitis B: Cessation versus continuation of treatment after HBeAg seroconversion.
Gish R, reviewer. GUT Journal. 2008.
18.
19.
Reviewer for Grant Application, National Research Foundation South Africa (NRF).
20.
21.
22.
Gish RG, Section Editor. Epidemiology and Natural History of Hepatitis B in Vietnam.
2008.
23.
Gish RG, Section Editor. HBV Prevalence, Natural History, and Treatment in Eastern
Europe, Turkey, and Turkish-Speaking Countries in Central Asia. 2008.
24.
Gish RG, Section Editor. Hepatitis B Virus Prevalence, Natural History, and Treatment
in Africans in Africa and the United States. 2008.
25.
Gish RG, Section Editor. HBV Prevalence, Natural History, Treatment, and Resistance:
a 2008 Update with a Special Perspective on Individuals from the Indian Subcontinent.
2008.
26.
Gish RG, Section Editor. Epidemiology, Presentation, and Treatment of Chronic HBV
Infection in Mainland China, in Taiwan, and in Chinese Americans in the United States.
2008.
Gish RG, Section Editor. HBV Prevalence, Natural History, and Treatment in Korea and
the United States. 2008.
27.
28.
Gish RG, Medical Reviewer. Understanding HCV A Patient Pocket Guide. 2009.
29.
Gish Robert G. Hepatitis B in the Greater San Francisco Area: An Integrated Program
to Respond to a Diverse Local Epidemic. Clinical Gastroenterology and Hepatotolgy.
Submitted for publication. 2009.
30.
31.
32.
Curriculum Vitae
78
Gish, R., Reviewer. Evaluation of the merits of the evidence regarding the identification
of hepatitis C virus (HCV) and HCV-Related Chronic Disease Among {ersons Born from
1945 to 1965, Division of Viral Hepatitis at the Centers for Disease Control and
Prevention.
34.
35.
Gish, R., Reviewer. Rationale For Selecting Chronic Hepatitis B Therapy With a High
Barrier to Resistance, The Lancet Infectious Diseases. Elsevier Ltd., THELANCETID-D10-00628R1;October 2011.
36.
Gish, R., Reviewer. Hepatitis B: Treatment and Clinical Trials, AASLD, San Francisco,
CA. October 2011.
37.
38.
Gish, R, Reviewer and Consultant, Screening for Hepatitis C Virus Infection in Adults,
Agency for Healthcare Research and Quality (AHRQ) HCV, December 2011.
39.
40.
Assessment of Professor Jun Yu, Chinese University of Hong Kong; January 13, 2013.
41.
Member, Hepatitis B: Treatment and Clinical Trials abstract review committee, American
Association for the Study of Liver Diseases (AASLD) Digestive Disease Week (DDW).
January 4, 2013.
42.
MD Thesis (Professor Chan See Ching). External Reviewer / Examiner, The University
of Hong Kong. May 31, 2013.
43.
44.
45.
46.
47.
Curriculum Vitae
79
"Zinc Monotherapy is Effective in Wilsons Disease Patients with Mild Liver Disease
Diagnosed in Childhood: A Retrospective Study," Alimentary Pharmacology & Therapeutics - APT-0841-2013, August 2013. 2013: Abstract Reviewer, Primary Surgical Resection versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients" (DDSJ-D-13-01088R); Digestive Diseases and Sciences, 2013.
49.
2014: Peer Abstract Reviewer, Digestive Disease Week 2014, American Association
for the Study of Liver Disease, McCormack Place, Chicago, IL
50.
Digestive Disease Week 2014: American Association for the Study of Liver Disease
(AASLD) Abstract Reviewer, Jan-2014.
51.
Reviewer, Chronic hepatitis B prevalence among children and mothers: results from a
nationwide, population-based survey in Lao People's Democratic Republic, Open Access Public Library of Science, PONE-D-13-44773R1, EMID:ccb2186b7e4e406c,
15Jan-2014.
52.
53.
Curriculum Vitae
80
Curriculum Vitae
81
PUBLICATIONS: ABSTRACTS
1.
Gish RG, Kaplowitz N, Langer AB. Calcium compartmentation and exchange rates in
rat hepatocyte monolayers. Hepatology. 1987;7:1128. Presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, 1987.
2.
3.
Young SG, Linton MF, Hubl ST, Gish RG, Esquivel CO, Wardell M, Concepcion W,
Nakazato P, Hardiman M. APO-E and APO-B phenotypes following liver transplantation. Clin Res. 1990;38:483A. Presented at the American Federation for Clinical Research Meeting, 1990.
4.
5.
Nakazato P, Gish RG, Cox K, Berquist W, Concepcion W, Imperial J, Burns W, GarciaKennedy R, Esquivel CO. Incidence of incidental hepatocellular carcinoma in endstage
liver disease patients undergoing liver transplantation with pre-transplant hepatitis C antibody reactivity. Hepatology. 1991;14:60A. Presented at the AASLD Liver Meeting,
1991.
6.
Fry KE, Gish RG, Nakazato P, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis
JB, Warmerdam M, Moeckli R, Yun-Chae K. Hepatitis C antibody testing in patients with
chronic liver disease. Gastroenterology. 1991;100:A742. Presented at the AASLD Liver
Meeting, 1991.
7.
Gish RG, Fry KE, Concepcion W, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis
JB, Warmerdam M, Moeckli R, Yun-Chae K. Hepatitis C infections in patients with orthotopic liver transplantation. Presented at the American Gastroenterology Association
(AGA) Meeting, 1991.
8.
Gish RG, Fry KE, Concepcion W, Reyes GR, Kuramoto RK, Lim J, Yarbough PO, Zeldis
JB, Warmerdam M, Moeckli R, Yun-Chae K. Early seroconversion to non-C100-3 antigens in acute HCV hepatitis. Gastroenterology. 1991;100:A747. Presented at the AGA
Meeting, 1991.
9.
10.
11.
Gish RG, Lee AH, Rome H, Concepcion W, Esquivel CO, Keeffe EB. Liver transplantation (OLTx) for patients with alcoholism and endstage liver disease. Hepatology. October 1992:A941. Presented at the AASLD Liver Meeting, 1992.
12.
Gish RG, Imperial JI, Esquivel CO, Keeffe EB. Ganciclovir treatment of severe hepatitis
B virus infection. Gastroenterology. April 1993;104:A908. Presented at the AGA Meeting, 1993
Curriculum Vitae
82
Gish RG, Concepcion W, So SKS, Esquivel CO, Keeffe EB. Orthotopic liver transplantation for hepatitis B virus cirrhosis; potential efficacy of therapy with HBIG. Gastroenterology. April 1993;104:A908. Presented at the AGA Meeting, 1993.
14.
Gonzales-Peralta RP, Fang JWS, Davis GL, Gish RG, Mizokami M, Kohara M, Mondelli
M, Lesniewski R, Phillips I, Lau JYN. Optimization for the detection of viral hepatitis C
(HCV) antigens in liver. Gastroenterology. April 1993;104:A909. Presented at the AGA
Meeting, 1993.
15.
Twu JS, Sherker AH, Fung K, Fernandez J, Yarbough PO, Gish RG, Bradley DW,
Robinson WS, Reyes GR. Hepatitis E virus infection of primary human hepatocytes and
identification of neutralizing antibodies. Presented at the International Symposium on Viral Hepatitis and Liver Disease, Eighth Triennial Congress, Tokyo, Japan, May 1993.
16.
Twu JS, Sherker AH, Fung K, Fernandez J, Gish RG, Bradley DW, Robinson WS,
Reyes GR. Inhibition of hepatitis E virus replication by Ribavirin, iron and human alphaInterferon in primary human hepatocyte culture. Presented at the International Symposium on Viral Hepatitis and Liver Disease, Eighth Triennial Congress, Tokyo, Japan, May
1993.
17.
Lau JYN, Davis GL, Ohno T, Nakano T, Mizoguchi N, Perrillo R, Lindsay K, Gish RG,
Wilber JC, Urdea MS, Tsukiyama-Kohara K, Kohara M, Mizokami M. Application of hepatitis C virus (HCV) subtyping in chronic hepatitis C in the United States. Hepatology.
October 1993;18. Presented at the AASLD Liver Meeting, 1993.
18.
Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Lau GKK, Wu PC, Lau JYN.
Hepatic Response in chronic hepatitis C virus (HCV) infection. Hepatology. October
1993; 18. Presented at the AASLD Liver Meeting, 1993.
19.
Fang JWS, Lau GKK, Marousus C, Gonzalez-Peralta RP, Davis GL, Gish RG, Moyer
RW, Kao KJ, Lesniewski R, Mizokami M, Houghton M, Lau JYN. Failure to detect cell
surface expression of hepatitis C virus (HCV) structural proteins using a vaccinia expression system. Gastroenterology. April 1994;106:A890. Presented at the AGA Meeting, 1994.
20.
Lau GKK, Fang JWS, Davis GL, Gish RG, Wu PC, Lau JYN. Detection of hepatitis C
virus (HCV) genome in liver by in-situ reverse transcription polymerase chain reaction (IRT-PCR). Gastroenterology. April 1994;106:A925. Presented at the AGA Meeting, 1994.
21.
Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Kohara M, Mondelli MU,
Mizokami M, Lau JYN. Significance of hepatic expression of hepatitis C viral (HCV) antigens in chronic HCV infection. Gastroenterology. April 1994;106:A899. Presented at
the AGA Meeting, 1994.
22.
Gish RG, Keeffe EB, Fang JWS, Garcia-Kennedy R, Lau JYN. Ganciclovir treatment of
recurrent hepatitis B virus (HBV) infection in orthotopic liver transplant (OLT) recipients.
Gastroenterology. April 1994;106:A899. Presented at the AGA Meeting, 1994.
23.
Gish RG, Krams S, Martinez OM. Interleukin 12 (IL-12): A possible cytotoxic tlymphocyte (CTL) differentiation factor in allograft recipients. International Transplantation Meeting, Kyoto, Japan, August 1994.
Curriculum Vitae
83
Fang JWS, Gonzalez-Peralta RP, Gottschall JA, Davis GL, Gish RG, Mizokami M, Lau
JYN. Hepatic expression of c-FAS and apoptosis in chronic hepatitis C virus (HCV) infection. Hepatology. October 1994;20:251A. Presented at the AASLD Liver Meeting,
1994.
25.
Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Mizokami M, Lau JYN.
Immunopathobiology of chronic hepatitis C virus infection. Hepatology. October
1994;20:232A. Presented at the AASLD Liver Meeting, 1994.
26.
27.
Cacciarelli T, Martinez OM, Villaneuva JC, Lau JYN, Gish RG, Krams SM. Immunoregulatory cytokines in hepatitis C virus (HCV) infection pre- and posttreatment with alphaInterferon. Gastroenterology. April 1995;108:A1042. Presented at the AGA Meeting,
1995.
28.
Ghany MG, Ayola B, Villamil FG, Gish RG, Roiter S, Vierling JM, Lok ASF. S Gene
escape mutants as a cause of HBV reinfection in patients who received HBIG post-OLT.
Hepatology. October 1995;22:174. Presented at the AASLD Liver Meeting, 1995.
29.
Gish RG, Xu YL, Brooks L, Leung J, Qian KP, Pike I, Lau JYN. Application of a simple
serology based genotyping assay in a prospective cohort of patients with chronic hepatitis C. Hepatology. October 1995;22(4):1258. Presented at the AASLD Liver Meeting,
1995.
30.
Ghany MG, Villamil FG, Gish RG, Roiter S, Vierling, JM, Lok ASF. Survival after liver
transplantation for HBV-liver failure is unrelated to pre-core stop codon mutation. Hepatology. October 1995;22(4):1255. Presented at the AASLD Liver Meeting, 1995.
31.
Bhardwai G, Ohno T, Mizokami M, Gish RG, Lau JYN. Host immune response in liver
in chronic hepatitis C: Both perforin and FAS-ligard are activated. Presented at the AGA
Meeting, May 1996.
32.
Ghany MG, Ayola B, Villamil FG, Gish RG, Roiter S, Vierling JM, Lok ASF. HBV
reinfection in liver transplant (LT) patients (PTS) who remained HBsAG negative postLT. Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
33.
Ayola B, Ghany MG, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. HBIGinduced gene mutations in liver transplant recipients can revert after withdrawal of HBIG.
Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
34.
35.
Gish RG, Xu YL, Brooks L, Leung J, Pike I, Qian KP, Lau JYN. Anti-HCV positive sera
that were not genotypeable or serologically genotypablewhat does it mean? Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
Curriculum Vitae
84
Ghardwai G, Ohno T, Gish RG, Lau JYN. In vivo activated of cytotoxic t-lymphocyte
pathways in HCV-related cirrhosisimplications on immunopathogenesis. Presented at
the AASLD Liver Meeting, 1996. Chicago, Illinois.
37.
38.
Bhardwai G, Ohno T, Gish RG, Lau JYN, In vivo activation of cytotoxic t-lymphocyte
(CTL) pathways in HCV-related cirrhosisimplications on immunopathogenesis Presented at the AASLD Liver Meeting, 1996. Chicago, Illinois.
39.
Gish RG, Lee A, Brooks L, Leung J, Block GD. Long-term follow-up of patients
evaluated for liver transplantation using a method of risk stratification for estimating recidivism. Presented at the American Society for Transplantation Physicians (ASTP) 15th
Annual Scientific Meeting, May 1997.
40.
41.
Xiang J, Klinzman D, Schmidt WN, Labrecque DR, Gish RG, Stapleton JT. Biophysical
characterization of hepatitis G virus. Presented at the 97th American Society for Microbiology Meeting (ASM), May 1997. Miami Beach, Florida.
42.
Xing J, Ghany M, Ayola B, Villamil F, Gish RG, Rojter S, Vierling J, Lok, ASF. HBIG
induces mutations in the HBV S but not pre-S gene in liver transplant patients. Presented at the AGA Annual Meeting, May 1997.
43.
Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Rosenthal P. Hepatitis GBV-C infection in children pre- and post-liver transplantation. Hepatology. October 1997; 94. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
44.
Terrault NA, Pessoa MG, Singleton S, Kim E, Martin P, Crippin J, Gish RG, Keeffe E,
Lake J, Ascher N, Wright TL. Improved survival of hepatitis B patients undergoing liver
transplantation: Effects independent of therapeutic interventions. Presented at the
AASLD Liver Meeting, October 1997. Chicago, Illinois.
45.
46.
Xing J, Ghany M, Villamil F, Roiter S, Gish RG, Vierling J, Lok ASF. Different patterns
of HBV S gene mutations in liver transplant (OLT) patients (PTS) with and without HBV
reinfection. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
Curriculum Vitae
85
Xing J, Hussain M, Roiter S, Gish RG, Villamil F, Vierling J, Lok ASF. Mutations in the
HBV pre-S regions are associated with more severe liver disease. Presented at the
AASLD Liver Meeting, 1997. Chicago, Illinois.
48.
Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish RG, Dickson
R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. Lamivudine for
suppression and/or prevention of hepatitis B when given pre/post liver transplantation
(OLT). Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
49.
Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell FJ, Gish RG, McCashland TM,
Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochromatosis. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
50.
Gish RG, Lee A, Brooks L, Leung J, Block GD. Long-term follow-up of patients
evaluated for liver transplantation using psychiatric risk factors for estimating recidivism.
Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
51.
52.
53.
Xing J, Ghany M, Villamil F, Rojter S, Gish RG, Vierling J, Lok ASF. Different patterns of
HBV S gene mutations in liver transplant patients with and without NBV reinfection. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
54.
Xing J, Hussain M, Rojter S, Gish RG, Villamil F, Vierling J, Lok ASF. Mutations in the
HBV pre-S regions are associated with more severe liver disease. Presented at the
AASLD Liver Meeting, 1997. Chicago, Illinois.
55.
Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish RG, Dickson
R, Adams P, Brown N, Self P, and the Lamivudine Transplant Group. Lamivudine for
suppression and/or prevention of hepatitis B when given pre/post-liver transplantation
(OLT). Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
56.
Terrault NA, Pessoa MG, Singleton S, Kim E, Martin P, Crippin J, Gish RG, Keeffe E,
Lake J, Ascher N, Wright TL. Improved survival of hepatitis B patients undergoing liver
transplantation: Effects independent of therapeutic interventions. Presented at the
AASLD Liver Meeting, 1997. Chicago, Illinois.
57.
Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell RJ, Gish RG, McCashland TM,
Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochromatosis. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
Curriculum Vitae
86
Elkayam O, Hassoba HM, Ferrell LD, Garcia-Kennedy R, Gish RG, Wright TL, Rosenthal P. Hepatitis GBV-C infection in children pre- and post-liver transplantation. Presented at the AASLD Liver Meeting, 1997. Chicago, Illinois.
59.
Pessoa MG, Kim E, Martin P, Crippin J, Keeffe E, Gish RG, Ascher N, Wright TL,
Terrault NA. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin
(HBIG) in educing the incidence of acute rejection post-transplantation. Presented at the
AASLD Liver Meeting, 1997. Chicago, Illinois.
60.
61.
62.
63.
64.
65.
66.
Gish RG, Yao F, Brooks L, Poordad F, Cain-Schulze G and the North American
RibaHep study group. A randomized trial of interferon alfa-2b, daily vs. three times a
week for one month, followed by three times a week for one year in combination with
ribavirin in patients who have failed a previous course of interferon. Presented at the
AASLD Liver Meeting, 1998.
67.
Yao F, Gish RG, Poordad F, Rodvien R. Hepatocellular carcinoma: data from the
California Cancer Registry. Presented at the AASLD Liver Meeting, 1998.
68.
Curriculum Vitae
87
Gish RG, Leung NWY, Schooley RT, Sykes A, Turner F, Shi H, Wakeford C, Delehanty
H, Rousseau F. Emtricitabin (FTC): Activity Against Hepatitis B Virus in a Phase I/II
Clinical Study. ICAAC for TRCB-101. May 1999.
70.
Gish RG. Lamivudine for Prevention of Recurrent Hepatitis B After Liver Transplantation: Final Result of U.S./Canadian Multicenter Trial. A2006 Study AASLD 1999.
71.
Tanaka A, Prindiville T, Solnick J, Coppel RL, Lake J, Keeffe E, Gish R, Gershwin ME.
Molecular identification of infectious agents in primary biliary cirrhosis. Presented at the
AASLD Liver Meeting, 1998.
72.
73.
74.
75.
76.
77.
78.
79.
Curriculum Vitae
88
81.
Jazayeri M, Sran N, Gish R, Basuni A, Cooksley G, Locarnini S, Carman WF. HBV Core
Sequence: Definition of Subtype-Specific Variability and Correlation With Geographic
Origin. Presented at the AASLD Liver Meeting, October 2000.
82.
83.
84.
85.
86.
87.
88.
Kowdley, Brandhagen, Crippin, Gish RG, Bacon, Keeffe, Sterling, Fontana, Cotler,
Emond, NHTR Investigators. Survival after Orthotopic Liver Transplantation Among Patients with Hepatic Iron Overload: Preliminary Results from the National Hemochromatosis Transplant Registry. Presented at the AASLD Liver Meeting, October 2000.
89.
Kowdley, Tung, Han, Bass, Gish RG, Brandhagen, Sterling, Cotler, Fontana, McCashland, NHTR Investigators. Prevalence of Hepatic Iron Overload and HFE Mutations
Among Orthotophic Liver Transplant Recipients: Preliminary Results from the National
Hemochromatosis Transplant Registry. Presented at the AASLD Liver Meeting, October
2000.
90.
Sanne I, Gish RG. FTC-302 Study Investigators and the FTC-302 Clinical Steering
Committee. Severe Liver Toxicity in Patients Receiving Two Nucleoside Analogues and a
Non Nucleoside Reverse Transcriptase Inhibitor. Presented at the AIDS and Retroviral
meeting, December 2000, Glasgow, Scotland, and DDW, May 2001, Atlanta, Georgia.
Curriculum Vitae
89
Hadlock, Gish RG, Rowe, Rajyaguru, Newsom, Warford, Foung. Cross Reactivity and
Clinical Impact of the Antibody Response to Hepatitis C virus (HCV) Second Envelope
Glycoprotein. DDW 2001.
92.
93.
Gish RG. Severe Liver Toxicity In Patients Receiving Two Nucleoside Analogues and a
Non-Nucleoside Reverse Transcriptase Inhibitor. Presented at the AGA Meeting, May
2001.
94.
95.
96.
Gish RG, Larry Corey, Nancy Leung, Amy Rigney, Lei Fang, Elsa Mondou, John
Dillberger, Antiviral Activity of 48 Weeks of Emtricitabine Treatment in Patients with
HbeAg Negative DNA Positive Chronic Hepatitis B (CHB). Hepatology 2001; 34: 323A.
Presented at the AASLD Liver Meeting, 2001. Dallas, Texas.
97.
Gish RG, Leung NEWY, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH,
Delehanty J, Rigney A, Mondou E, Sykes A, and Rousseau F. A Dose Ranging Study of
the Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults
with HBV Infection. 2001.
98.
Gish RG, Fuminaka S, Etsuro O, et al. Recombination of HBV Genotypes. Nagoya City
University Medical School, December, 6, 2001.
99.
Jazayer M, Basuni A, Sran N, Gish R, Cooklesy G, Locarnini S, Carman WF. HBV Core
Sequence: Definition of Genotype-Specific Variability and Correlation with Geographic
Origin. Journal of General Virology. 2001.
100.
101.
Curriculum Vitae
90
McHutchison J and the IHIG Study group (Gish RG). Durability of sustained virologic
response in patients with chronic hepatitis C after treatment with interferon alfa-b alone
or in combination with ribavirin. Abstract 281. Presented at the AASLD Liver Meeting,
2001. Dallas, Texas.
103.
104.
Tong M, Shiffman M, Heathcote J, Gish RG, et al. Long-term safety beyond 48 weeks of
adefovir dipivoxil (ADV) 10 mg once daily for chronic hepatitis B (CHB): an integrated
analysis of two phase III studies. 2002.
105.
Javaheri S, Bzowej N, Wakil A, Gish RG, et al. A new clue in HBV fibrosis progression:
negative HBV DNA levels in treatment nave patients are associated with cirrhosis regardless of duration of disease. 2002.
106.
Bzowej N, Gish RG, Wakil AE, Brooks l, Shaffer M, et al. Comparison of peginterferon
Alfa-2B and ribavirin with or without induction therapy for the treatment of chronic hepatitis C (HCV) nonresponders. 2002.
107.
Terrault N, Friesenhahn M, Gish RG, et al. Decline in HCV viral load in chronicallyinfected patients during the first eight weeks of therapy with standard interferon/ribavirin
is highly predictive of virologic outcome. Presented at the National Institutes of Health
Management of Hepatitis C Meeting, June 10-12 2002.
108.
Selmi C, Mayo M, Gish RG, et al. Occurrence of primary biliary cirrhosis in identical
twins. 2002.
109.
110.
Zarski J, McHutchison J, Bronowicki J, Gish RG, et al. Rate of natural disease progression in patients with chronic hepatitis C. 2002.
111.
112.
Elbeik T, Friesenhahn M, Gish RG, et al. Decline in HCV viral load in chronicallyinfected patients during the first eight weeks of therapy with standard interferon/ribavirin
is highly predictive of virologic outcome. Presented at the AASLD Liver Meeting, 2002.
113.
114.
Shiffman ML, Angelino A, Gish RG. Side Effects Associated with the Treatment of
Hepatitis C, Infection: Recommendations for Improved Management. 2002.
Curriculum Vitae
91
116.
117.
118.
119.
120.
121.
Gish RG. HCV The Case for Selective Treatment. Nurses CE Symposium, Controversies in Hepatitis C Therapy, Does the Patient Really Need Treatment? Does the Patient Really Need a Liver Biopsy? Presented at Medical Education Collaborative Conference, May 18, 2003. Atlanta, GA.
122.
123.
124.
125.
126.
Afdhal NH, Gish RG. New Data on Managing Anemia with Growth Factors for Patients
on Anti-HCV Therapy: A Case Based Series. October 2002.
127.
Study Group 435 International Investigators Group (Gish, RG). Adefovir Dipivoxil
Therapy for Lamivudine-Resistant Hepatitis B in Pre- and Post- Liver Transplantation
Patients. Presented at the AASLD Liver Meeting, 2003.
128.
Bzowej N, Gish RG, Newsom, M. Eight Genotypes (A-H) for Hepatits B Virus Infecting
Patients from San Francisco and their Demographic Clinical and Virological Characteristics. Presented at the AGA Meeting. 2003.
Curriculum Vitae
92
Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am.
December 2003.
130.
131.
132.
133.
134.
Gish RG. Maximizing the Benefits of Antiviral Therapy for HCV: The Advantages of
Treating Side Effects, Treating Hepatitis C: State of the Art, March 2004.
135.
Gish RG. Hepatitis C Combination Therapy with Virmadine and Peginterferon Alfa-2a
Reduces Potential for Ribavirin-Related Hemolytic Anemia. DDW AASLD, 2004.
136.
137.
Gish RG. HCV in San Francisco and their demographic, clinical and virologic characteristics. Journal of Medical Virology. March 2004.
138.
139.
Gish RG, Arora S, Nelson D, Fernandez H, Lamon K. Safety and efficacy of Viramidine
in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapynave patients. Presented at the 39th Annual EASL Meeting, 2004.
140.
Gish RG, Patt Y, Garcia-Vargas J, Gallo J, Suplick G. Demographics from the ETHECC
trial: A randomized comparison between Thymitaq and doxorubician for the treatment of
unresectable hepatocellular carcinoma (HCC) in terms of survival. 2004.
141.
Curriculum Vitae
93
Lok A, Regev A, Keeffe E, Han SH, Emre, S, Ishitani, M, Luketic V, Brown R, Fung SK,
Hussain M, HBV-OLT Study Group (Gish RG). Relation between HBV genotypes and
HBV variants and indications for liver transplant (LT) in hepatitis B patients in the US.
2004.
143.
144.
Chang T, Gish RG, de Man R, Gadano A, Sollano J, Han KH, Goodman Z, Cross Z,
Dehertogh D, Apelian D and the Entecavir study group. Entecavir is Superior to Lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV022 in nucleoside-nave patients. Presented at the AASLD Liver Meeting, 2004. Boston,
Massachusetts.
145.
Terrault N, Godofsky E, Gish RG. New Hepatitis C Drugs: Can Safety, Efficacy be
Improved. Gastroenterology and Endoscopy News. 2004.
146.
147.
Gish RG, et al. ETV Efficacy across Disease-Related Baseline Subgroups. Presented at
the EASL Meeting, April 2004. Berlin, Germany.
148.
Gish RG, Arora S, Nelson D, Fried M, Reddy KR, Xu Y, Peterson J, Murphy, B. End-ofTreatment (EOT) Response in Therapy-Nave Patients Treated for Chronic Hepatitis C
with Viramidine in Combination with Pegylated Interferon. Presented at the AASLD Liver
Meeting, 2004. Boston, Massachusetts.
149.
Gish RG, de Man RA, Pedersen C, et al. Sustained response off-treatment to entecavir
and lamivudine after 48 weeks of treatment in nucleoside-nave, HBeAg+ patients: 24week follow-up results of phase 3 study ETV-022. J Hepatol. 2005; 42(suppl 2):177.
Presented at the EASL Meeting, April 2005.
150.
Gish RG, Trinh H, Leung N, Chan FKL, Fried MW, Wright TL, Wang C, Anderson J,
Mondou E, Snow A, Sorbel J, Rousseau F, Corey L., from Journal of Hepatology. JHE2004-00980.R1. Safety and Antiviral Activity of Emtricitabine (FTC) for the treatment of
Chronic Hepatitis B Infection: A Two Year Study. CAB Abstracts. 2005.
151.
Porta C, Gish RG, Patt Y, Suplick G, Garcia-Vargas J, Gallo J. Demographics from the
ETHECC (Evaluation of THYMITAQ [nolatrexed dihydrochloride] in the Hepatocellular Carcinoma [HCC]) trial population. June 2005.
152.
Porta C, Gish RG, Patt Y, Suplick G, Garcia-Vargas J, Gallo J. Improved safety profile
of nolatrexed dihydrochloride (THYMITAQ) IN THE Phase III Hepatocellular Carcinoma
(HCC) trial when compared to the safety of the Phase II program.
Curriculum Vitae
94
Nguyen T, Tong M, Brown R, Columbia, Gish R, Grant G, Viridae, Pico CS, Joshi S,
Siegal S, Lin C. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Remofovir in Chronic HBV Patients in US and Canada Following Daily Dosing for 28 days.
Presented at the EASLMeeting, April 2005. Paris, France.
154.
155.
156.
157.
Lurie Y, Manns MP, Gish RG, Chang TT, Yurdaydin C, Lai CL, Shouval D, Brown RS,
Jr., Apelian D, Kiescziwski K, Cross A, Wilber R. The Efficacy of Entecavir is Similar Regardless of Disease-Related Baseline Subgroups in Treatment of Nucleoside-Nave,
HBeAg(+) Patients with Chronic Hepatitis B. Presented at the 40th Annual EASL Meeting, April 2005.
158.
Shouval D, Senturk H, Gish RG, Chang TT, Yurdaydin C, Lai CL, Lok A, Brown RS, Jr.,
Apelian D, Fernandes L, Kiesczewski K, Cross A, Wilber R. Entecavir Demonstrates
Consistent Responses Throughout Baseline, Demographic Subgroups for the Treatment
of Nucleoside-Nave, HBeAg(+) and HBeAg(-) Patients, with Chronic Hepatitis B. Presented at the 40th Annual EASL Meeting, April 2005.
159.
Gish RG, De Man RA, Pedersen C, Bialkowska J, Chang TT, Apelian D, Fernandes L,
Zhu J, Cross A, Wilber R, and the BEHoLd Study Group. Sustained Response Offtreatment to ntecavir and lamivaudine After 48 Weeks of Treatment in Nucleoside-nave,
HBeAg(+) Patients: 24-week Follow-Up Results of Phase 3 Study ETV-022. Presented
at the 40th Annual EASL Meeting, April 2005.
160.
Manns MP, Raptopoulou-Gigi M, Soliano J, Gish RG, Chang TT, Sherman M, Yurdaydin
C, Shouval D, Lok A, Cooney E, Hindes R, Yang J, Cross A, Wilber R. Entecavir is Welltolerated for the Treatment of Nucleoside-Nave and Lamivudine-Refractory Chronic
Hepatitis B Viral Infection: Phase II/III Safety Results. Presented at the 40th Annual
EASL Meeting, April 2005.
161.
Curriculum Vitae
95
Gish R, Chang TT, de Man R, Dadano A, Sollano J, Han KH, Goodman Z, Zhu J, Cross
A, Brett-Smith H, the BEHoLD Study Group. Entecavir is Superior to Lamivudine for the
Treatment of HBeAg(+) Chronic Hepatitis B: Results of Phase III Study ETV-022 in Nucleoside-nave Patients. Presented at the 13th World Congress of Gastroenterology,
September 10-14, 2005. Montreal, Canada.
163.
164.
Behrsing HP, Tam J, Gray B, Do A, Zhao D, Jung J, Bundey R, Gish RG, McGuire BM,
Suh D-J, Park S-S. Characterization of a novel porcine liver slice-filled bioartificial liver
(BAL) for treatment of liver failure patients. ASAIO Journal. March/April 2006;52(2):10A.
Presented at the ASAIO Meeting, 2006.
165.
166.
167.
Veenstra DL, Iloeje UH, Tafesse E, Sullivan SD, Cross A, Di Bisceglie A, Gish RG.
Cost-effectiveness of Antivirals in HBeAg-positive Chronice Hepatitis B: Impact of Seroconversion and Viral Suppression. Presented at DDW, May 20-25, 2006. Los Angeles,
California.
168.
Gish R, Behrsing HP, Tam J, Gray B, Do A, Park Y, Yun H, Zhao D, Gropper C, Jung J,
McGuire BM, Panoskaltsis-Mortari A, Lau GK, Lim Y-S, Lee HC, Suh D-J, Park S-S. In
vivo characterization of a novel procine liver slice-filled bioartificial liver (BAL) for treatment of liver failure patients. HepaHope Inc. Presented at the World Tranplant Congress, 2006.
169.
170.
171.
Curriculum Vitae
96
173.
DeMan RA, Mutimer D, Gish RG, Chang T-T, Zhu J, Cross A, Brett-Smith H. Entecavir
(ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic patients (Study ETV-022).
Presented at the International Association for the Study of the Liver (IASL) Meeting,
2006.
174.
Gish R. This Study Compared the Efficacy and Safety of Zadaxin plus TACE with TACE
alone in Patients with Unresectable HCC. Final Abstract. EASL 2006.
175.
Gish R, Park S-S, Jung J, Zhao D, Yun H, Tam J, Park Y, Gropper C, McGuire B,
Panoskaltsis-Mortari A, Han JJ, Lim Y-S, Lee HC, Suh D-J. Assessment of a Novel Pocine Liver Slice-filled Bio-artificial Liver (BAL) for Dialysis of Liver Failure Patients. Presented at the AASLD Liver Meeting, October 27-31, 2006. Boston, MA.
176.
177.
178.
179.
180.
181.
Schiff ER, Everson GT, Tsai N, Bzowei NH, Gish RG, McHutchison JG, Jacobson IM,
Tong MJ, Jensen DM, Lauer GM, Cruickshank S, Ferraro J, Haller A, Duke R, Rodell T,
Apelian D. HCV-Specific Cellular Immunity, RNA Reductions, and Normalization of ALT
in Chronic HCV Subjects after Treatment with GI-5005, a Yeast-Based Immunotherapy
Targeting NS3 and Core: A Randomized, Double-blind, Pacebo Controlled Phase 1b
Study. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
Curriculum Vitae
97
Gish RG, McGuire M. Acute Liver Failure and Artificial Liver Support. Presented at the
AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
183.
Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, BrettSmith H, Hindes R. Four-Year Entecavir Treatment in Nucleoside-Nave HBeAg (+) Patients: Results from Studies ETV-022 and -901. Presented at the AASLD Liver Meeting,
November 2-6, 2007. Boston, MA.
184.
185.
Chang TT, Caho YC, Lai CL, Yoon SK, Han KH, Tan CK, Gish RG, Cheinquer H, Han
S, Zhang H, Smith HB, Hindes R. Four-Year Treatment with Entecavir Results in High
Proportions of Nucleoside-Nave HBeAg-Positive Patients with Undetectable HBV DNA:
Results from Studies ETV-022 and -901. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
186.
187.
188.
Park S-S, Yang Y-K, Lee Y-I, Jung J, Zhao D, Park Y, Yoon H, Tam J, Ganda C, Lee HT, Park J, Yang S, Groupper C, Gish RG, McGuire BM, Panoskaltsis-Mortair A, Lim Y-S,
Lee HC, Suh D-J, Ferguson J. Preclinical Assessment of HepaHope Bioartificial Liver
System. Presented at the AASLD Liver Meeting, November 2-6, 2007. Boston, MA.
189.
190.
Gish RG. Epidemiology Of Chronic Hepatitis B Patients. Presented at DDW, May 17-22,
2008. San Diego, CA.
191.
Frederick RT, Zagorski J, Gish RG, Hofmann JC. Treatment of Hepatitis C Associated
Severe Mixed Cryoglobulinemic Syndrome With Plasma Exchange Improves Tolerability
and Response to Interferon-Based Therapy. Presented at DDW, May 17-22, 2008. San
Diego, CA.
192.
Curriculum Vitae
98
Sung-Soo Park, Jaeho Jung, Sunny Yang, Sunnie Kim, Sam Lee, Young Park, Hyoung
Yoon, Nercy Fernandez, Paul Hernandez, Nick Haman, Daren Cox, Robert Gish, Brendan McGuire, Dong-Jin Suh, Han Chu Lee. How to Improve Bioartificial Liver (BAL)
System for Clinical Trials? Poster. ILC/ASAIO 2008.
194.
Sung-Soo Park, Jaeho Jung, Delai Zhao, Sunny Yang, Sunnie Kim, Sam Lee, Hyoung
Yoon, Young Park, Nercy Fernandez, Robert G. Gish, Brendan M. McGuire, Angela
Panoskaltsis-Mortari, Han chu Lee, Dong-Jin Suh. Assessment of HepaHope bioartificial liver (BAL) system for treating liver failure patients. Hong Kong, China. ILC 2008.
195.
Park S-S, Jung J, Yang S, Kim S, Lee S, Yoon H, Park Y, Fernandez N, Fernandez P,
Haman N, Cox D, Gish R, McGuire B, Suh D-J, Lee HC. How to Improve Bioartificial
Liver (BAL) System for Clinical Trials. Presented at the 54th Annual ASAIO Conference,
2008.
196.
Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, BrettSmith H, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of
Nucleoside-Nave HBeAg-Positive Patients with Undetectable HBV DNA: Results from
Studies ETV-022 and ETV-901. Presented at the 18th Conference of the Asian Pacific
Association for the Study of Liver (APASL), March 2008. Seoul, Korea.
197.
Levy AR, Kowdley KV, Iloege U, Tafesse E, Mukherjee J, Gish R, Bzowej N, et al. The
impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008 May-Jun; 11(3) :527-38.
198.
RT Frederick, J Zagorski, R Courville, Gish RG. Negative tissue PCR does not confer
reduced risk of relapse after treatment of HCV in patients. Presented at the European
Association for the Study of Liver Disease (EASL), April 2008. Milan, Italy.
199.
Han S, Chang TT, Chao Y, Yoon S, Gish RG, Cheinquer H, Carrillho F, Zhang H, BrettSmith H, Hindes R. Four-Year Treatment with Entecavir Results in High Proportions of
Nucleoside-Nave HBeAg-Positive Patients with Undetectable HBV DNA: Results from
Studies ETV-022 and ETV-901. Presented at the Hong Kong-Shanghai ILC Meeting,
June 2008. Hong Kong, China.
200.
Morris Sherman, Cihan Yurdaydin, Halis Simsek, Marcelo Silva, Yun-Fan Liaw, Vinod K.
Rustgi, Hoel Sette, Naoky Tsai, Daniel J. Tenney, James Vaughan, Bruce Kreter, Robert
Hindes, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study
Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. RG Gish included in
BEHoLD Study Group. Hepatology. July 1, 2008.
201.
Gish R, Marrero JB, Tong MJ. Medical therapties to extend survival in hepatocellular
carcinoma. Clin Adv Hematol Oncol. 2008 Aug;6(8) :1-14; quiz 5.
202.
Curriculum Vitae
99
203.
204.
Steven Han, Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert Gish,
Raymond Chung, Bulent Degertekin, Anna Lok. Hepatocellular Carcinoma (HCC) is the
Main Inidcation for the Liver Transplantation (OLT) among HBV Patients in the Era of
Nucleos/Tide Analogue Therapies.
205.
Paul Gaglio, Sundeep Singh, Bulent Degertekin, Michael Ishitani, Munira Hussain,
Robert Perrillo, Anna S Lok, and the NIH HBV OLT Study Group. Impact of HBV Genotype on Pre- and Post- Liver Transplantation Outcomes.
206.
Debbie Hana Yi, Sumbella Baqai, Robert Gish. Characteristics of Hepatitis Delta in
Northern CA.
207.
208.
Debbie Hanna Yi, Sumbella Baqai, Robert G. Gish. Characteristics of Delta Hepatitis
in Northern California. Poster presented at AASLD. October 2008.
209.
210.
Steven-Huy B. Han, Ting-Tsung Chang, You-Chen Chao, Seung Kew Yoon, Robert G.
Gish, Hugo Cheinquer, George E. Kitis, Hui Zhang, Uchenna LLoeje. Five Years of
Continuous Entecavir for Nucleoside-nave HBeAg(+) chronic hepatitis B: Results from
study ETV-901. 2008.
211.
212.
Patrick Marcellin, Robert G. Gish, Norman Gitlin, Jamie Heise, Deanine G. Halliman,
Eric Chun, Maribel Rodriguez-Torres. Randomized, Double-Blind, Multicenter Study
Comparing the Safety and Efficacy of Viramidine and Ribavirin in Treatment-Nave Patients With Chronic Hepatitis C: Results of ViSER2. Manuscript Submitted for Publication. 2008.
213.
Robert G. Gish. Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants
and Mutations. The American Journal of Medicine. September 2008.
214.
Curriculum Vitae
100
215.
Steven-Huy B. Han, Ting-Tsung Chang, You-Chen Chao, Seung Kew Yoon, Robert G.
Gish, Hugo Cheinque, George E. Kitis, Hui Zhang, Uchenna IIoeje. Five Years of Continuous Entecavir for Nucleoside-nave HBeAg (+) Chronic Hepatitis B: Results from
Studies ETV-022/-901. Poster presented at AASLD. San Francisco, CA. October
2008.
216.
217.
Robert Gish. Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management. Medscape Volume 4. November 2008.
http://www.medscape.com/viewprogram/17750
218.
219.
220.
221.
222.
223.
224.
225.
226.
Curriculum Vitae
101
227.
228.
Robert G. Gish. Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants
and Mutations. The American Journal of Medicine. 121,S12-S21.
229.
Robert Gish, Robert Osorio, Kenneth Binmoeller. New Strategies for Hard-to-Treat
Gastrointestinal Cancer. California Pacific Medical Center Research Institute Currents 2008.
230.
231.
232.
Sumbella Baqai, Robert G. Gish. High Rate of Core and Precore Mutations in a
Patient Population with Chronic Hepatitis B at a Tertiary Referral Center. 19th Conference of the APASL. Hong Kong Convention and Exhibition Centre. February 13-16,
2009.
233.
Sumbella Baqai, Debbie Hanna Yi, Robert G. Gish. Characteristics of Hepatitis Delta
in Northern California. 19th Conference of the APASL. Hong Kong Convention and Exhibition Centre. February 13-16, 2009
234.
Robert G. Gish. What do we know about the Difficult-to-Treat Patient with Chronic
Hepatitis C Infection. 19th Conference of the APASL. Hong Kong Convention and Exhibition Centre. February 13-16, 2009.
235.
Robert G. Gish, Stuart C. Gordon, David Nelson, Vinod Rustgi, Isreal Rios. A
Randomized Controlled Trial of Thymalfasin plus Transartierial Chemoembolization
(TACE) for Unresectable Hepatocellular Carcinoma. Hepatology International. In
press. 2009.
236.
Robert G. Gish, Ting-Tsung Chang, ching-Lung Lai, Robert de Man, Adrian Gadano,
Fred Poordad, Joanna Yang, Ricardo Tamez, Helena Brett-Smith. Loss of HBsAg Antigen During Treatment With Entecavir or Lamivudine in Nucleoside-Nave HBeAgPositive Patients With Chronic Hepatitis B. Journal of Viral Hepatology. Submitted for
publication. 2009.
237.
Adrian M. Di Bisceglie, Robert G. Gish, Steven-Huy B. Han, W. Ray Kim, Naoky C.S.
Tsai. HBV Advanced Certificate Program IV Launches with First Course. Projects In
Knowledge. 2009.
238.
239.
Robert G. Gish, Steven Locarnini. Chronic Hepatitis B Viral Infcction. Gastroenterology Textbook. 2009.
Curriculum Vitae
102
Adrian Di Bisceglie, Robert G. Gish, Patty Peterson, Elaine Rudell. HBV Management:
Gaps in Clinical Competence and Practice Performance US Survey Findings. Abstract for EASL 2009.
241.
Robert G. Gish. Update New Therapies for Hepatitis B and Hepatitis C. 16th Annual
Alimentary Update. South Lake Tahoe. March 27, 2009.
242.
Robert G. Gish. Using a new palette of treatment options to paint the portrait of cure for
patients infected with hepatitis C on our clinical canvas. NATAP/EASL: New HCV
Drugs Report. EASL 2009. April 23-26, 2009.
243.
244.
Adrian Di Bisceglie, Robert G. Gish, Patty Peterson, Elaine Rudell. HBV Management
Among US Clinicians: Gaps in Clinical Competence and Practive Performance-Survey
Findings. DDW Poster. May 2009.
245.
Robert G. Gish. Wilsons Disease Symposium. California Pacific Medical Center. San
Francisco, CA. May 2, 2009.
246.
Michele Tana, Kaveh Hoda, Jackson Wong, Yiqiu Wei, Wylie Liu, Nanette Hinojales,
Paula Lykins, Germaine Andrews, David Stone, Doug Wong, Grace Estevez, Eddie
Cheung, Judy Li, Robert Gish, Stewart Cooper. DDW 2009 HBV Abstract. DDW
poster. May 30, 2009 June 3, 2009.
247.
Adrian Di Bisceglie, Robert Gish. Hepatitis B Combined. DDW poster. May 30,
2009 June 3, 2009.
248.
249.
Terry Conway, Vernon Smith, Gaylee Morgan, Jack Meyer, Dennis Roberts, Esther
Reagan. Robert Gish, Member of Expert Working Group. Early Medicaid Coverage
of Chronic Hepatitis B May Reduce Medicaid Spending and is Associated with Positive
Health Outcomes. JAMA. 2009.
250.
Robert Gish. Loss of HBsAG antigen during treatment with entecavir or lamivudine in
nucleoside-nave HBeAg-positive patients with chronic hepatitis B. Journal of Viral
Hepatitis. 2009.
251.
252.
Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. Clinical Epidemiology of Wilson Disease in Patients With Concurrent Liver Disease. Poster. APASL 2010.
April 2009.
253.
Curriculum Vitae
103
Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. Clinical Epidemiology of Wilson Disease in Patients With Concurrent Liver Disease. Poster. Wilson Disease Meeting. San Francisco, CA. May 2, 2009.
255.
R.G. Gish, T.T. Chang, C.L. Lai, R. de Man, A. Gadano, F. Poordad, J. Yang, H. BrettSmith, R. Tamez. Loss of HBsAg antigen during treatment with entecavir or lamivudine
in nucleoside-nave HbeAg-positive patients with chronic hepatitis B. Journal of Viral
Hepatitis, 2009.
256.
T.T. Chang, Y.C. Chao, V.V. Gorbakov, K.h. Han, R.G. Gish, R. de Man, H. Cheinquer,
F. Bessone, H. Brett-Smith, R. Tamez. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-nave HBeAg-positive patients with chronic hepatitis B.
Journal of Viral Hepatitis, 2009.
257.
Michele Tana, Kaveh Hoda, David Hutton, Jackson Wong, Yiqiu Wei, Wylie Liu, Nanette
Hinojales, Paula Lykins, Germaine Andres, David Stone, Doug Wong, Grace Estevez,
Eddie Cheung, Judy Li, Robert Gish, Stewart Cooper. HBV Screening in Asians and
Pacific Islanders: An interim cost effectiveness analysis of a single center San Francisco
program. 2009.
258.
Adrian M. Di Bisceglie, Robert G. Gish, Steven-Huy B. Han, W. Ray Kim, Nancy C.S.
Tsai. Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV. Projects in Knowledge. 2009.
259.
Adrian M. Di Bisceglie, Robert G. Gish,. Case Study: HBsAg-Positive, Anti-HBeNegative Black Immigrant from Somalia. Bridging Cultural Differneces to Improve HBV
Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV.
Projects in Knowledge. 2009
260.
Adrian M. Di Bisceglie, Robert G. Gish, Case Study: HBsAg-Positive, Anti-HBeNegative Black Immigrant from Somalia. Bridging Cultural Differneces to Improve HBV
Treatment in Asian and Other Diverse Communities. Advanced Certificate Program IV.
Volume 4, Issue 5. Projects in Knowledge. 2009
261.
Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. Clinical Epidemiology of Wilson Disease in Patients With Concurrent Liver Disease. Liver International
Journal. Submission. November 2009.
262.
Robert Wong, Todd Frederick, Natalie Bzowej, Robert Gish, Catherine Frenette.
Clinical Profile of Autoimmune Hepatitis Patients withConcurrent Development of Hepatocellular Carcinoma. Submitted EASL abstract. November 2009.
263.
264.
Robert Gish. United network for Organ Sharing regional Review Analysis: Heterogeneity of MELD Upgrade Scores for MELD Exceptions. Abstract Submission to American
Transplant Congress. December 2009.
Curriculum Vitae
104
265.
266.
Adrian M. Di Bisceglie, Robert G. Gish,. Expert Insight Into: Hepatitis B Testing and
Vaccination Among Vietnamese-andCambodian-Americans (Part 2 of Series). Bridging
Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse Communities. Advanced Certificate Program V. Projects in Knowledge. 2010.
267.
268.
269.
270.
Adrian M. Di Bisceglie, Robert G. Gish. Expert Insight Into: Incidence and Risk Factors
of Progression to Cirrhosis in Inactive Carriers of Hepatitis B Virus (part 5 of Series)
Bridging Cultural Differneces to Improve HBV Treatment in Asian and Other Diverse
Communities. Projects In Knowledge. 2010.
271.
Robert Gish, Ji-Dong Jia, Stephen Locarnini, Fabien Zoulim. Principles for Selecting
Chronic Hepatitis B Therapy with a High Barrier to Resistance. Submitted for publication. 2010.
272.
Robert Wong, Robert Gish, Michael Schilsky, Catherine Frenette. A Clinical Assessment of Wilson Disease in Patients With Concurrent Liver Disease. Journal of Clinical
Hepatology. 2010.
273.
Norah A. Terrault, Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, T.R. Levin,
Robert Gish, Michael busch, Miriam J. Alter. Sexual Transmission of HCV Among Monogamous Heterosexual Couples: The HCV Partners Study. New England Journal of
Medicine. 2010.
274.
Robert G. Gish. International and National Priorities for Liver Cancer Control. John
Hopkins Bloomberg School of Public Health IRB. February 2010.
275.
Curriculum Vitae
105
277.
Chari Cohen, Scott Holmberg, Joan Block, Carol Brosgart, Brian McMahon, W.T.
London, Robert G. Gish, Timothy Block. Is Chronic Hepatitis B Being Under Treated in
the United States? JVH. Submitted 6/2010, Published 4/2011
278.
Robert Wong, Robert Gish, Todd Frederick, Natalie Bzowej, Catherine Frenette.
Development of Hepatocellular Carcinoma in Autoimmune Hepatitis. ILCA Poster.
September 10-12, 2010.
279.
Heiner Wedemeyer, Robert Gish, Tuan Nguyen, Ching-Lung Lai, Cyril Llamoso, TingTsung Chang. Efficacy and Safety of Entecavir in the Older Patient (>50 years of age).
Submitted to AASLD November 2010 Boston Meeting.
280.
Sung-Soo Park, Jaeho Jung, Hong Bock Lee, Delai Zhao, Young Park, Hyoung Yoon,
Jason Lee, Sunny Yang, Jun Choi, David Goldberg, Vickie Sheckler, Robert G. Gish,
Todd Frederick, Brendan M. McGuire, Norman L. Sussman, Angela PanoskaltsisMortari, Han Chu Lee, Dong Jin Suh. Acute Liver Failure and Artificial Liver. Poster.
AASLD November 2010 Boston Meeting.
281.
Sung-Soo Park, Jaeho Jung, Hong Bock Lee, Delai Zhao, Young Park, Hyoung Yoon,
Jason Lee, Sunny Yang, Jun Choi, David Goldberg, Vickie Sheckler, Robert G. Gish,
Todd Frederick, Brendan M. McGuire, Norman L. Sussman, Angela PanoskaltsisMortari, Han Chu Lee, Dong Jin Suh. Development of a Canine Acute Liver Failure
Model that is Suitable for Evaluating Safety and Efficacy of Bioartificial Liver Systems.
Poster. AASLD November 2010 Boston Meeting.
282.
Catherine Frenette, Robert Gish. Clinical Management and Case Reports for the
Treatment of Hepatocellular Carcinoma with Sorafenib. Journal of Clinical Gastroenterology. Submitted for publication. 2010.
283.
Robert G. Gish, Norman Sussman. The Current Status of Artificial Liver Support
(ALS). The Gastroenterology Exchange. 2010.
284.
Robert Gish. Is Chronic Hepatitis B Being Undertreated in the United States, Journal
of Viral Hepatitis. August 2010.
285.
286.
287.
Curriculum Vitae
106
Steven Huy Han, K. Rajender Reddy, Emmet B. Keeffe, Consuelo Soldevila-Pico, Robert
Gish, Raymond T. Chung, Bulent Degertekin, anna Lok, NIH-HBV OLT Study Group. Clinical Outcomes of Liver Transplantation for HBV-Related Hepatocellular Carcinoma: Data
from the NIH HBV-OLT Study. Clinical Transplantation. 2010. CLTX-10-OA-0087.R1.
289.
Robert Gish. HCC Treatment Options and Their Associated Adverse Events.
Integrating Recent Data in Managing Adverse Events in the Treatment of Hepatocellular
Carcinoma. Clinical Roundtable Monograph. September 2010.
290.
291.
Mary Ann Cmunale, Mengjun Wang, Lucy Rodemich-Betesh, Julie Hafner, Anne
Lamontagne, Andrew Klein, Jorge Marrero, Adrian M. Di Bisceglie, Robert Gish, Timothy Block, Anand Mehta. Novel Changes in Glycosylation of Serum Apo-J in Patients
with Hepatocellular Carcinoma. 2010.
292.
R.G. Gish, S.L. Cooper. Hepatitis b in the greater san francisco bay area: an integrated
programme to respond to a diverse local epidemic. Journal of Viral Hepatitis. 2010.
293.
Heiner Wedemeyer, Robert Gish, Tuan Nguyen, Ching-Lung Lai, Cyril Llamoso, TingTsung Chang. Efficacy and Safety of Entecavir in the Older Patient (50 years of age).
APASL 2010.
294.
Robert Gish, Naoki Tsai, Calvin Pan, Kris Kowdley, Ke-Qing Hu, Lai CL, Ting-Tsung
Chang, Kwang-Hyub Han, David Coehn, Hong Tang, Myron Tong. Efficacy and Safety
of Entecavir in Nucleos(t)ide Nave Asians with HBeAg Positive and Negative Chronic
Hepatitis B: Results from Studies ETV-022/027. APASL 2011 - Thailand.
295.
Catherine T. Frenette, Richard Todd Frederick, Robert Gish. Clinical Management and
Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib. Journal of
Clinical Gastroenterology. 2010.
296.
Robert Gish, Pamela Norton, Hongyan Liang, Timothy Block, Mengjun Wang, Ronald
Long. Hepatocellular Carcinoma Biomarker GP73: Effects of IL-6 Family Cytokines and
Interferon- in Human Hepatocytic Cells and in People with Liver Disease (lower case
alpha). Cancer Epidemiology, Biomarkers & Prevention. 2010.
297.
298.
299.
Curriculum Vitae
107
301.
302.
Gish, R, Kohla M, Predictive Factors for Hepatic Decompensation after TACE for
Hepatocellular Carcinoma (HCC): A Single Center Experience, accepted for Poster
Presentation, International Liver Cancer Association, September 2011.
303.
Robert G. Gish MD, Alexander, Colleen Tu BS, Kuo MD, Cyndy Collins NP, Shirley M.
Tsunoda, Pharm.D. Effect of Sirolimus on Immune Cell Function Assay in Liver Transplant Recipients, September 2011.
304.
305.
Gish, Robert G., HCV In At Risk Populations: Who Can Be Treated And How?,
Current Hepatitis Reports, September 2011.
306.
307.
Gish, Robert G., Drug-Induced Liver Disease (DILI) and Acute Liver Failure, Armenia
Journal: BLOOD. September 2011.
308.
Gish, Robert G., Autoimmune Hepatitis and Acute Liver Failure, Armenia Journal:
BLOOD. September 2011.
309.
Gish, Robert G., Serologic and Virologic Tools For the Workup and Management of
Hepatitis B, Armenia Journal: BLOOD. September 2011.
310.
Gish, Robert G., Wilson Disease, Armenia Journal: BLOOD. September 2011.
311.
Gish, Robert G., Liver Cancer Biomarkers, Armenia Journal: BLOOD. September
2011.
312.
Gish, Robert G., Current Management of Liver Cancer, Armenia Journal: BLOOD.
September 2011.
313.
Gish, Robert G., Liver Transplantation in 2011, Armenia Journal: BLOOD. September 2011.
314.
Gish, Robert G., Chronic HBV Infection Outside Treatment Guidelines: Is Treatment
Needed? Journal of Viral Hepatitis, (Submitted for Publication), December, 2011.
Curriculum Vitae
108
Robert G. Gish MD, Heather Patton MD, Michael Misel PharmD., Acute Liver Failure:
An Evidence-Based Management Protocol for Clinicians, Gastroenterology & Hepatology, January 2012.
316.
Gish, Robert G., Shirley Tsunoda, Pharm D, Effect of Sirolimus on Immune cell
function assay in liver transplant recipients, January, 2012.
Gish, Robert G., Binh Tran, PharmD, Barriers to Hepatitis B screening and Hepatitis B
knowledge among Asian populations in San Diego County, January 2012.
317.
318.
Gish, Robert G., Serum Albumin and AFP Levels as Predictors of Hepatic Decompensation After TACE for Hepatocellular Carcinoma (HCC), Presented at: APASL, Taipei,
Taiwan. February 2012.
319.
Gish, Robert G., Frenette, Catherine, Targeted Systemic Therapies for Hepatocellular
Carcinoma: Clinical Perspectives, Challenges and Implications, World Journal of Gastroenterology, February, 2012.
320.
Gish, Robert G., Martinez, Anthony D, HCV In At-Risk Populations: Who Can Be
Treated and How? Current Hepatitis Reports, Volume 8, Number 1, February 2012.
321.
Sumbella F. Baqai MD, Debbie H. Yi MD, Michael Mangahas, Robert G. Gish MD, High
Rate of Core Promoter and Precore Mutations in Patients with Chronic Hepatitis B and
Their Impact on Liver Disease, Journal of Viral Hepatitis, (Submitted for Publication),
2012.
322.
Norah A. Terrault, Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, Alexi Kiss, T.R.
Levin, Robert Gish, Michael Busch, Arthur L. Reingold, Miriam J. Alter: Sexual Transmission of HCV Among Monogamous Heterosexual Couples: The HCV Partners Study,
study was supported by a cooperative agreement with the Centers for Disease Control
and Prevention, U50 CCU915651, U01 DK60345 (J.E.T), Accepted Article, doi:
10.1002/hep.26164; November 25, 2012.
323.
Maja Kodani, Alyssa Martin, Tonya Mixson-Hayden, Jan Drobeniuc, Robert Gish, and
Saleem Kamili, One-Step Real-Time PCR Assay for Detection and Quantification of
Hepatitis D Virus RNA by Short-Form Paper, Journal of Clinical Microbiology, Virology
Section, Control number JCM00554-13; February 26, 2013
324.
Robert G. Gish, Ting-Tsung Chang, Ching-Lung Lai, Robert A de Man, Adrian Gadano,
Cyril Llamoso, Hong Tang: Quantitative Hepatitis B Surface Antigen Analysis in Hepatitis B e Antigen-Positive, Nucleoside-Naive Patients Treated With Entecavir, Antiviral
Therapy, Manuscript ID AVT-12-OA-2806.R1, doi: 10.3851/IMP2559, International Medical Press Ltd., http://www.intmedpress.com/journals/avt/abstract.cfm?id=2559&pid=48;
February 28, 2013.
325.
Maja Kodani, Alyssa Martin, Tonya Mixson-Hayden, Jan Drobeniuc, Robert Gish,
Saleem Kamili, One-Step Real-Time PCR Assay for Detection and Quantification of
Hepatitis D Virus RNA One-Step qRT-PCR for HDV Detection, Journal of Clinical Microbiology, Virology Section, JCM0054-13, March 2013.
Curriculum Vitae
109
327.
328.
Shirley M. Tsunoda, Stephanie Wang, Linda Awdishu, Nina Phak, Alicia Somers, Robert
G. Gish, Utilizing Intracellular ATP Activity as a Biomarker for Predicting Rejection in
Hepatitis C Liver Transplant, submitted to 2013 ATC Conference; May 2013.
329.
330.
331.
332.
Session Chairman, Transforming Science to Clinical Practice, APASL Liver Week 2013
Singapore: Session Chairman, Singapore; June 6-10, 2013.
333.
Dr. Robert Gish, Dr. Lynn Huang, Hec1 as a Novel Approach to Liver Cancer, submitted
for publication, June 24, 2013.
334.
335.
336.
Curriculum Vitae
110
338.
Luke Huang; Simon Shih-Hsien Chuang, KJ Kao, Diana Wu; Jinn Wu, Gish, Robert;
Johnson Lau; Inhibition of Hec1 as a Novel Approach to the Treatment of Primary Liver
Cancer, Taivex Therapeutics, 2013.
339.
Gish RG, VIRGIL ((Vigilance Against Viral Resistance) Study Establishes Clinical
Benefit of Virologic Suppression With Entecavir, Commentary, Clinical Care Options, Virology, September, 2013.
340.
Gish RG, Delta Virus Infection: Epidemiology and Initiatives to Intercept It, Commentary, Gastroenterology & Hepatology, September 2013
341.
Gish RG, Global Hepatitis Overview and How to Respond to the Epidemic, Armenia
Liver Conference 2013, September 6-8, 2013.
342.
Gish RG, Current Therapy of Hepatitis B: Planning for 2013 and Beyond, Armenia
Liver Conference 2013, September 6-8, 2013.
343.
Gish RG, Hepatitis E, Armenia Liver Conference 2013, September 6-8, 2013.
344.
Gish RG, Hepatitis C Virus: The Basics, Current Status and the Future, Armenia Liver
Conference 2013, September 6-8, 2013.
345.
346.
347.
348.
Sandy Chong et al, Collaborative Efforts to Screen at-risk Populations for Hepatitis B
and C in San Diego County, abstract approved for HepDart 2013, Kohala, Hawaii, December 10, 2013.
349.
Nguyen CT, Gish RG, et al; POC Testing for Hepatitis C Screening at CommunityBased-Organizations Facilitates Disease Control, abstract approved for HepDart 2013,
Kohala, Hawaii, December 10, 2013.
Curriculum Vitae
111
Julio Gutierrez, et al, Efficacy of Screening for Hepatitis B Infection and Immunity in Low
Resource Settings with an Inexpensive Point of Care Immunoassay, abstract approved
for HepDart 2013, Kohala, Hawaii, December 10, 2013.
351.
352.
Xuan Phan, et al, Targeting Populations At-Risk for Hepatitis B Using the Research
Electronic Data Capture (RED Cap) Program, abstract approved for HepDart 2013, Kohala, Hawaii, December 10, 2013.
353.
354.
Sandy Chong et al, Collaborative Efforts to Screen at-risk Populations for Hepatitis B
and C in San Diego County, poster submitted to European Association for the Study of
Liver Diseases (EASLD), Spring 2014.
355.
Julio Gutierrez, et al, Efficacy of Screening for Hepatitis B Infection and Immunity in Low
Resource Settings with an Inexpensive Point of Care Immunoassay, poster submitted
to European Association for the Study of Liver Diseases (EASLD), Spring 2014.
356.
Xuan Phan, et al, Targeting Populations At-Risk for Hepatitis B Using the Research
Electronic Data Capture (RED Cap) Program, poster submitted to European Association for the Study of Liver Diseases (EASLD), Spring 2014.
357.
Christina Thuy Nguyen, et al; POC Testing for Hepatitis C Screening at Community
Based Organizations Facilitates Disease Control, poster submitted to European Association for the Study of Liver Diseases (EASLD), Spring 2014.
358.
Kono Y, Gish RG. HCC Surveillance: An Inquiry into Current Practices in the United
States . Poster submitted for Digestive Disease Week 2014. CID: 1901686. McCormick
Place Convention Center, Chicago, IL., 5 May-2014.
359.
Chong SI, Gish RG, Nguyen C, Tran BN, Tsunoda S, Navarro-Cazarez N, Gutierrez J, P
Taylor P: Collaborative Efforts to Screen At-Risk Populations for Hepatitis B and C in
San Diego County: Singapore Hepatitis Conference, 6-7 June-2014.
360.
Nguyen L.T., Tran BN, Fontanesi J, Gish RG; Cost-Effectiveness Analysis of Point-of
Care versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders: Singapore Hepatitis Conference, 6-7 June-2014.
361.
Given BD, Locarnini A, Schluep T, Lau J, Lewis D, Gish RG, Lickliter J., A Phase I, first
in human clinical trial of ARC-520, a siRNA-based therapeutic for the treatment of chronic hepatitis B virus infection, in normal healthy volunteers, submitted for publication,
American Association for the Study of Liver Disease 2015., June 2014.
Curriculum Vitae
112
Gish, RG, Tran B, Nyguyen C, Pharm D., Cost effectiveness Analysis of Point-of-care
versus Standard of Care Tests for Hepatitis B in Asian and Pacific Islanders, Poster Abstract presentation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.
363.
Gish, RG, Tran B, Nyguyen C, Pharm D., Point-of-care testing for hepatitis C screening
at Community-Based-Organizations facilitates disease control, Poster Abstract presentation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.
364.
Gish, RG, Tran B, Nyguyen C, Pharm D., Targeting populations at risk for hepatitis B
using the Research Electronic Data Capture Program (REDCap), Poster Abstract
presentation, Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.
365.
Gish, RG, Tran B, Nyguyen C, Pharm D., Pearls gained from hepatitis B screening in the
Community setting), Poster Abstract presentation, Singapore Hepatitis Conference
2014, Singapore, June 5-7, 2014.
366.
Gish, RG, Tran B, Nyguyen C, Pharm D., Collaborative Efforts to screen at risk
populations for hepatitis B and C in San Diego County, Poster Abstract presentation,
Singapore Hepatitis Conference 2014, Singapore, June 5-7, 2014.
367.
368.
Wong RJ, Gish RG, Ahmed A; Hepatic Encephalopathy is Associated with Significantly
Increased Mortality among Patients Awaiting Liver Transplantation, Manuscript ID: LT14-198.R3; DOI: 10.1002/lt.23981, Wiley Online Library, 2014 Aug 25.
369.
Huang LY, Chang CC, Lee YS, Huang JJ, Chuang SH, Chang JM, Kao KJ, Lau GM,
Tsai PY, Liu CW, Lin HS, Gish RG, Lau JY; Inhibition of Hec1 as a novel approach for
treatment of primary liver cancer. Cancer Chemother Pharmacol. Sept2014;74(3):51120. doi: 10.1007/s00280-014-2540-7. Epub 20Jul2014.
370.
Ahn J, Gish RG, Hepatitis D Virus: A Call to Screening, Gastroenterology & Hepatology, 634-640, Gastroenterology & Hepatology Volume 10, Issue 10 Oct2014.
371.
Yuen MF, Lewis DL, Chan HLY, Lai CL, Given BD, Locarnini SA, Hamilton J, Lau
Johnson YN, Schluep T, Gish RG; Phase II, dose ranging study of ARC-520, a siRNAbased therapeutic, in patients with chronic hepatitis B virus infection, Abstract Poster
Presentation Publication Number: LB-21, American Association for the Study of Liver
Disease (AASLD), The Liver Meeting 2014, Boston, MA, 10Nov2014.
372.
Ramers CB, Wallace D, Gish RG, Lewis R, Wyles DL, Reyes L, Kuo A, One Year
Results of a Community-Based Hepatitis C Testing and Linkage to Care Program, Abstract ID 2094798, 22nd Conference on Retroviruses and Opportunistic Infections (CROI
2015). Washington State Conference Center, Seattle, WA, February 23 - February 26,
2015.
Curriculum Vitae
113
2.
3.
4.
Gish RG. Treating Chronic Hepatitis C: New Strategies for non-responders and
relapsers. AALSD Meeting Highlights. A CME monograph. Presented at an AALSD
Symposium. November 8, 1998.
5.
Gish RG. Management of End-Stage Liver Disease from Viral Hepatitis. Placerville CA.
April 25, 199.
6.
Gish RG. Liver Assist Device. Presented at a California Pacific Specialty Services
Continuing Medical Education. February 3, 2000.
7.
8.
Gish RG. Objective Structured Clinical Exercise (OSE). Presented at the University of
California, San Francisco. April 15, 2000.
9.
Gish RG. Plenary I & Presidential Address I. Presented at the American Society of
Transplantation (AST) Meeting. May 13, 2000.
10.
11.
Gish RG. Concurrent Communications. Presented at the AST Meeting. May 13, 2000
12.
13.
Gish, RG. Concurrent Communications III. Presented at the AST Meeting. May 13,
2000.
14.
Gish RG. Clinical Science Symposium: Practice Guidelines. Presented at the AST
Meeting. May 13, 2000.
15.
16.
Gish RG. Physicians on the Attack against Hepatitis C. Office.com. December 21,
2000.
Curriculum Vitae
114
Gish RG. Hepatitis C: Building a Response to the North State Crisis. Sacramento April
28, 2000.
18.
19.
20.
Gish RG, Afdhal N. New data on managing anemia with growth factors for patients on
anti-HCV therapy: a case-based series. Treatment Reporter: Gastroenterology.
September 2002.
21.
22.
Gish RG. Managing Liver Related Challenges. Presented at the AASLD Expert
Consensus. 2003
23.
Gish RG. Autoimmune Liver Disease. Presented at a Special CME Conference. March
18, 2003
24.
Gish RG. Hepatitis B. Presented at Sunrise Hospital, April, 2003. Las Vegas, NV.
25.
26.
27.
Gish RG, Surveying the Hepatitis C Landscape: Current Treatment and a Look at New
Options on the Horizon. Medical Media Communications. May 2004.
28.
Gish RG. Implications & Management of Anemia in Liver Disease. CME Monograph
Series, Volume 2, Issue 2, October 2004.
29.
30.
Gish RG. Plan for Success: Effective Side Effect Management in Anti-HCV Therapy.
DDW May 16, 2004.
31.
32.
Gish RG. HBV Infection in Clinical Practice. Tx Reporter: Gastroenterology. March 22,
2005.
33.
Gish RG. Phoenix Educational Initiative. Presented at The France Foundation, 2005.
34.
Gish RG. New Data on Emerging Therapies for the Treatment of Chronic Hepatitis B
Virus. PVI and University of Florida, January 2005.
Curriculum Vitae
115
36.
37.
38.
39.
Gish RG. Therapies for Hepatocellular Carcinoma. Informed, The Newsletter of the
Hepatitis B Foundation. No. 43:Spring, 2005.
40.
Gish RG. Controversies in Management of HBV: Lessons from Case Studies. October
12, 2005. CME-CD-ROM for Projects In Knowledge.
http://www.projectsinknowledge.com/Init/G/1718/
41.
Gish RG. Part I: Diagnosing HBV: Signs, Symptoms, and Diagnostic Tests for Chronic
Infection. December 7, 2005.
42.
43.
Gish RG. Immediately Useful Strategies for Improving Patient Outcomes. The
Treatment Reporter: Gastroenterology. Volume 1, Issue 6 2006.
44.
Gish RG. Part 7 of 9: Management of the HBV Coinfected Patient. The Treatment
Reporter: Gastroenterology. 2006.
45.
Gish RG. Part 8 of 9: A Steady Advance: Latest Findings from Anti-HBV Clinical
Trials. The Treatment Reporter: Gastroenterology. February 17, 2006.
46.
47.
Afdhal N, Gish R. Decreased Resistance and Good Safety With Newer Nucleos(t)ides
for Hepatits B. University of Florida/Peer View: Course Director Review. 2006.
48.
Curriculum Vitae
116
Gish RG, Di Bisceglie AM. In-Depth and Timely Response to Pressing Educational
Needs. Advanced Certificate Program in the Management of Chronic Hepatitis B: Members Update. 2006;1(7):2.
50.
Gish RG. HBV Review based on the proceedings from our satellite symposium at
AASLD 2006. CME activity for Projects in Knowledge.
51.
Gish RG, Newer Nucleos(t)ide Analogues Suppress Hepatitis B Virus, Reverse Disease
in Multiple Patient Populations. PeerView Press. February 15, 2006.
52.
Gish RG. Selecting Antiviral Therapy for a Treatment-Naive Patient with Hepatitis B
Posting 3. Practical Guidelines for Managing HBV in Special Patient Populations. August
16, 2006. CME activity for Projects in Knowledge.
53.
Dusheiko GM, Gish RG, Keeffe EB, Perrillo RP. Latest Findings in HBV Management. CCO Independent Conference Coverage of the 2005 Annual Meeting of the
American Association for the Study of Liver Diseases. San Francisco, CA. November
11-15, 2005. Slideset for Clinical Care Options, posted February 1, 2006.
54.
Gish RG. Assessing Antiviral Treatment Effect: Recognizing Primary and Secondary
Treatment FailurePosting 9. Practical Guidelines for Managing HBV in Special Patient
Populations. February 14, 2007. CME activity for Projects in Knowledge.
55.
56.
57.
Gish RG, expert commentary. Expert Insight Into: Provider Knowledge and Practice
Regarding Hepatitis B Screening in Chinese-Speaking Patients. Advanced Certificate
Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other
Diverse Communities. October 10, 2007. CME activity for Projects in Knowledge.
58.
Gish RG, expert commentary. Expert Insight Into: Why We Should Routinely Screen
Asian-American Adults for Hepatitis B: A Cross-Sectional Study of Asians in California.
Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. December 20, 2007. CME activity for
Projects in Knowledge.
59.
Gish RG, expert commentary. Expert Insight Into: A Randomized Controlled Trial of
Lamivudine to Treat Acute Hepatitis B. Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.
January 28, 2008. CME activity for Projects in Knowledge.
60.
Curriculum Vitae
117
Gish RG, Lau GKK. Case Study: Managing Genotype B HBV Infection in an Asian
Patient. TX Reporter Newsletter. Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities. November 29, 2007. CME activity for Projects in Knowledge.
62.
63.
Gish RG, Kim RW. Case Study: Managing Confounding Herbal Hepatotoxicity and
Familial Hepatocellular Carcinoma Risk in an HBeAg-Negative Vietnamese Immigrant.
TX Reporter Newsletter. Advanced Certificate Program III: Bridging Cultural Differences
to Improve HBV Treatment in Asian and Other Diverse Communities. February 27, 2008.
CME activity for Projects in Knowledge.
64.
Gish RG. Update on Hepatitis C Virus: epidemiology, natural history and treatment.
Saint Marys Regional Medical Center. July 24, 2008. 2 AMA Physicians Recognition
Award Category 1 Credits.
65.
Gish RG, Terry Baker, Misha Cohen, Stewart Cooper, Randy Dietrich, Gregory T.
Everson, Sylvia Flesner, Peter Hauser, Randy Horwitz, David W. Indest, Jessica Irwin,
Julia Jernberg, Joyce S. Kobayashi, Douglas R. LaBrecque, Lark Lands, Shri K. Mishra,
Sharon D. Montes, Julie Nelligan, J. Lyn Patrick, Bharathi Ravi, Aparna Roy, Lorren
Sandt, Kathleen B. Schwarz, Tina M. St. John, Amy E. Smith, Diana L. Sylvestre, Norah
Terrault, Sivarama Prasad Vinjamury, Qing Cai Zhang, Susan L. Zickmund. Hepatitis C
Choices, 4th Edition Diverse Viewpoints and Choices for Your Hepatitis C Journey.
Caring Ambassordors Program. 2008.
66.
Gish RG, Al B. Benson III, Morris Sherman, Barbara Sigler Morgan. Cases in Point:
Risk Factors, Surveillance Strategies and Treatment Options for HCC. Gastroenterology and Hepatology. Volume 5, Issue 1, Supplement 3. January 2009
67.
68.
69.
Gish RG, Update in Hepatocellular Carcinoma - The Latest Information on Pathogenesis, Screening and Treatment (Course HCC01.07). The Advanced Certificate Program
in Heptocellular Carcinoma Projects in Knowledge, Feb.2010.
70.
Gish RG, Hepatitis B Testing and Vaccination Among Vietnamese- and CambodianAmericans (Part 2 of Series) (Course HBV5.03), Advanced Certificate V, Bridging cultural Differences to Improve HBV Treatment in Saian and Other Diverse Communities, Project of Knowledge, March 2010.
71.
Robert Gish, USA Co-author White Letter A Plan of Action for Liver Disease in Viet
Nam March 2010
Curriculum Vitae
118
Wong, Robert, Robert Gish, A Clinical Assessment of Wilson Disease in Patients With
Concurrent Liver Disease" JCG9314 Accepted for publication. March 2010
73.
Robert Gish. Staying the Course: Patient Adherence Strategies in the Era of New
Frontline HBV Therapies Barriers to Treatment, Adherence in Asian Americans. Clinical Care Options CME/CE Certified Treatment Update. 2010.
74.
Robert Gish, The Secret Epidemic: Hepatitis C Affects Between Four and Six Million
Americans, , Bottom Lines Daily Health News, www.bottomlinesecrets.com, Feb, 7,
2006
75.
Robert Gish, New Drug for Hepatitis C, Bottom Lines Daily Health News,
www.bottomlinesecrets.com, May 19, 2011
76.
77.
Robert Gish, 35th Annual CAPA Conference, September 22- 25, 2011
78.
Gish, Robert., Learn About Hepatitis and Liver Diseases, www.BenhGan.org.; 2011.
79.
80.
81.
Robert G. Gish, Risk Assessment and Clinical Management of Patients with CHB,
Fullerton, CA Speaker, August 15, 2011
82.
Robert Gish, The Pacific Health Foundation Presents: Fourteenth Annual Liver
Symposium, Speaker, San Jose, CA, September 17, 2011
83.
84.
Robert Gish, Moores Cancer Center, San Diego, CA. November 2011.
85.
Robert Gish, Center for Biomedical Continuing Education, HCC Local CME Speaker
Program, 2011 2012.
86.
Robert Gish, University of Nevada, School of Medicine Grand Rounds, 2011 2012
87.
Robert Gish, Chronic HBV, Clinics in Liver Disease (Accepted for Publication),
May 2012.
88.
Speaker, Hepatitis Hot Topics GRS (?) (Short notice). Scripps Mercy Hospital San
Diego, February 22, 2013.
89.
Curriculum Vitae
119
91.
Wide Spread Hepatitis B screening and treatment in Vietnam CME meetings in Ha Noi
and HCMC, March 3-5, 2013.
92.
93.
Speaker, Current Insights into the Management of Hepatic Encephalopathy. The Chronic
Liver Disease Foundation, 2013 Hepatology Centers of Educational Expertise Lecture
Series. Ruths Chris Steak House, San Diego, CA. May 28, 2013.
94.
Speaker. Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center,
San Diego, CA. June 21, 2013.
95.
HCV Update. Sponsored by Duke University School of Medicine & the Chronic Liver
Disease Institute. Phoenix, AZ. January 20, 2014.
96.
Speaker & Educator, Viral Hepatitis Action Plan Webinar, Office of HIV/AIDS and
Infectious Disease Policy, Department of Health and Human Services, December 13,
2013.
97.
98.
Instructor, State of the Art Therapy for HCV, University of Washington, University of
Alabama Birmingham, IAS-USA online training module, Funded by a grant from the Centers for Disease Control and Prevention. March 15, 2014.
http://hepatitisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy
Curriculum Vitae
120
October 28th, 1997: Senate Interim Hearing, Public Safety Subcommittee on Prison
Construction and Operation (Senator Polanco, Chairman).
June 9th, 1998: Advisory Group on Hepatitis C, for the California Assembly Health
Committee on merits of Senate Bill 694 introduced by Senator Polanco (Public education
and screening for hepatitis C virus)
April 14, 2000: Coalition Members, Deparment of Health and Human Services (DHHS) Task
Forced On Hepatitis C.
June 6th, 2000: Advisory Group on Hepatitis C for the California Assembly Health
Committee on merits of Senate Bill 1256 introduced by Senator Polanco (Public education
and screening for hepatitis C virus)
May 4, 2001. CASG HCV/Civacir protocol re: NIAID Collaborative Antiviral Study Group
(CASG) clinical trial A Randomized Open-label, Phase I/II Study to Evaluate the Safety and
Pharmacokinetics of Hepatitis C Immune Globulin (Human) Civacir in Liver Transplant
Recipients
2002: Center for Policy Reform Senate Bill AB 2529 (Hep C prevention education for
prisoners).
March 26, 2014: Liver Capitol Hill Day in association with the American Association for the
Study of Liver Diseases, Washington, D.C.
Meeting Participant, The White House Initiative on Asian Americans and Pacific Islanders
(AAPI); Data.gov & AAPI Stakeholder Conference Call, September 30, 2014.
Curriculum Vitae
121
EDUCATIONAL EVENTS
X550 Dinner Program with Temecula-Area Group of Heptologists, Temecula, CA. October,
2011.
Facilitator, Academic Health Centers & Health Reform: Re-establishing the Social
Contract, University of California, San Diego Department of Medicine Grand Rounds, February 8, 2012.
EASL, The International Liver Congress 2013, 48th Annual Meeting of the European
Association for the Study of the Liver. Amsterdam, Netherlands. 24 hours. April 26, 2013
Grand Rounds, Internal Medicine Residents & Fellows, Penn State University Medical
Center, Hershey, PA, October 18, 2013.
Facilitator, HBV Task Force, St Josephs Medical Center, Phoenix, AZ March 19, 2014.
Endoscopic Ultrasound: Lok Tio M.D., and Therapeutic Biliary Endoscopy: Kees
Huibregtse, M.D. Academic Medical Center, Amsterdam, Netherlands, June 1-30, 1989.
AASLD Annual Postgraduate Course and Research Meeting, Chicago, Illinois, 1984present.
DDW Annual Postgraduate Course and Research Meeting. Various 1985, 1988, 1991,
1992, 1993, 1994.
Laparoscopy and Liver Biopsy. Under the direction of Lennox Jeffers, M.D., University of
Miami, Miami, Florida, 1992.
Liver Transplantation and Viral Hepatitis. NIH, AASLD Symposium, Reston, Virginia, March
25, 1993.
Liver Transplantation for Alcoholic Liver Disease, ASTP/AASLD Forum, Bethesda, Maryland,
December 3, 1996.
Curriculum Vitae
122
Liver Transplantation for Alcoholic Liver Disease, The National Institute of Diabetes and
Digestive and Kidney Diseases, Washington, DC, December 6, 1996.
Testing for Hepatitis C: New Technologies for Optimal Therapy. Trevose, PA. November 14,
2001; December 13, 2001; December 17, 2001.
HCV Side Effects Consensus Conference. San Francisco, CA. May 18, 2002.
AASLD Annual Meeting and Postgraduate Course, Boston, MA October 24-28, 2003.
Evolving Concepts in Liver Allocation in the MELD/PELD Era. Washington DC, December 8,
2003.
Attendee, PBC: Past, Present & Future, The Royal College of Physicians, London, United
Kingdom, April 8. 2014.
Attendee, Towards HCV elimination in Georgia: epidemiology, care and treatment options,
and evidence based control strategies. International Liver Congress 2014, European Association for the Study of the Liver, London. United Kingdom, April 9, 2014.
Curriculum Vitae
123
Hepatitis B Prevention and Transplantation. Viacom Cable Channel 6, City Lights. June, 1992.
Hepatitis B Prevention and Transplantation. Nationally televised program hosted by Dr. Dean
Edell. June, 1992.
The Three H's: Headaches, High Blood Pressure, and Hepatitis B. Presentation to the Liver
Transplant Recipient Support Group, California Pacific Medical Center. San Francisco,
California. July 8, 1992,
Organ Donation. Kaiser Permanente Medical Center. Walnut Creek, California. November 10,
1993.
Hepatic Hotline. Moderator, American Liver Foundation patient and community conference on
hepatitis, St. Mary's Hospital. San Francisco, California. October 29, 1994.
Liver Disease. Liver Disease Support Group. Modesto, California. January 22, 1995.
Viral Hepatitis: Vaccination and Prevention. San Francisco Veteran's Administration Medical
Center. San Francisco, California. October 17, 1995.
Your Liver, Your Life. Public Education workshop. American Liver Foundation, San
Francisco, California. October 7, 1995.
Liver Disease, Liver Transplantation and Organ Donation. Moderator, Public Round Table
Forum, American Liver Foundation. San Francisco, California. October 25, 1995.
Chronic Hepatitis. Public questions and answer period. Eureka, California. December 13,
1995.
Evaluation of Patients with Elevated Liver Enzymes and Viral Hepatitis. Shasta Community
Health. Redding, California. May 14, 1996.
Recurrent Disease after Liver Transplantation. American Liver Foundation, San Francisco,
California. May 18, 1996.
Organ Transplantation and its Psychosocial Implications. Chico Support Group. Chico,
California. September 13, 1996.
Curriculum Vitae
124
Hepatitis C in the Correction System. Folsom State Prison. Folsom, California. October 8,
1996.
Hepatitis A-Z. North Coast Society of Health System Pharmacists. Santa Rosa, California.
January 22, 1997.
Patient Support Group Lectures. John Muir Hospital. Walnut Creek, California. January 30,
1997.
Nutrition for the Liver. Support Group Lecture. Sutter General Hospital. Sacramento,
California. February 19, 1997.
Patient Support Group Lecture. Sacramento Support Group. Sacramento, California. March
1, 1997.
HVC Support Group. Sutter General Hospital., Sacramento, California. March 19, 1997.
The ABC's of Hepatitis. East County (Contra Costa) Times. May 6, 1997.
Dialogue on Digestive Health Awareness. DDW Telephone Program. May 15, 1997.
Hepatitis C: An Epidemic in the Prison System. National Radio News Show: 14 Radio
Interviews between October 23-24, 1997.
Hepatitis C: Setting up and continuing support groups, ALF effort, San Francisco, California,
5/6/98.
Hepatitis C: New treatment options. American Liver Foundation North California Chapter
newsletter, San Francisco, California. June 13, 1998.
Patient Support Group Lecture. San Francisco Veterans Administration Hospital. April 14,
1998.
Hepatitis C Increasing public awareness. Radio America interview with 19 national radio
shows. June 10, 1998.
Curriculum Vitae
125
Alternatives in the treatment of chronic hepatitis C infection. American Liver Foundation, Liver
Lifeline. June, 1998
National Youth Leadership Conference: Forum on Medicine. Berkeley, California. July 16,
1998.
The silent epidemic: Hepatitis C. San Jose, California. August 21, 1998
I Will Survive. Sacramento Area Support Group. Sacramento, CA. March 15, 2000.
Hepatitis Central guest speaker, questions and answers on line. San Francisco, California.
January 27, 2000.
Is Hepatitis an Epidemic? What are current treatments? KSUF Radio Interviews, San
Francisco, California. April 22, 2000.
Dark to dawn: A lesson in living: Liver Transplant patient Wendy Marx. San Francisco
Examiner. San Francisco, California. May 7, 2000.
Hepatitis: Cases of disease rising, and it could get worse. Santa Barbara News. Santa
Barbara, CA. January 18, 2001.
Hepatitis Neighborhood Town Hall hosted chat sessions. San Francisco, California. March 7,
2001.
Galileo High School Students discussion on cirrhosis and liver failure. December 13, 2001.
Hepatitis C education: The Need at the Professional Level. The First inter-county California
Statewide HSC Task Force Conference. Sacramento, California. March 13, 2002
Managing Treatment Outcomes for HCV-Related Anemia. AdvancMed. May 29, 2002
2002 Laguna Development Meeting for Clinicians Companion VI. Secaucus, NJ. August 2002.
Advances in the Care of Patients with Autoimmune Liver Disease. AXCAN Scandipharm.
Honolulu, HI. September 17, 2002.
Hepatitis C Community Health Update. San Francisco, CA. October 24, 2002.
Curriculum Vitae
126
Alameda County Health Care Services Agency. Oakland, CA. November 14, 2002.
Hepatitis B providers event. NICOS Chinese Health Coalition. May 28, 2003.
AWARE Talk Radio. Interview with Dr. Robert Gish. November 9, 2004.
The 4th Annual Asian Heritage Street Celebration. Japantown. San Francisco, CA. May 17,
2008.
CP#384 event launching on the West side of the City. Picture and comments listed. Ming
Pao News Reporting. November 27, 2008.
Robert Gish takes the helm of hepatitis B prevention. San Francisco Examiner
Newspaper. Article by: Andrea Koskey. May 27, 2010.
Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2011.
Hepatitis Screening Education with Asian Pacific Health Foundation, Wesley First United
Methodist Church, San Diego, CA May 29, 2011.
Spring Community Health Fair, Wesley First United Methodist Church, May 22, 2011
FAIR Foundation Support Group, Rancho Mirage, CA, June 27, 2011
Clinical Care Options, Bringing into Focus: A Practical Guide to Using Virologic and
Serologic Tests in the Management of Hepatitis B June 2011
Community Health Outreach; Hep B & C Screening, San Diego, June 26, 2011
Curriculum Vitae
127
Hepatitis Screening Education with Asian Pacific Health Foundation, Chinese Evangelical
Church, San Diego, CA July 31, 2011.
Update on the Treatment of Liver Cancer, CancerCare Teleconference, August 18, 2011
UDW 2nd Annual San Diego County Health and Resource Fair (hosted by Skaggs School of
Pharmacy and the Asian Pacific Health Foundation), San Diego, CA August 2011.
Domino liver transplants treats two rare diseases, Donate Life, features Allan Hemming,
MD and Robert Gish, MD. CBS 8, KPBS, NBC-SanDiego, 10News, The La Jolla Light, Fox
5, 760AM and BioPortfolio, September 2011
Hepatitis Screening Education with Asian Pacific Health Foundation, Tzu Chi, San Diego,
CA September 11, 2011.
Hepatitis Screening Education with Asian Pacific Health Foundation, Hzi Fang Temple, San
Diego, CA September 25, 2011.
HBV Chinese Community Event held at the office of the Asian Pacific Health Foundation.
October 2011.
Health Fair for the Vietnamese Federation of San Diego, San Diego, presented topic:
Updates on Hepatitis B, October 2011.
Hepatitis Screening Education with Asian Pacific Health Foundation, Vietnamese Federation, San Diego, CA October 14, 2011.
Hepatitis Screening Education with Asian Pacific Health Foundation, La Jolla Country Day,
San Diego, CA November 6, 2011.
Hepatitis Screening Education with Asian Pacific Health Foundation, Middlebrook Middle
School, San Diego, CA , December 3, 2011.
Asian Journal-Los Angeles, San Francisco, Las Vegas, New York, November 2011.
Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2012
Participant: Buddhist Tzu Chi Foundation San Diego Service Center: Lunar New Year
Blessing Ceremony, San Diego, CA, January 2012.
Curriculum Vitae
128
Event Organizer, Hepatitis Free San Diego Introductory Meeting, Skaggs School of
Pharmacy, Sponsored by Merck Co, La Jolla, CA January 31, 2012.
Bottom Line Personal (Home of Americas Top Experts in Everything), Everyone born
between 1945 and 1965 should be tested for Hepatitis C, Volume 33, Number 3, February
1, 2012.
The Doctors TV program, Topic: Nail Salon Dangers, featuring Robert Gish, MD.
February 2012.
Facilitator, Asian Pacific Health Foundation Training Session: Handling and Disposal of
Supplies and Barriers Study Surveys, Asian Pacific Health Foundation, San Diego, CA
February 14, 2012.
Hepatitis Screening Education with Asian Pacific Health Foundation, Wesley First United
Methodist Church, San Diego, CA April 4, 2012.
Hepatitis Screening Education with Asian Pacific Health Foundation, Thai Temple (New
Year), San Diego, CA April 19, 2012.
Hepatitis Screening Education with Asian Pacific Health Foundation, Taiwanese American
Community Center, San Diego, CA May 19, 2012
Hepatitis Screening Education with Asian Pacific Health Foundation, Vietnamese Federation, San Diego, CA June 10, 2012.
Hepatitis Free San Diego, Family Health Day Hepatitis B and C screening Organized by the
Tzu-Chi, St. Peters Church, Fallbrook, CA; June 29, 2012.
Hepatitis Free San Diego, Participant, 2012 Annual Convention of the Vietnamese American
Medical Association, Orlando, FL; August 5, 2012.
Hepatitis Free San Diego Community Outreach, Union of Homecare Workers (UDW), Joan
Kroc Community Center, San Diego, CA; August 25, 2012.
Hepatitis Free San Diego Hepatitis B and C pilot run Wesley First Methodist Church, San
Diego, CA; August 27-29, 2012.
Hepatitis Free San Diego Hepatitis C screening at the UCSD HERE Initiative (Health + Education
+ Research = Empowerment), Jacobs Center, San Diego, CA; September 8, 2012.
Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation targeting
Laotian and Cambodians in East San Diego, Colina Park, San Diego, CA; December 16,
2012.
Facilitator, La Jolla High School Organ Tour, University of California, La Jolla, CA, 2013.
Curriculum Vitae
129
Hepatitis B Screening, Asian Pacific Health Foundation, Good Shepherd Church, San
Diego, CA; January 12, 2013.
Feature Article, A Hep B Free San Diego, Discoveries Magazine, Innovations in Research,
Health Care and Education Volume 3 / 2012.
Tzu-Chi Family Health Day, Asian Pacific Health Foundation, Asian Hepatitis B Screening
for Asians, Saint Peters Church, Fallbrook, CA.; January 13, 2013.
Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation, Our Lady of
Sacred Heart Church, San Diego, CA; January 20, 2013.
Hepatitis B Screening with Dr. Julio Gutierrez, Asian Pacific Health Foundation, Coolidge
Park, San Diego, CA; January 27, 2013.
32nd Annual Advanced Nephrology: Nephrology for the Consultant, San Diego, CA; January
31, 2013 February 02, 2013.
National AIDS Treatment Advocacy Project, Sexual Transmission of HCV Among Monogamous Heterosexual Couples: The HCV Partners Study, Abstract by: Norah A. Terrault,
Jennifer L. Dodge, Edward L. Murphy, John E. Tavis, Alexi Kiss, T.R. Levin, Robert Gish,
Michael Busch, Arthur L. Reingold, Miriam J. Alter, (Center for Disease Control and Prevention); February 22, 2013.
Liver Cancer Webinar: Liver Cancer and Hepatitis B: What You Need to Know, Presented
by the Hepatitis B Foundation, Doylestown, PA; March 6, 2013.
Hepatitis B Consultative Meeting: National Viral Hepatitis Task Force (NVHTF) and Viral
Hepatitis Foundation (VHF) a public private partnership to formulate a Road Map for Viral
Hepatitis Control and Prevention in the Philippines, Manila Philippines; March 11, 2013.
Hepatitis B and C screenings: presented by Asian Pacific Health Foundation San Diego
Chinese School, San Diego, CA; March 16, 2013.
Robert Gish, Baby Boomers & Hepatitis C Test, UCSD Online Content, March 2013.
Hepatitis Screening Education with Asian Pacific Health Foundation, San Diego Chinese
School, San Diego, CA March 16, 2013
Hepatitis B and C screenings: presented by Asian Pacific Health Foundation Health Fair:
Wesley First United Methodist Church, San Diego, CA; March 17, 2013.
Curriculum Vitae
130
Hepatitis B Screening, Asian Pacific Health Foundation with Dr. Binh Tran, Nhu Lai Temple,
San Diego, CA, March 19, 2013.
Hepatitis Screening Education with Asian Pacific Health Foundation Vietnamese Federation
of San Diego, San Diego, CA. April 14, 2013
Gish RG, Alain, Litwin, An Evolving Therapeutic Landscape for Chronic Hepatitis C Virus:
Optimizing the Linkage to Care. MD Magazine, Peers & Perspectives Special Issue. May
2013.
Hepatitis B screening, Asian Cultural Festival, Naval Training Center Liberty Station, San
Diego, CA; May 11, 2013.
Attendant, Representing Coalition for the Eradication of Viral Hepatitis in Asia Pacific
(CEVHAP) and National Viral Hepatitis Roundtable (NVHR) Organizations, Viral Hepatitis
Action Coalition, Atlanta, GA.; May 17, 2013.
Hepatitis B screening with Dr. Binh Tran, Asian Pacific Health Foundation, Nhu Lai Temple ,
San Diego, CA May 19. 2013.
Hepatitis Screening Education with Asian Pacific Health Foundation, Mabuhay FilippinoAmerican Festival, National City, CA. June 8, 2013.
Speaker. Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center, San
Diego, CA. June 21, 2013.
Hepatitis B and C screenings with Yi Liu, PhD: presented by Asian Pacific Health Foundation, Zion Market, San Diego, CA; June 29, 2013.
Guest Speaker, PBS Television, PBS radio and NPR; Hepatitis B Prevalent in San Diego's
AsianCommunities, Global update, July 1, 2013.
Hepatitis B and C screenings with Yi Liu, PhD: presented by Asian Pacific Health Foundation, Zion Market, San Diego, CA; June 29, 2013.
Health Fair & Hepatitis B Screening in association with Binh Tran & Asian Pacific Health
Foundation; San Diego Lantern Festival; San Diego CA, July 20-21, 2013.
Health Fair & Hepatitis B Screening in association with Binh Tran & Asian Pacific Health
Foundation; Vietnamese Catholic Center; July 27, 2013.
Curriculum Vitae
131
Hepatitis Screening Education with Asian Pacific Health Foundation, Tzu Chi Foundation,
San Diego, CA, October 19, 2013.
Hepatitis Screening Education with Asian Pacific Health Foundation Nov 2 Health Wellness
Fair at Paradise Valley Hospital, San Diego, CA, November 2, 2013.
Hepatitis B Special Interest Group: SIG Business Meeting, Washington D.C., November 3,
2013.
Sponsor & Supervisor, Hepatitis B Screening, Asian Pacific Health Foundation with Dr. Binh
Tran, Tet Festival, San Diego, CA; February 1, 2014.
Asian Pacific Health Foundation with Dr. Binh Tran, Spring Health Fair at Vietnamese
Federation, San Diego, CA; February 9, 2014
Hepatitis B screening and Bone densitometry Asian Pacific Health Foundation with Dr. Binh
Tran, Living Water Church, San Diego, CA; March 9, 2014.
Liver Capitol Hill Day in association with the American Association for the Study of Liver
Diseases, Washington, D.C., March 26, 2014.
Video Interview, HBV treatment and reactivation, Center for Liver Disease (CLD) Journal,
European Association for the Study of the Liver, London, United Kingdom, April 10, 2014.
Public Service Announcement for National Viral Hepatitis Testing Day. Produced by CBS
local affiliate KPIX-TV and KBCW-TV, San Francisco for national distribution, April 18, 2014.
La Jolla High School, Anatomy and Physiology class, Organ tour of cadaveric organs 2
hours, April 28, 2014.
Boy Scout Troop 4, La Jolla, CA, Organ tour of cadaveric organs, 1 hour, April 28, 2014.
Community Outreach and Screening, Asian Pacific Health Foundation, Wesley First United
Methodist, San Diego CA, May 18, 2014.
Guest Speaker, (HELP!) Community Event, Speaker; Hepatitis C Today & Tomorrow:
Triage or Treatment?, Santa Cruz Bible Church, Santa Cruz, CA. July 21, 2014.
Community Outreach and Screening, Asian Pacific Health Foundation, Vietnamese Alliance
Church of North San Diego , San Diego, CA, July 20, 2014.
Community Outreach and Screening, Asian Pacific Health Foundation, Holy Family Church,
San Diego, CA; August 10, 2014.
Community Outreach and Screening, Asian Pacific Health Foundation, Wesley First United
Methodist, San Diego CA, August 23, 2014.
Curriculum Vitae
132
Curriculum Vitae
133
Robert Gish, Nguyen Tien Duc, Bui Duy Tam. Detection, Prevention, Control and Treatment
of Viral Hepatitis, Liver Cancer and Other Liver Disease in Viet Nam. February 11, 2010.
Robert Gish, Huy Trinh. Overview of US Medical Schools and comparison to the Viet Nam
and University of Ha Noi programs Ha Noi Medical University, Ha Noi, Viet Nam 8 30 10
Robert Gish, Yerevan, Armenia Yerevan Hepatology Days, Aug 31 Sep 4, 2011
Robert De man and Robert G Gish, et al (INCOMPLETE AUTHORS), Abstract A-5330019-01294 entitled: Impact of Entecavir Versus Lamivudine on Hepatic Covalently ClosedCircular DNA and Total Hepatic HBV DNA in Nucleoside-Nave HBeAg Positive Chronic
Hepatitis B Patients. Both ePoster and Paper poster, International Liver Congress 2013
(ILC), Amsterdam, Netherlands; April 26, 2013.
Robert Gish, Binh Tran, John Fontanesi, Lilly Nguyen Co-Author, Cost Efficiency Analysis
of Point-of-Care versus Standard of Care Tests for Hepatitis B in Asian Americans in San
Diego Count. Asian Pacific Health Foundation, UCSD. Summer 2013.
Robert Gish, Binh Tran, John Fontanesi, Thuy Nguyen, Co-Authors. Cost-Effectiveness of
Hepatitis C Screening: Point of Care (POC) vs. Standard of Care Tests. Hepatitis Free San
Diego, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Summer 2013.
Robert Gish, Binh Tran, John Fontanesi, Xuan Phan. Co-Authors Viral Hepatitis: Early
Identification and Linkage to Care for Persons with Chronic HBV and HCV infections Hepatitis Free San Diego. UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences,
Summer 2013.
Participant, Hepatitis B Prevention PLAN for HCMC University of Health, San FranciscoHCMC Sister City Committee & International Liver Foundation for Viet Nam. Hepatobiliary
Hospital. Bach Mai, Hanoi, Viet Nam. 2013 Present
Curriculum Vitae
134
Thrive: The Cutting Edge: New Therapies for Hepatitis B and C. 1998.
Speaker, Liver Cancer and Hepatitis B - What You Need to Know, 2013 Liver Cancer
Webinar Series, Hepatitis B Foundation, March 6, 2013.
Curriculum Vitae
135
Liver transplantation for malignancy, and The use of databases in the management of a liver
transplant program, in Spanish, Associacion Andaluza de Cirujanos, Cordoba, Spain,
12/13/90.
Acute and chronic liver disease, Straub Clinic, Honolulu, Hawaii, 1/30/91.
Liver cancer, Sixth International Conference on Health Problems Related to the Chinese in
North America, San Francisco, California, 6/19/92.
Liver transplantation for patients with alcoholism and endstage liver disease, American
Society of Addiction Medicine, Los Angeles, California, 5/1/93.
Liver transplantation for alcoholic liver disease, University of Nebraska, Omaha, Nebraska,
4/29/94.
HCV workup meeting, Tufts University School of Medicine, Boston, Massachusetts, 3/23/963/24/96.
Curriculum Vitae
136
Hepatitis A-Z and its relationship to organ transplantation, National Association of Transplant
Coordinators, San Diego, California, 8/5/96.
Viral hepatitis and liver transplantation, Ochsner Medical Clinic, New Orleans, Louisiana,
3/23/97.
Diagnosis and treatment of chronic hepatitis, Alaska Regional Medical Center, Anchorage,
Alaska, 5/7/97.
Diagnosis and treatment of elevated liver enzymes, Providence Hospital, Anchorage, Alaska,
5/9/97.
The outpatient management of patients with chronic viral hepatitis, Washington, DC, 5/15/97.
Diagnosis and treatment of hepatitis C, Summary of the NIH Conference, St. Louis,
Missouri, 5/16/97.
Diagnosis and treatment of liver cancer, Las Vegas Gastroenterology Group, Las Vegas,
Nevada, 6/2/97.
Curriculum Vitae
137
New and Emerging Therapy for Hepatitis C, Canadian Digestive Disease Week, Banff,
Canada, 3/5/98.
Selection of patients for liver transplantation with liver cancer, NIH/AASLD Single Topic
Conference, Saint Louis, Missouri, 3/28/98
Interferon and ribavirin treatment for chronic hepatitis C: A review of recent data, Cheng Si
Yuan, Conference on Viral Hepatitis, Shenzen, China, 9/14/98
The Therapeutic Standard Strategy for Chronic Hepatitis C, Luncheon Seminar, DDW
Japan 1999
Hepatitis C new therapies, Interferon and Ribavirin Japanese DDW, invited lecture, 9/2000
HCV Research and Prevention, New approaches to HCV therapy HCV Global Foundation,
San Francisco, CA 08/10/01.
Hepatitis B and Liver Transplantation Beijing Friendship University, Beijing, China,
8/30/2001
Interferon and ribavirin treatment for chronic hepatitis C: A review of recent data,
Autoimmune Hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis,
Conference of Science and Technology, Conference on Liver Disease, Beijing, China,
8/13/2001
Curriculum Vitae
138
Hepatitis and liver transplant, current standards of therapy, Barcelona Liver Disease
Symposium, Barcelona Spain, 9/24/2001
Interferon and ribavirin, importance of dosing and compliance Japanese DDW, Osaka and
Tokyo, Japan 10/24/2001
Hepatitis C: 2001, a virus odyssey, New Horizons in Hepatology, UCSD Liver Center 2001,
San Diego, California 9/15/2001
Testing for Hepatitis C: New Technologies for Optimal Therapy. US teleconference. CME
accredited 11/14/2001, 12/3/2001, 12/17/2001.
The workup and evaluation of liver tumors Early AM workshop, AASLD 11/5/2001
CSY China Itl Hepatitis Research Foundation. Hong Kong, China 10/20/2001
Hepatitis C management advances in therapy. William Earl Clark Society. April 30, 2002
Treatment and the HCV Patient including the role of Alternative and Complimentary
Medicine Hepatitis Foundation International. Los Angeles, CA. July 18, 2002
Living Longer, Living Stronger: Maintaining the Quality of Life for Patients with Anemia &
HIV Infection. Institute for Continuing Healthcare Education. Las Vegas, NV. September 4,
2002. Earned CME credit.
Autoimmune hepatitis, PSC and PBC. U-Japan Meeting on Autoimmune Liver Diseases.
Oahu, HI. 9/12-14/2002
Advances in the use of molecular testing for HCV: Diagnosis and treatment. Bayer
Diagnostics. Taipeo, Taiwan. 9/27/02
Curriculum Vitae
139
Parallel Session XXXIV Primary Biliary Cirrhosis. ILTS Transplant Course. AASLD. Dallas
Texas. 10/27/2002
Cholestatic and Autoimmune Liver Diseases: ILTS Transplant Course. AASLD. Dallas
Texas. 10/27/2002
Hepatitis C: Mechanisms & other treatment issues: ILTS Transplant Course. AASLD.
Dallas Texas. 10/27/2002
106-Optimal Use of Lamivudine before & after liver transplantation? When should
Lamivudine be initiated in patients awaiting liver transplantation?. Liver Transplantation for
Viral Hepatitis. AASLD. 11/01/2002
Maximizing the Benefits of Antiviral Therapy for HCV, The Advantages of Treating Side
Effects, Orlando, FL 5/20/03
HVC Disease Update: Diagnosis and Management, Las Vegas, Nevada, 8/25/2003
Curriculum Vitae
140
Case Histories in the Management of Patients Chronically-Infected with HBV Hong Kong,
China, 2/17/04.
Surveying the Hepatitis C Landscape, Emerging Treatment Options on the Horizon, Berlin,
Germany, 4/14/04.
HBV Hardball-An in-dept Analysis and Fiery Debate on Optimizing Outcomes in the
Treatment of Hepatitis B Virus Nov. 9, 2004, New York.
Face B- Bristol Myers Squibb Hepatitis B Speakers Bureau Conference : Facing a New
Future, Washington, D.C., April 2005
Virologic Response and Safety Outcomes in Therapy-Nave Patients Treated for Chronic
Hepatitis C with Virmadine in Combination with Pegylated Interferon ALFA-2A, DDW
Chicago, IL, May 2005
Entecavir is Well Tolerated for the Treatment of Nucleoside-Nave and LamivudineRefractory Chronic Hepatitis B: Phase 2/3 Safety Results, DDW Chicago, IL May 2005
Alanin Aminotrasferease (ALT) Flares are les Frequent with Entecavir than Lamivudine
Treatment Both On- and Off- Treatment in HBeAg(+) Patients, DDW Chicago, IL, May 2005
Current Diagnostics and Management of HBV Drug Resistant. Saigon, Vietnam. August
29, 2010.
NAT/PCR Role as a Decisions Tool for the Management of Chronic Hepatitis B. Saigon,
Vietnam. August 29, 2010.
Curriculum Vitae
141
NAT/PCR Role as a Decisions Tool for the Management of Chronic Hepatitis B. Hanoi,
Vietnam. September 1, 2010.
New Hepatitis B Treatments: Long-Term Therapy: Balancing the Risk and Benefits as We
Pursue Sustained Viral Clearance. Viral Hepatitis Conference 2010. Melbourne, Australia.
September 6, 2010.
CHB Treatments, Endpoints & Stopping Rules. New Agents, Better Outcomes. Viral
Hepatitis Conference 2010. Melbourne, Australia. September 7, 2010.
Boceprevir in Practice; MSD Singapore. MSD Hepatitis Advisory Board Meeting, October
2011.
Speaker, Advancing Hepatology in New Era: Milestones and Perspectives, 67TH Annual
Conference of the Association of Physicians of India, Science City, Kolkata, India, January
12 15, 2012.
Speaker, Asian Pacific Association for the Study of the Liver (ASPASL), Taipei, Taiwan,
February 15, 2012.
Participant, Polaris Group Lunch and Investigator Meeting on: A Randomized, DoubleBlind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus
Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have
Failed Prior Systemic Therapy, The Intercontinental San Francisco Hotel, , San Francisco,
CA January 19, 2012.
Speaker, Simply Speaking, HBS: An Expert Educators CME Lecture Series, Grand Hyatt,
San Antonio, TX, January 21, 2012.
Facilitator, Guest Lecture Series, M. Bishr Omary, Chair, Department of Molecular &
Integrative Physiology, University of Michigan, Ann Arob, Keratins: Genetic Modifiers of
Liver disease and Required Components of Mallory-Denk Bodies, January 26. 2012.
Curriculum Vitae
142
Asian Pacific Association for the Study of the Liver. Taipei. February 12-19, 2012
Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP). Taipei, February 19, 2012
Speaker, Gilead GS09620 Protocols Investigators Meeting, St Francis Hotel, San Francisco, CA., March 3, 2012.
Speaker, Management of Chronic Hepatitis C Infection, One Patient at a Time, Merck March
Talks, Reno, NV, March 15, 2012.
Speaker, Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Merck March Talks, San Diego, CA, March 20 - 21, 2012.
Speaker, HBV update, Moderator, Panel Discussion, National Liver Conference 2012, San
Antonio, TX, September 22, 2012.
Speaker, Liver Transplantation, University of Nevada, School of Medicine, Las Vegas, NV,
January 30, 2013.
Presentation on Liver Disease, Digestive Disease Forum. Patient Case Conference, Good
Samaritan Regional Medical Center, 3600 NW Samaritan Drive, Corvallis, OR. February 22,
2013.
Speaker, Hepatitis B World Advocacy Meeting, Philadelphia, PA, March 16, 2013.
Speaker, Part 2: Review of HCV Data from AASLD; Liver Journal Club, NEED CITY,
March 5, 2013.
Speaker, Liver Cancer and Hepatitis B? What You Need to Know, 2013 Liver Cancer
Webinar Series, Hepatitis B Foundation, March 6, 2013.
Moderator & Speaker, National Viral Hepatitis Task Force and Viral Hepatitis Foundation
Convention, Makati, Philippines, March 11-12, 2013.
Curriculum Vitae
143
Speaker, Chronic Viral Hepatitis: Epidemiology, Who to Screen, How to Screen and
Linkage to Care A Focus on Viral Hepatitis B and C in Viet Nam, Bach Mai Hospital,
Hanoi, Viet Nam, March 15, 2013.
Chronic Hepatitis C Therapy: Current and Future Perspectives. St. Lukes 4th Liver and
2nd Gastroenterology International Symposium. St. Lukes Medical Center, Global City,
Philippines. June 2, 2013.
Meet the Expert 2: Individualized Therapy in Chronic Hepatitis B. St. Lukes 4th Liver and
2nd Gastroenterology International Symposium. St. Lukes Medical Center, Global City,
Philippines. June 2, 2013.
Speaker, Summary of the Viral Hepatitis Action Committee Meeting May 16-17 in Atlanta,
GA, CEVHAP General Meeting, Singapore. June 2013.
Speaker, The Histologic Improvement due to the Oral Anti Viral Treatment Treatment in
CHB Patients, 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul
120-752,Korea; July 5, 2013.
Speaker, Combination TDF + ETV Therapy in Chronic Hepatitis B Patients with Previous
Treatment Failure, 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul
120-752, Korea; July 5, 2013.
Panelist, 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2013), Seoul 120752,Korea; July 6, 2013.
Curriculum Vitae
144
Management of Chronic Hepatitis B in Asian Americans, Vietnamese Physicians Associations of America (VAMA), Seattle, WA; August 8-11, 2013.
Speaker, Viral Hepatitis E The 2nd Biannual International Conference of Armenian Hepatological Forum, September 6, 2013.
Chair and Speaker, Global Hepatitis Overview, The 2nd Biennial International Conference
of Armenian Hepatological Forum, Yerevan, Armenia, September 6, 2013.
Speaker, Current Therapy of Hepatitis B. Planning for 2013 and Beyond, Where East
Meets West, Search for a Cure, The 2nd Biennial International Conference of Armenian
Hepatological Forum, Yerevan, Armenia, September 7, 2013.
Speaker, Hepatitis E, The 2nd Biennial International Conference of Armenian Hepatological Forum, Yerevan, Armenia, September 7, 2013.
Speaker, The Liver Meeting, Hepatitis Delta International Network Meeting, Participant,
Washington, D.C., November 2, 2013.
Moderator, The Liver Meeting, Liver Cancer Roundtable in Association with Caring
Ambassadors, Robert Gish moderator. Washington, D.C., November 5, 2013.
Facilitator, The Liver Meeting, Panel Discussion, HCC Surveillance Protocol Utilizing
Biomarkers, Robert Gish, MD; Facilitator, Walter E. Washington Convention Center, Washington, D.C. (in association with Wako Life Sciences, Inc.), November 3, 2013.
Curriculum Vitae
145
Speaker, Treatment of HIV-Coinfected Patients in the Era of the DAAs. 3rd Annual Asian
Pacific Study of the Liver(APASL) Conference, 21 November 2013. Cebu Philippines.
Speaker, HBV: State of the Art. 3rd Annual Asian Pacific Study of the Liver Conference
(APASL). November 22, 2013. Cebu, Philippines.
Speaker, Novel Approaches for the Treatment of Hepatitis B, Viral Hepatitis Grand
Rounds, Perelman School of Medicine, University of Pennsylvania CME; January 15,
2014. Speaker, Viral Hepatitis Grand Rounds from the University of Pennsylvania, Philadelphia, PA; January 15, 2014.
Speaker, State of the Art Therapy for HCV, University of Washington, University of Alabama
Birmingham, IAS-USA online training module, Funded by a grant from the Centers for Disease Control and Prevention. March 15,
2014. http://hepatitisc.uw.edu/browse/all/lectures#page/featured/lectures/state-art-therapy
Co-Presenter & Speaker, Asian Pacific Health Foundation in collaboration with UCSD to
screen at-risk individuals in San Diego County for hepatitis B. Cost-effective point-of-care
testing expands pharmacist screening activities in pharmacies, optimizing linkage-to-care,
16th World Conference on Education, San Diego, CA June 16, 2014. .
Speaker, Disease Management Interventions for Patients with Cirrhosis, National Liver
Conference 2014; Austin, TX. September 19, 2014.
Curriculum Vitae
146
Liver transplantation: state of the art, Kaweah Delta Hospital, Visalia, California, 10/22/88.
1989
Indications and controversies in liver transplantation, Queen of the Valley Hospital, Napa,
California, 1/28/89.
Update on peptic ulcer disease, Mather Air Force Base, California, 2/6/89.
Treatment of peptic ulcer disease and reflux esophagitis, Mercy General Hospital, Denver,
Colorado, 2/23/89.
Liver transplantation: indications and timing, House Staff Noon Conference, Santa
Teresa/Kaiser Hospital, San Jose, California, 3/16/89.
Advances in liver transplantation, Medical Grand Rounds, Seton Medical Center, San
Francisco, California and Hawaii, 3/17/89.
Treatment of chronic liver disease, Ukiah Valley Medical Center, Ukiah, California, 9/17/89.
Curriculum Vitae
147
Rounds on liver disease and Peptic ulcer disease, Scenic General Hospital, Modesto,
California, 10/4/89.
New treatment for PUD, Killeen Hospital Medical Staff, Killeen, Texas, 11/13/89.
Peptic esophagitis: new treatments, Andrews Air Force Base, Tempe, Arizona, 11/17/89.
New treatment for esophagitis and PUD, Regional Conference, Sun Valley, Idaho, 12/2/89.
1990
Advances in therapy for acid related disorders, Kaiser Permanente, Roseville, California,
2/20/90.
Advances in therapy for acid related diseases, Brookside Hospital, San Pablo, California,
2/27/90.
Orthotopic liver transplantation state of the art, Tripler Medical Center, Honolulu, Hawaii,
4/18/90.
Liver transplantation for Wilsons disease, Community Hospital, Santa Rosa, California,
4/25/90.
Management of peptic ulcer disease in the multi-risk patient, Saint Marys Medical Center,
Liver disease: an update on treatment and liver transplantation, Redding Medial Center,
Redding, California, 5/25/90.
Curriculum Vitae
148
Advances in the management of liver disease, Western Medical Center, Santa Ana,
California, 6/4/90.
Acid pump inhibitor a new option, Ralph K. Davies Medical Center, San Francisco,
California, 6/22/90.
Controversies in ulcer management in the intensive care unit, Good Samaritan Hospital,
San Jose, California, 7/3/90.
Acid pump inhibitora new option, Delta Memorial Hospital, Antioch, California, 8/28/90.
Management of peptic ulcer in the multi-risk patient, Santa Barbara GI Symposium, Santa
Barbara, California, 10/20/90.
Hepatitis C, Medical Grand Rounds, Seton Medical Center, Daly City, California,
11/16/90.
1991
Liver transplantation and life after liver transplantation, Ukiah Valley Medical Center,
Ukiah, California, 4/4/91.
Acute and chronic liver failure, Highland Hospital, Oakland, California, 8/16/91.
Endstage liver disease, Mills-Peninsula Hospital, San Mateo and Burlingame, California,
9/10/91.
Multiple organ failure, cytokines, Sequoia Hospital, Redwood City, California, 11/12/91.
Curriculum Vitae
149
Liver transplantation state of the art, San Jose Medical Center, San Jose, California,
11/14/91.
1992
Management of the patient with endstage liver disease, L.D.S. Hospital, Salt Lake City,
Utah, 5/2/92.
State of the art: chronic hepatitis, Mercy Medical Center, Redding, California, 8/12/92.
Endstage liver disease in liver transplantation, Queens Health Care Plan and
Physicians, Honolulu, Hawaii, 9/28/92.
Hepatitis B infection and treatment, Kuakini Medical Center, Honolulu, Hawaii, 9/28/92.
Patient selection for liver transplantation, Queens Hospital, Honolulu, Hawaii, 9/28/92.
Case presentations, endstage liver disease, Tripler Army Medical Center, Honolulu,
Hawaii, 9/30/92.
1992
Curriculum Vitae
150
Hepatitis serology, American Liver Foundation, St. Mary's Medical Center, San
Francisco, California, 10/24/92.
Evaluation of elevated liver tests, Kansas City Southwest Clinical Society, Kansas City,
Missouri, 11/06/92.
Evaluation of abnormal liver tests and Helicobacter Is This A Real Disease, 19th
Annual Gastroenterology Symposium, Enloe Hospital, Chico, California, 11/11/92.
1993
Interferon and hepatitis, Queen of the Valley Hospital, Napa, California, 7/16/93.
Hepatitis update, Travis Air Force Base Medical Center, Travis, California, 9/24/93.
The workup and evaluation of patients with chronic liver disease, University of California
at Davis, Family Practice Program, Merced, California, 12/29/93.
1994
Chronic liver disease and viral hepatitis, California Pacific Teleconference, 1/12/94.
NSAID induced GI injury, Maui Memorial Hospital, Wailuku, Maui, Hawaii, 1/22/94.
Curriculum Vitae
151
Current diagnosis and treatment of chronic viral hepatitis, St. Francis Medical Center,
Honolulu, Hawaii, 1/24/94.
Diagnosis and treatment of hepatitis C, San Quentin State Prison, San Quentin,
California, 2/28/94.
Portal hypertension, part I, University of Nevada, Reno, Washoe Medical Center, Reno,
Nevada, 3/4/94.
1994
Post-liver transplant patient management for nurses, Mercy Medical Center, Redding,
California, 3/15/94.
The diagnosis and treatment of chronic hepatitis, Highland General Hospital, Oakland,
California, 3/21/94.
Alcoholic liver disease, University of California Davis, Medical School, 2nd Year Lecture,
Davis, California, 3/31/94.
Portal hypertension, part II, University of Nevada, Reno, Veterans Hospital, Reno,
Nevada, 4/1/94.
The epidemiology of viral hepatitis, Merced Community Medical Center, Grand Rounds,
Merced, California, 5/2/94.
Liver cancer update, Merced Community Medical Center, Grand Rounds, Merced,
California, 6/29/94.
Hepatitis C: management in the primary care setting, San Francisco Public Health
Department, Wadell Clinic, San Francisco, California, 7/6/94.
Hepatitis C: diagnosis, management and prognosis, Las Vegas Gut Club, Las Vegas,
Nevada, 7/11/94.
Curriculum Vitae
152
The diagnosis and treatment of chronic liver diseases, Fremont-Rideout Health Group,
Peachtree Clinic, 7/19/94.
Hepatitis B treatment past, present and future, California Pacific Medical Center,
8/4/94.
Hepatitis C diagnosis and treatment, Visalia Primary Care Group, Visalia, California,
9/8/94.
Liver disease pathology conference, Fresno Gut Club, Fresno, California, 9/8/94.
Liver enzymes and liver function tests, Kansas City Southwest Clinical Society Annual
Meeting, Kansas City, Missouri, 11/3/94.
Diagnosis and treatment of hepatitis C, San Quentin State Prison, San Quentin,
California, 11/8/94.
1995
Liver pathology rounds, Liver Biopsy Conference moderator, St. Mary's Hospital, Reno,
Nevada, 1/6/95, 3/95, 5/95, 7/95, and 9/95.
Liver biopsy diagnosis, Mercy San Juan Hospital, Sacramento, California, 1/24/95.
Curriculum Vitae
153
Hepatitis update and histopathology conference, Redding Gut Club, Redding, California,
1/25/95.
Hepatitis diagnosis and treatment, Tracy Prison System, Tracy, California, 1/25/95.
Hepatitis and hemochromatosis, Las Vegas Gut Club, Las Vegas, Nevada, 1/26/95.
Hepatitis: drugs that cause and drugs that treat, Northern California System of VA
Clinics, Martinez, VA Hospital, N. Lake Tahoe Conference, Incline Village, Nevada,
2/11/95.
Hepatitis C, a silent disease, St. Francis Medical Center, Primary Care conference,
Honolulu, Hawaii, 2/11/95.
The virology of hepatitis C infection, Kaiser Medical Center, Honolulu, Hawaii, 2/15/95.
The liver in systemic disease, Maui Memorial Hospital, Wailuku, Maui, Hawaii, 2/17/95.
Fulminant liver failure, Sequoia Medical Center, Redwood City, California, 2/28/95.
Hepatitis: drugs that cause and drugs that treat, Northern California System of VA
Clinics, Martinez, VA Hospital, San Francisco, California, 3/2/95.
Hepatitis viruses: the alphabet soup, diagnosis and treatment, Petaluma Valley Hospital,
Petaluma, California, 3/27/95.
Alcoholic liver disease, University of California at Davis Medical School, 2nd Year
Lecture, Davis, California, 3/31/95.
Liver update: alcoholic liver disease, selection criteria for transplantation, Therapeutic
and Diagnostic Pancreaticobiliary Endoscopy Course, California Pacific Medical Center,
San Francisco, California, 7/22/95.
Hepatitis: an alphabet soup, Queen of the Valley Hospital, Napa, California, 8/18/95.
Curriculum Vitae
154
Evaluation of patients for Wilson's disease, St. Mary's Hospital, San Francisco,
California, 8/29/95.
1995
Wilson's disease, GI Conference, St. Mary's Hospital, San Francisco, California, 8/29/95.
Evaluation of acute and chronic liver disease, San Quentin State Prison, San Quentin,
California, 8/30/95.
Recurrent disease after liver transplantation, USC Medical Center, Los Angeles,
California, 9/22/95.
New forms of viral hepatitis, Honolulu Gut Club, St. Francis Hospital, 10/10/95.
Acute and chronic hepatitis: the alphabet soup, Napa State Hospital, Napa, California,
10/20/95.
Hepatitis issues for correctional facilities, San Francisco STD-HIV Prevention Training
Center, 2nd Annual Infectious Disease Conference, California Department of Corrections,
Natoma, California, 11/1/95.
The evaluation of elevated liver enzymes in acute and chronic liver disease, and The
role of medication in the cause of acute and chronic liver disease, 21st GI Symposium,
Chico, California, 11/15/95.
Curriculum Vitae
155
Controversies in the management of chronic hepatitis, Pelican Bay Prison, Pelican Bay,
California, 12/14/95.
1996
Viral hepatitis: the alphabet soup, California Pacific Medical Center Teleconference
Network, San Francisco, California, 1/23/96.
1996
Hepatitis A-G: diagnosis, natural history and epidemiology, Dameron Hospital, Stockton,
California, 2/23/96.
Hepatitis A-G: diagnosis and treatment, Medical Grand Rounds, California Pacific
Medical Center, San Francisco, California, 2/27/96.
Metabolic and autoimmune liver disease, Gastroenterology Club of Las Vegas, Las
Vegas, 4/15/96.
Endstage liver disease and cirrhosis, San Quentin State Prison, San Quentin, California,
5/1/96.
Curriculum Vitae
156
Primary care for the '90s, University of Nevada School of Medicine, Reno, Nevada, 5/1011/96.
Viral hepatitis: the alphabet soup, University of Reno, Reno, Nevada, 5/11/96.
Hepatitis A, B and C, San Jose Pharmacy Group, Santa Clara, California, 5/22/96
Update on hepatitis C, Santa Rosa Gut Club, Santa Rosa, California, 5/29/96.
Hepatitis C lecture, California Pacific Medical Center, San Francisco, California, 7/3/96.
1996
Hepatitis A-G: evaluation, diagnosis and prognosis, Mt. Diablo Hospital, Concord,
California, 8/8/96.
Curriculum Vitae
157
Metabolic causes of chronic liver disease, Merced Community Medical Center, Merced,
California, 8/15/96.
Hepatitis A-G: diagnosis, prognosis and treatment, Redding Medical Center, Redding,
California, 9/19/96.
The diagnosis and treatment of chronic hepatitis C infections, Kaiser Permanente, South
Sacramento, California, 9/26/96.
Current trends in hepatitis treatment, Marin Consortium's Grand Rounds, Marin General
Hospital, Larkspur, California, 10/1/96.
Viral hepatitis and liver transplantation, Dept. of Internal Medicine, University of Iowa,
Iowa City, Iowa, 10/3/96.
Viral hepatitis and the immune system, Case Conference on Infectious Disease,
University of Iowa, Iowa City, Iowa, 10/3/96.
Chronic viral hepatitis C: immunology, University of Iowa, Iowa City, Iowa, 10/3/96.
Portal hypertension, Merced Community Medical Center, Merced, California, 10/9 &
10/16, 1996.
State-of-the-art Interferon therapy for chronic viral hepatitis, Chronic Viral Hepatitis
(CVH) in the era of Managed Care, AASLD, Chicago, Illinois, 10/17/96.
Should we offer renal transplantation to patients with hepatitis B? What, if any, role is
there for Lamivudine, Grand Rounds, California Pacific Medical Center, San Francisco,
California, 10/18/96.
Hepatitis A-G, Santa Rosa Community Hospital, Santa Rosa, California, 10/23/96.
Curriculum Vitae
158
1996
Hepatitis A-G: evaluation and treatment, Nevada Academy of Family Physicians, Reno,
Nevada, 10/24/96.
Hepatitis A-G: the alphabet soup, Lassen Hospital, Susanville, California, 11/12/96.
Hepatitis C: current diagnosis and treatment, Mad River Hospital, Arcata, California,
11/21/96.Chronic liver disease and hepatitis A-G, St. Joseph's Hospital, Eureka,
California, 11/21/96.
Liver transplantation, House Staff Conference, California Pacific Medical Center, San
Francisco, California, 12/9/96.
1997
Hepatitis C update, Santa Rosa Memorial Hospital, Santa Rosa California, 1/16/97
Chronic hepatitis A-G: an alphabet soup, San Ramon Regional Medical Center, San
Ramon, California, 1/23/97.
Diagnosis and treatment of hepatitis C, Mill Creek Prison, Ione, California, 1/29/97.
Curriculum Vitae
159
Elevated liver tests: when is it hepatitis C and what do you do?, Lake Tahoe, California,
2/6/97.
Diagnosis and treatment of hepatitis A-G, Eden Hospital, Castro Valley, California,
2/28/97.
The role of the primary care physician's diagnosis & treatment of hepatitis, Eden Medical
Center, Castro Valley, California, 2/28/97.
Hepatitis C update, Santa Rosa Memorial Hospital Grand Rounds, Santa Rosa,
California, 3/21/97.
1997
Hepatitis A-Z: a review, Grand Rounds, Department of the Air Force, 60th Medical
Operations Squadron (AMC), Travis Air Force Base, Travis, California, 5/2/97.
Update on chronic hepatitis B & C, Chinese Hospital, San Francisco, California, 6/25/97.
Hepatitis as a systemic disease, John Muir Medical Center, Walnut Creek, California,
6/26/97.
Hepatitis C, the exploding epidemic, medical management, initial diagnosis, pre- and
post-liver
Chronic liver disease update, Symposium Moderator, San Francisco, California, 9/9/97.
Curriculum Vitae
160
New and evolving issues in acute and chronic liver disease: the evaluation of elevated
liver enzymes and liver function tests. Sacramento, California, 9/11/97.
Hepatitis B and C: who and when to treat Alexian Brothers Hospital. San Jose,
California, 9/16/97.
Why and how hepatitis B and C should be part of an infectious disease practice, IDSA
Symposium, San Francisco, California, 9/15/97.Chronic liver disease - focus on hepatitis
B and C, Providence Medical Center. Kansas City, Kansas, 10/16/97.
Hepatitis: who, when and where. Resuscitation 5, Redding Medical Center, Redding,
California, 10/25/97.
1998
Liver enzymes and liver function, CPMC GI nurse organization, California Pacific
Medical Center, San Francisco, California, 2/7/98.
AASLD Review, Las Vegas Gut Club, Las Vegas, Nevada, 2/5/98.
Alcohol and Liver Cancer, Mercy Regional Cancer Center, Redding, California, 4/18/98.
1998
Hepatitis C: Third World Disease in a Developed Country, River City Medical Group,
Mercy Hospital Sacramento, Sacramento, California, 4/23/98.
Curriculum Vitae
161
An Epidemic of Awareness: New tests and treatments for hepatitis B and C, Conference:
New Technologies and current trends in infectious disease, Mercy General Hospital,
Sacramento, California 8/8/98.
Combination therapy for relapser and nonresponder patients with hepatitis C, cost
effectiveness of therapy, Hepatitis C Global, Oakland, California 8/24/98.
Hepatitis B: Current treatment options and HIV interactions, Davies Campus of California
Pacific Medical Center, San Francisco, California 9/6/98.
New Treatments for Hepatitis C, Davies Campus of California Pacific Medical Center,
San Francisco, CA 11/20/98.
Curriculum Vitae
162
Elevated Liver Enzymes & the Diagnosis of Liver Disease, College of Osteopathic
Medicine, San Francisco, CA 2/16/99.
1999
Hepatitis Update, UNOS Region 5 OPO and Clinical Forum, San Francisco, CA 04/08/99.
Viral Hepatitis and the Surgeon, California Pacific Medical Center, San Francisco, CA
6/4/99
Present and future therapies for Hepatitis C, University of California, San Francisco, CA
6/21/99
Whats Your Specialty? San Francisco Medical Forums, National Youth Leadership Forum,
San Francisco, CA 6/30 and 7/14/99.
Hepatitis C, Amgen Medical Education Services, David Grant USAF Medical Center,
Travis Air Force Base, CA 07/02/99
Curriculum Vitae
163
The Role of the ID Physician in the Treatment of Chronic Hepatitis, Laguna, CA 08/28/99
Liver Disease and The Veterans Health Administration: New Advances in the Management
of Hepatitis C, Dover Communications Inc., Scottsdale, AZ 09/17/99
Hepatology for the ID Specialist and Treatment of Hepatitis C, Hepatitis for the New
Millennium, IDSA Annual Conference, Philadelphia, PA 11/18/99
2000
Managing Fulminate, Acute and Chronic Liver Disease, CPSS Liver Disease Symposium,
San Francisco, CA, 02/03/00
Viral Hepatitis: Into the New Millennium, Sutter Medical Center of Santa Rosa, Santa
Rosa, CA 03/07/00
Therapy of Viral Hepatitis Including Alternative Therapies Panel, Sutter Roseville Medical
Center, Roseville, CA 04/01/00.
Objective Structured Clinical Exercise University of CA, San Francisco, CA. 04/08/00.
Current Issues Regarding Transmission & Prevention Current Standards for Diagnosis &
Medical Management Hepatitis C: Building a Response to the Northstate Crisis, Red Bluff,
CA 04/28/00
Curriculum Vitae
164
New Trends in Treatment and Long Term Survival Hepatitis C: Building a Response to the
Northstate Crisis, Red Bluff, CA 04/28/00
Hepatitis C Part 2: Liver Transplants and Hepatitis C:, Eden Medical Center, Castro Valley,
CA 05/05/00
Acute Hepatic Failure, Critical Care Training Program, California Pacific Medical Center,
San Francisco, CA 05/11/00
2001
Department of Transplantation Hep-C and HIV Cal Pacific Medical Center 5/14/01
Current Issues in HIV and Hepatitis C co-infection Institute for Continuing Health Care
Education, CME program, San Francisco CA, 6/27/2001
Living Longer, Living Stronger: Maintaining the Quality of Life for Patients with Anemia and
HIV Infection; Current Issues in HIV and Hepatitis C Coinfection, Le Colonial, San Francisco, CA 7/16/01
Curriculum Vitae
165
2001
Hepatitis C on the Front Line of Community Health, 5th International HCV Conference,
San Francisco, CA 8/2/01
Start of the art treatment of viral hepatitis Chico GI Community Lecture, Chico California,
10/8/2001
Liver Cancer Abstract Review, Post AASLD Review Course Southern California Society of
Gastroenterology, 11/17/2001
Interpretation of liver function tests and new therapies in hepatitis C Sacramento Valley
Society of Health-System Pharmacists, Sacramento California 12/4/2001
2002
The Ninth Annual Alimentary Update. 2002. Univ. of Nevada School of Medicine. Lake
Tahoe, Nevada. 3/7-9/2002
Therapy of Chronic Viral Hepatitis: An Update. The Medical and Surgical Aspects of
Gastrointestinal Disease A One Day Course. Roseville CA, 4/6/2002
Curriculum Vitae
166
Current Issues in HIV and Hepatitis C Coinfection. Institute for Continuing Healthcare
Education. San Mateo, CA. 5/15/02
Managing Treatment Outcomes for HCV - Related Anemia. Advancmed. Santa Barbara,
CA. 5/29/02
CME audio tape/CD Review of the NIH Consensus Conference on Management of Hepatitis
C: 2002. 6/10-12/2002
Hepatitis C. St. Elizabeth Community Hospital CME Meeting. Redding, CA. August 2, 2002
Updates in the Treatment of Hepatitis B. East Bay Gut Club, Berkeley, CA. 12/12/02
2003
Liver Transplant Grand rounds, Department of Surgery faculty, University of California, Los
Angeles 4/8/03
Patients with ESLD and Decompensated Cirrhosis, HCV Summit Meeting, Mandarin Hotel,
San Francisco, CA 4/12/03
Hepatitis B, Sunrise Hospital and Medical Center, Las Vegas, April, 2003
Trends in Hepatitis Testing and Treatment, Bayer HealthCare, Grand Hyatt, San
Francisco, 6/17/2003
Hepatitis B and C are Curable, Infectious Diseases Symposium, Emerging Clinical Issues,
May, 2003
Curriculum Vitae
167
Treating and Managing Chronic Viral Hepatitis in Patients Living in the Pacific Rim, The
Lodge at Sonoma, CA July, 2003
NASH July
Managing Treatment Outcomes for Hepatitis C Virus Related Anemia, AdvancMed. August
2003.
Advancing Hepatitis C Education (AHE), Scotts Seafood Grill & Bar, Sacramento, CA,
August,
Liver Transplant, Galileo High School, San Francisco, CA. September 2003.
From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C, Sheraton Boston
Hotel, October 2003.
From Diagnosis to Treatment: The Full Spectrum of Care in Hepatitis C, AASLD Satellite
Symposium, Boston, Massachusetts. October 2003.
Molecular Testing in the Diagnosis and Management of Chronic HBV and HCV, Liver and
Digestive Health Medical Clinic and Stanford University Medical Center, October 2003.
Provider Update: Hepatitis C, Alexis Park Resort, Las Vegas. November 2003
Patient Update: Hepatitis C & Liver Transplantation, Alexis Park Resort, Las Vegas.
November 2003.
Curriculum Vitae
168
Liver Transplant: Complications & When to be Evaluated: The MELD System and Living
Related, Reno Hilton, November 2003.
Issues Related to HCV Treatment in Patients Co-infected with HCV and Management of
Anemia Associated with Combination Therapy for Patients Co-infected with HCV, San
Diego, California. November 2003.
Treatment Options for Patients with HCV, San Bernadino County of Public Health,
November 2003.
MELD, Sunrise Hospital and Medical Center, Las Vegas, Nevada. December 2003.
Liver Biopsy Conference, St. Marys Hospital, San Francisco, CA, December 2003.
2004
Update n Depression Management DDW Faculty Conference Call, San Francisco, CA.
February 2004.
Controversies in HBV: What is on the Horizon for Clinical Management of HBV Infections
Rochester, MN, January 2004.
Hepatitis C: Side Effect Profiles and Current Treatment Paradigms, Las Vegas, NV, June
2004.
Update on the NIH conference on HBV and HCC Las Vegas, NV, June 2004.
Curriculum Vitae
169
2nd Annual UC Davis Conference on Primary Care for Hepatitis C & Other Liver Diseases,
Napa, November 20-21, 2004
Hepatitis B: Evolving Treatment Strategies @ 5th International Annual Hot Topics in Lever
Disease Conference, October, 2004
2005
Hepatitis C A Public Health Concern: the Role of Pharmacists, San Rafael, CA July 11,
2005 Sunrise Hospital and Medical Center Continuing Medical Education, Las Vegas, NV,
January May 2005
Treatment Approaches for Hepatitis B: A Critical Appraisal, San Francisco January, 2005
Drugs and the Live: What the primary care physician should know, Honolulu, HI, January
2005
Liver Diseases: An Update for the Primary Care Provider, Honolulu, HI, January 15, 2005
Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B. Washington
Hospital. Fremont, CA. January 25, 2005.
HCV Treatment Modalities, Dosage and Duration, South Lake Tahoe, February 2005
Sunrise Hospital & Medical Center: Heavy Metal: Wilsons Disease & Hemochromatosis,
Las Vegas, February 1, 2005
Curriculum Vitae
170
Recognition & Management of Shock: New Standard of Care, San Francisco, CA. May 6,
2005.
Emerging Treatments for Liver and Complex GI Diseases, Omni Hotel, San Francisco.
September 16-17, 2005.
Adult Donor Liver Transplantation, San Francisco, CA. October 21, 2005.
Clinical Case Consults in Chronic Hepatitis B September 26, 2005, October 24, 2005
Hot Topics in Liver Disease St. Lukes Episcopal Hospital. October 7-8, 2005
2005
Curriculum Vitae
171
Treatment Strategies for the HCV Nonresponder. InterMune. Roseville, CA. November
28, 2005.
Expert Council Meeting, ACT-HBV. The Clift Hotel, San Francisco. December 2, 2005.
General Session, ACT-HBV. The Clift Hotel, San Francisco. December 3, 2005.
Primary Care Special Committee ACT-HBV, The Clift Hotel, San Francisco. December 3,
2005.
AASLD Update. Mountain View Hospital. Las Vegas, NV. December 6, 2005.
HBV Resistance Roundtable Meeting The Fairmont Orchid, Kona, HI December 9-10,
2005.
New Date on Hepatitis Drug Development, HEP DART, Kohala Coast, Big Island, Hawaii.
December 11-15, 2005.
A Rising Tide: The Next Wave of Treatment Options in HBV and HCV. AdvancMed. The
Fairmont Orchid. Kona, Hawaii. http://www.advancmed.org/807. December 11, 2005.
Clevudine Advisory Board. Pharmasset. The Fairmont Orchid. Kona, Hawaii. December
12, 2005.
Next Generation of HBV/HCV Inhibitors. HEP DART, The Fairmont Orchid. Kona,
Hawaii. www.ihlpress.com/gaj_120605. December 13, 2005
HCC: Future Therapies, HEP DART, The Fairmont Orchid. Kona, Hawaii. December 13,
2005.
Hepatitis B Treatment: 2005 and beyond: an overview, HEP DART, The Fairmont Orchid.
Kona, Hawaii. www.ihlpress.com/gaj_120605. December 13, 2005.
Curriculum Vitae
172
Reno-Sparks Community Wide Liver Conference. Saint Marys Regional Medical Center.
Reno, NV. January 19, 2006.
Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B, Washington
Hospital. Fremont, CA. January 25, 2005.
Hot Topics in Hepatology: Updates, Strategies and Future Trends Hyatt Regency
Monterey, CA. February 4, 2006.
Reno-Sparks Community Wide Liver Conference. Saint Marys Regional Medical Center.
Reno, NV. February 16, 2006.
MELD Exception Study Group Meeting Westin OHare Hotel. Chicago, IL. March 1-2,
2006.
COS Shampions of Organ Sharing. Clark County Library. March 14, 2006.
Major Advances in Treating HCV: entering a new era targeted therapy and
immunotherapy, SciClone Pharmaceuticals. Shanghai, China. March 25, 2006.
Application of Viral Load Measurement in HCV Patients on Antiviral Therapy, ShanghaiHong Kong International Liver Congress 2006. Shanghai, China. March 26, 2006.
Overview of Global and China. Shanghai-Hong Kong International Liver Congress 2006.
Shanghai-China. March 26, 2006.
Curriculum Vitae
173
Has Antiviral Therapy Altered the Natural History of HBV, Shanghai-Hong Kong
International Liver Congress 2006. Shanghai, China. March 27, 2006.
Medical need for a prophylactic vaccine against HCV, Shanghai-Hong Kong International
Liver Congress 2006. Shanghai, China. March 28, 2006.
2006
A Case Based Approach to the Modern Management of HCV, San Francisco, CA. Meet
the HCV Masters. April 3, 2006.
Results of a Phase III Randomized Controlled Study Comparing the Survival of Patients
with Unresectable Hepatocellular Carcinoma (HCC) Treated with Nolatrexed (NOL) or
Doxorubicin (DOX), EASL, Vienna. April 27, 2006.
Hepatitis B, C and Liver CA Update, Sunrise Hosptial and Medical Center. Cilis
Restaurant. Las Vegas, NV. May 8, 2006. 1.0 AMA PRA Category Credit.
CLDF Content Development Meeting on HCV Treatment Failures. Hyatt Regency Century
Plaza. Los Angeles, CA. May 19, 2006.
Curriculum Vitae
174
Refining the HBV Treatment Paradigm. Westin Bonaventure Hotel. Los Angeles, CA.
May 20, 2006.
Scientific Advisory Panel at DDW. Wilshire Grand Hotel. Lost Angeles, CA. May 20,
2006.
Whats New in the Treatment of Hepatitis B & C. Double Tree Hotel. Modesto, CA. June
7, 2006.
Idenix/Novartis HCV Clinical Expert Panel. Las Vegas, NV. June 9-10, 2006.
Treating HCV Maximizing Response and Minimizing Injury. Wild Ginger Restaurant.
Seattle, WA. June 12, 2006.
Treatment Strategies for the HCV Nonresponder. Fifth Floor Restaurant. San Francisco,
CA. June 13, 2006.
Chronic Hepatitis B National Advisory Board Meeting. New Haven, CT. June 15-17, 2006.
Reno Sparks Community Wide Liver Conference: Medical & Surgical Aspects of Liver
Transplantation 2006. Reno, NV. June 22, 2006.
Focus on the Virus: A New Paradigm for the Management and Treatment of HBV,
Sheraton Boston Hotel, Boston, MA. October 30, 2006.
The NCSCG Yosemite GI Retreat 2006. Yosemite, CA. November 3-5, 2006.
2007
Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse
Communities Expert Insight Intro: Provider Knowledge and Practice Regarding Hepatitis B
Screening in Chinese-Speaking Patients. Course HBV3:03. 2007.
ESLD and ICU Care Lecture. University of Nevada School of Medicine. February 12,
2007.
New Therapies in Liver Cancer and Hepatitis. Spain, Barcelona. April 12, 2007.
Curriculum Vitae
175
American Transplant Congress. San Francisco, CA. May 5-9, 2007 (CME Credit)
Molecular Tests for HBV: Genotype, Core and Precore Testing, Quatification Tests. San
Francisco, CA. May 7, 2007.
Molecular Tests for HBV: Genotype, Core and Precore Testing, Quantification Tests.
Seattle, WA. May 9, 2007
Strategies for the Treatment of the HCV Refractory Patient. Seattle, WA. May 9, 2007
April 07 Advanced Issues in the Management of Chronic Hepatitis B. San Francisco, CA.
May 17, 2007.
The Next Steps in Viral Eradication for HCV Treatment Failures. Sacramento, CA. May
23, 2007
The Next Steps in Viral Eradication for HCV Treatment Failures. Reno, NV. May 24, 2007
Metabolic Liver Disease. University of Nevada, School of Medicine, Las Vegas. June 11,
2007.
Hepatology in the ICU. CPMC. San Francisco, CA. June 26, 2007.
Vertex Pharmaceuticals Physician Advisory Forum. Chicago, IL. June 30, 2007.
Case 1 - Patient RD: Management of HCV genotypes 2/3. CARES. July 2007.
Case 4 Patient AR: Hematologic Toxicities in Patients Undergoing Treatment for HCV.
CARES. July 2007.
Hepatology in the ICU. CPMC. San Francisco, CA. July 17, 2007.
Evaluation of Abnormal Liver Tests. University of Nevada School of Medicine. July 23,
2007.
April 07 Advanced Issues in the Management of Chronic Hepatitis B. Reno, NV. July 26,
2007.
Hepatology in the ICU. CPMC. San Francisco, CA. July 31, 2007.
Curriculum Vitae
176
Evolving Strategies in the Management of HCV. San Jose, CA. July 31, 2007.
Case 5 Patient KM: Psychiatric Issues in Patients Undergoing Treatment for HCV.
CARES. August 2007.
2007
Update on Hepatitis. University of Nevada School of Medicine. Las Vegas, NV. August
22, 2007.
Management of CHB in the era of Ptent Antivirals. Workerhill Hotel, Korea. August 29,
2007.
Management of CHB in the era of Ptent Antivirals. Asan Hospital, Korea. August 30,
2007.
Management of CHB in the era of Ptent Antivirals. Samsung Hospital, Korea. August 30,
2007.
HBV Treatment, do we need a compass, roadmap or GPS? (or a seeing eye dog?)
September 1, 2007.
Emerging Data in the Management of HBV. Mortons Steakhouse. San Francisco, CA.
September 6, 2007.
April 07 HCP Guide. Tarpys Roadhouse. Monterey, CA. September 17, 2007.
Liver Pathology Rounds. Community Medical Center. Fresno, CA. September 18, 2007.
HEP B Free 2007 CME. Tommy Toys. San Francisco, CA. September 19, 2007.
HEP B Free 2007 CME with Dr Eddie Cheung. Griffin Room St Lukes Campus.
September 25, 2007.
Evaluation of a Liver Mass. University of Nevada School of Medicine. October 17, 2007.
Managing the Patient with Advanced Liver Disease. Spencers Spokane, WA. October
26, 2007.
Curriculum Vitae
177
Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment
in Asian and Other Diverse Communities. Projects In Knowledge/AASLD. November
2007.
Hepatitis Medicaid Expansion Project. Expert Working Group Meeting Boston, MA.
November 1, 2007.
Frontiers in Drug Development for Viral Hepatitis. Emory University. December 9-13,
2007.
Fund Raising Study Task Force Conference Call. AASLD. December 18, 2007.
2008
Aug 07 Resistance. BMS. Mitchells Steak House - Columbus, OH. January 8, 2008.
Aug 07 Resistance. BMS. Ohio State University Medical Center - Columbus, OH.
January 9, 2008.
Simply Speaking HBV. The Westin Casuarina. Las Vegas, NV. January 12, 2008.
Drug Induced Liver Disease. University of Nevada School of Medicine. Las Vegas, NV.
January 14, 2008.
Hepatology in the ICU. CPMC. San Francisco, CA. January 22, 2008.
Therapeutical strategies and advances on HBV. Shanghai Westin Hotel. Chinese Medical
Association. Shanghai, China. February 2, 2008.
Therapeutical strategies and advances on HBV. Shanghai Hilton Hotel. Chinese Medical
Association. Shanghai, China. February 3, 2008.
Curriculum Vitae
178
HBV New Therapies. St Marys Hospital Grand Rounds. San Francisco, CA. February 8,
2008.
Clinical Drug Assessment, A Clinicians View of the Development and Assessment of Drugs
to Treat Hepatitis. Road Map to Drug Discovery, Development and Approval. February 12,
2008.
Session 5: Management of HBV Resistance Case Presentation and Discussion. EASLAASLD-APASL-ALEH-IASL Conference: Hepatitis B and C Virus Resistance to Antiviral
Therapies. Paris, France. February 14-16, 2008.
LT, Referral and Indications, pre/post transplant care. Sunrise Hospital. Las Vegas, NV.
February 26, 2008.
American Association for the Study of Liver Disease Update. Saint Marys Regional
Medical Center. Reno, NV. February 28, 2008.
Evolving Treatment Options for Chronic HCV Infection Optimizing Current Treatment
Options. Palms Restaurant. Fresno, CA. March 3, 2008.
HBV Resistance and the Role of Baraclude in CHB. Rice Bowl Restaurant. Sacramento,
CA. March 5, 2008.
Hepatitis B Liver Symposium. Cathedral Hill Hotel. San Francisco, CA. March 15, 2008.
NASH and Fatty Liver. University of Nevada School of Medicine. Las Vegas, NV. March
17, 2008.
Hepatitis C Questions? We have answers. Sunrise Medical Center. Las Vegas, NV.
March 17, 2008.
2008
Healthcare Providers Guide to Chronic Hepatitis B. BMS. Las Vegas, NV. April 14, 2008.
Curriculum Vitae
179
Portal hypertension and treatment. Renown. Reno, NV. April 17, 2008.
Medical Overview of Hepatitis C. Hepatitis C Community Outreach Event. Las Vegas, NV.
April 19, 2008.
HCV Update. Schering-Plough. Rhema Restaurant. Fresno, CA. April 30, 2008.
Overview Slide Presentation. BMS Advisory Board Meeting. Los Angeles, CA. May 3,
2008.
Questions and Answers. BMS Advisory Board Meeting. Los Angeles, CA. May 3, 2008.
Autoimmune liver disease, including PSC and PBC/PBH. Nevada School of Medicine.
Las Vegas, NV. May 13, 2008.
European Association for the Study of Liver Disease Update. Reno Sparks Community
Wide Liver Conference. Beaujulais Bistro. Reno, Nevada. May 15, 2008.
2008 Expert Working Group Meeting. Gilead. San Diego, CA. May 16, 2008.
Editorial Advisory Board DDW Breakfast. Gastroenterology and Hepatology. San Diego,
CA. May 19, 2008.
An Updated Review of Management Strategies for the HCV Non-Responder. Three Rivers
Pharmaceuticals. Roys Restauarnt. Las Vegas, NV. May 28, 2008.
Alcoholic Hepatitis. Alameda County Medical Center. Oakland, CA. May 30, 2008.
Treatment End Points: Translating Clinical Trials into Clinical Practice. Hong KongShanghai International Liver Congress BMS Satellite Symposium. Hong Kong, China.
June 14, 2008.
Management of acute liver failure Biological and nonbiological liver support methods.
Hong Kong-Shanghai International Liver. Hong Kong, China. June 14, 2008.
Liver Support System Workshop What Do You Need to Know about Liver Support System
in 2008. Hong Kong-Shanghai International Liver Congress Hong Kong, China. June 14,
2008.
Curriculum Vitae
180
Nucleic acid testing: role in HBV and HCV management. Hong Kong-Shanghai
International Liver. Hong Kong, China. June 14, 2008.
Combination therapy for CHB: Are we focusing too much on viral suppression rather than
on antiviral ressistance as a sign of efficacy? (Pro). Hong Kong-Shanghai International
Liver. Hong Kong, China. June 15, 2008.
Road map to long term treatment success. Hong Kong-Shanghai International Liver.
Hong Kong, China. June 15, 2008.
2008 Post Conference Update: EASL. Simply Speaking. San Francisco, CA. June 23,
2008.
An Updated Review of Management Strategies for the HCV Non-responder. Three Rivers
Pharmacueticals. Garibaldis Restaurant. Oakland, CA. June 24, 2008.
Strategies for Optimizing Successful Outcomes in the Management of HCV Difficult-toTreat Population. Three Rivers Pharmaceuticals. Bricks Restaurant. Reno, Nevada. June
26, 2008.
HBV Update. APAC Quarterly Meeting. Four Seas Restaurant. July 9, 2008.
Hepatology in the ICU. CPMC. San Francisco, CA. July 10, 2008.
How do healthcare providers teach about hepatitis b? With the goals, prevelance, natural
history treatment testing. BMS. E&O Trading. San Francisco, CA. July 15, 2008.
Clinical Implications of HBV Resistance. Ruth Cris Steak House. Honolulu, Hawaii. July
17, 2008.
The Future of Hepatitis B and C. Fourth Annual Liver Update Seminar. Queens
Conference Center. July 19, 2008.
Curriculum Vitae
181
Updates on the Management & Treatment of Hepatitis B. Fourth Annual Liver Update
Seminar. Queens conference Center. July 19, 2008.
Panel Discussion. Fourth Annual Liver Update Seminar. Queens conference Center.
July 19, 2008.
LFTs. Nevada School of Medicine. Las Vegas, NV. July 23, 2008.
Liver Enzyme Elevation. Renown Nevada School of Medicine. Reno, NV. July 24,
2008.
Update of Hepatitis C Virus: epidemiology, natural history and treatment. Saint Marys
Regional Medical Center. 4th Street Bistro. Reno, NV. July 24, 2008.
Management of the Advanced Liver Disease Patient. Roche Pharmaceuticals. Lodi, CA.
August 18, 2008.
Management of the HCV Patient. Schering-Plough. Daily Grill. Fresno, CA. August 19,
2008.
Hepatology in the ICU. CPMC. San Francisco, CA. August 21, 2008.
Advances in Managing Patients with Hepatitis B. Duke Liver Disease Update and
Symposium. Duke Clinical Research Institute. Durham, North Carolina. September 6,
2008.
Addressing Real World Challenges in the Treatment of Chronic Hepatitis C. Roche. Ruth
Cris Steak House. Kansas City, MO. September 11, 2008.
Clinical Implications of HBV Resistance. BMS. Il Fornaio Restaurant. San Jose, CA.
September 16, 2008.
Treating the Hospitalized Liver Patient. University of Nevada School of Medicine. Las
Vegas, NV. September 22, 2008.
HCV Update. Schering-Plough. Cheese Board Restaurant. Reno, NV. September 22,
2008.
Curriculum Vitae
182
CME Talk. Renown Nevada School of Medicine. Reno, NV. September 23, 2008.
2008 Post Conference Update: EASL. HRL Communications. El Paseo Restaurant. Mill
Valley, CA. September 24, 2008.
2008 Pegasys Hep B Regional Advisory Board. San Francisco, CA. October 9, 2008.
Biliary Disease Work Up of Jaundice. Nevada School of Medicine. Las Vegas, NV.
October 13, 2008.
Healthcare Provider's Guide to Chronic Hepatitis B. BMS. Del Friscos Restaurant. Las
Vegas, NV. October 14, 2008.
Fatty Liver Evaluation. Renown Nevada School of Medicine. Reno, NV. October 16,
2008.
Update on Liver Cancer from EASL, ILC, and DDW. CME Saint Marys Continuing
Medical Education. 4th Street Bistro. Reno, NV. October 16, 2008.
Views on Living Donor Transplants, Hepatocellular Carcinoma Pre and Post Transplant.
Canadian Speaker Tour. London Health Sciences. London, Ontario. October 22, 2008.
Viral Resistance. Canadian Speaker Tour. Toronto Western Hospital. October 23, 2008.
Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for
Hepacellular Carcinoma. Marriott. San Francisco, CA. November 1, 2008.
Curriculum Vitae
183
Models for Hepatitis B Screening and Linkage to Care. Gilead Medical Affairs dinner.
Town Hall Restauarnt. San Francisco, CA. November 2, 2008.
Approved Agents for HBV Treatment. Clinical Care Options. Le Meridien. San Francisco,
CA. November 3, 2008.
Approved Agents for HBV Treatment. Clinical Care Options. Le Meridien. San Francisco,
CA. November 4, 2008.
Standard of Care for the Treatment of Hepatitis B & C. Update in Gastroenterology and
Hepatology. Las Vegas Symposium. November 15, 2008.
Debate Monotherapy is Suitable for HBV. Las Vegas Symposium. November 15, 2008.
HBV Highlights from CCOs Coverage of the 2008 AASLD Meeting, Grand Caf. San
Francisco, CA. December 2, 2008.
VIREAD: A New Treatment Option for Chronic Hepatitis B in Adults. Gilead. Fifth Floor
Restaurant. San Francisco, CA. December 8, 2008.
HBV. Nevada School of Medicine. Las Vegas, NV. December 15, 2008.
Chronic Hepatitis B. BMS. Roys Restaurant. Las Vegas, NV. December 15, 2008.
VIREAD: A New Treatment Option for Chronic Hepatitis B in Adults. Gilead. Las Vegas,
NV. December 16, 2008.
Nexavar in the Treatment of Patients With Unresectable HCC. Onyx. Beaujolais Bistro.
Las Vegas, NV. December 18, 2008.
Curriculum Vitae
184
Curriculum Vitae
185
NASH = Non-alcoholic Fatty Liver Disease. CME Talk. Reno, NV. January 8, 2009.
HBV Screening and Linkage to Care. Simply Speaking. Scottsdale, AZ. January 10,
2009.
Guidelines to Screen for and Treat Chronic Viral Hepatitis B and C Infections. Department
of Medicine. Grand Rounds at CPMC. San Francisco, CA. January 13, 2009.
Speaker Training. 2009 Pegasysm Speaker Training. Estancia. La Jolla, CA. January
16-17, 2009.
Treatment Approach of a Patient with CHB. 2nd St Lukes International Liver Conference
Scientific Program. Manilla, Philippines. January 19, 2009.
Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and
challenges in the treatment of Chronic Hepatitis B). BMS Edinburgh and Birmingham.
UK and Netherlands Roadshow. January 20, 2009.
Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and
challenges in the treatment of Chronic Hepatitis B). BMS Newcastle and Manchester.
UK and Netherlands Roadshow. January 21, 2009.
Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and
challenges in the treatment of Chronic Hepatitis B). BMS London. UK and Netherlands
Roadshow. January 22, 2009.
Treat to Succeed: A Case by Case Study of Hepatitis B (Discussing current trends and
challenges in the treatment of Chronic Hepatitis B). BMS Utrecht. UK and Netherlands
Roadshow. January 23, 2009.
VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults. Gilead. Nola
Restaurant. Palo Alto, CA. February 4, 2009.
CHB Hypothetical Case Studies. BMS. Tommy Toys Restaurant. San Francisco, CA.
February 5, 2009.
Curriculum Vitae
186
Hepatitis B & C Update. Grand Rounds Talk. Highland Hospital. Oakland, CA. February
6, 2009.
Strategies for Improved Response in the Treatment of Hep B: Patient Case Approach.
Roche. Tanglewood Restaurant. San Jose, CA. February 9, 2009.
Liver Transplant. APASL Meeting. Hong Kong, China. February 12, 2009.
Chinese American Physicians Association Joint Symposium What Do You Need to Know
about Liver Support System in 2009. APASL Meeting. Hong Kong, China. February 13,
2009.
Approach to difficult-to-treat patients. APASL Meeting. Hong Kong, China. February 14,
2009.
Improving Patient Quality of Life: Preventing CHB disease progression with Baraclude.
APASL Meeting. Hong Kong, China. February 14, 2009.
Update on Hepatitis Viral B. Hue College of Medicine and Pharmacy. Hue, Vietnam.
February 18, 2009.
Update on Hepatitis Viral C. Hue College of Medicine and Pharmacy. Hue, Vietnam.
February 18, 2009.
Update on the Treatment of Liver Cancer. Hue College of Medicine and Pharmacy. Hue,
Vietnam. February 18, 2009.
Liver Transplant. Hue College of Medicine and Pharmacy. Hue, Vietnam. February 18,
2009.
VIREAD: A First Line Treatment Option for Chronic Hepatitis B in Adults. Oliveto.
Oakland, CA. March 3, 2009.
Be a Hero Dinner. South Seafood Restaurant. San Francisco, CA. March 5, 2009.
Curriculum Vitae
187
Autoimmune and metabolic diseases: genetic. Nevada School of Medicine. Las Vegas,
NV. March 10, 2009.
Roundtable Discussion. Three Rivers. Ruth Chris Restaurant. Las Vegas, NV. March
10, 2009.
Resistance: Resistance: The Role of Baraclude. BMS. Sasso Restaurant. Boston, MA.
March 16, 2009.
Resistance: The Role of Baraclude. BMS. Jianan Comprehensive Care. Brooklyn, New
York. March 17, 2009.
New Therapies for Hepatitis B and Hepatitis C. University of Nevada School of Medicine.
16th Annual Alimentary Update. Harveys Resort. Lake Tahoe, CA. March 27, 2009.
Advances in the Treatment of HCV/HIV Coinfection With Pegasys and Copegus. Roche.
The Grand Caf. San Francisco, CA. March 30, 2009.
New Paradigm in Treatment of Chronic Hepatitis B. South Bay Gut Club/BMS. Amber
India Restaurant. San Jose, CA. April 1, 2009.
HCV. GLG Roundtable Meeting. Silks Restaurant. San Francisco, CA. April 8, 2009.
Viral hepatitis over view B and C. Renown Medical Center. Reno, NV. April 29, 2009.
Curriculum Vitae
188
Hepatitis C Fight. Roche. Town Hall Restaurant. San Francisco, CA. May 4, 2009.
Nexavar in the Treatment with Unresectable HCC. Onyx. Scotts Seafood. May 5, 2009.
VIREAD: A First-Line Treatment Option for Chronic Hepatitis B in Adults. Gilead. La Folie
Restaurant. San Francisco, CA. May 6, 2009.
2009 Post Conference Update: EASL. Simply Speaking. El Paseo Restaurant. Mill
Valley, CA. May 13, 2009.
HCV and Cryoglobulinemia: How Cool Can You Get. Saint Marys Regional Medical
Center. Reno, NV. May 14, 2009.
Unbranded Professional Programs Program. Gilead. Nove Italiano at The Palms. Las
Vegas, NV. May 19, 2009.
Fatty Liver. Nevada School of Medicine. Las Vegas, NV. May 20, 2009.
Case 6: Patient With HBV Infection: When to Treat and How to Treat. CARES.
McCormick & Kuleto's Restaurant. San Francisco, CA. June 4, 2009.
Nexavar in the Treatment of Patients with Unresectable HCC. Onyx. Renown Hospital.
Reno, NV. June 30, 2009.
Weekly Emergency Medicne Conference. CME talk. Alameda County Medical Center,
Highland Hospital. Oakland, CA. July 1, 2009.
Faculty of John Hopkins University School of Medicine CME Program. Kuleto Trattoria
Restaurant. Burlingame, CA. July 14, 2009.
HCV and Cryoglobulinemia: How Cool Can You Get? Saint Marys Regional Medical
Center. Reno, NV. July 27, 2009.
Chronic Hepatitis B (CHB_: Screening, Diagnosis and Patient Considerations. BMS talk.
Kings Winery Clinic. Fresno, CA. August 5, 2009.
VIREAD An Overview Including Safety and Efficacy. Gilead. Palms Restaurant. Fresno,
CA. August 5, 2009.
Curriculum Vitae
189
An Updated Review of Management Strategies for the HCV Treatment Failure Patient.
Three Rivers. Gordon Biersch Brewing Company. Las Vegas, NV. August 18, 2009.
Work up of Elevated Liver Tests. Las Vegas, NV. August 19, 2009.
CHB Hypothetical Case Studies. BMS talk. Scotts Seafood. Oakland, CA. August 26,
2009.
2010
HCC Diagnosis and Treatement. Sonoma Valley Gut Club. Santa Rosa, CA. January 11,
2010.
State of the Art Liver Transplantation for Hepatocellular Carcinoma: Recurrence of primary
and secondary disease; what is more important? VIVA Restaurant. Los Gatos, CA.
February 25, 2010.
One Therapy From Day One 5 Year Resistance Update. Oak Brook, IL. March 5, 2010.
Updates on Viral Hepatitis and Liver Diseases. Hue college of Medicine and Pharmacy.
Vietnam. March 22-23, 2010.
Liver Suport System for the Management of Liver Failure. APASL. Beijing, China. March
25, 2010.
New Concepts in the Treatment of HCV. Plumed Horse Restaurant. Saratoga, CA.
March 29, 2010.
Curriculum Vitae
190
The Clinical Implications of Managing Cirrhotics. CLDF. San Francisco, CA. April 12,
2010.
One Therapy From Day One 5 Year Resistance Update. San Francisco, CA. May 3,
2010.
Chronic Viral Hepatitis: Can we C our way to B cured? CME Talk. St Lukes Grand
Rounds. San Francisco, CA May 5, 2010.
Newest Multi-Disciplinary Treatment Modalities for Liver and locally advanced Pancreatic
Cancer. Renown. Reno, NV. May 11, 2010.
2010
VIREAD: An Overview Including Safety and Efficacy. Ritz Carlton Hotel. San Francisco,
CA. May 12, 2010.
Long Term Considerations in Chronic Hep B (CHB) Therapy. Tommy Toys Restaurant.
San Francisco, CA. May 17, 2010.
+Bay Area Non-Doc (BAND). LePapillion Restaurant. San Jose, CA. May 19, 2010.
The Clinical Implications of Managing Cirrhotics. Ruth Chris Steakhouse. San Francisco,
CA. May 25, 2010.
Curriculum Vitae
191
Long Term Considerations in Chronic Hep B Therapy Lecture w/HBV Treaters. Ounce
Steakhouse. San Antonio, TX. June 10, 2010.
2010 National Hepatitis B&C Training Program & Treatment Update. Omni Hotel. San
Francisco, CA. June 12, 2010.
Hepatitis C: What is the current diagnostic and treatment paradigm? Community Hospital
of Monterey. Monterey, CA. June 16, 2010.
Coming to your area: Case3: On the Cusp of Change: New Therapeutic Modalities for HCV.
Sienna Restaurant. El Dorado Hills, CA. June 16, 2010.
Remarks from CPMC. Health Forum. Southeast Asian Community Center. San
Francisco, CA. June 13, 2010.
Coming to your area: Case 3: On the Cusp of Change: New Therapeutic Modalities for
HCV. El Dorado Hills, CA. June 16, 2010.
CHB Hypothetical Case Studies. Las Vegas, NV. July 28, 2010.
Use only the A Team to Beat Hepatitis B. Chinese Hosptial. San Francisco, CA.
August 3, 2010.
The Clinical Implications of Managing Cirrhotics. San Jose, CA. September 13, 2010.
Use Only the A Team to Beat Hepatitis B. Saint Francis Memorial Hospital. September
21, 2010.
Risk Assessment and Clinical Management of Patients with CHB. Reno, NV. September
29, 2010.
Curriculum Vitae
192
Risk Assessment and Clinical Management of Patients with CHB. Sacramento, CA.
September 30, 2010.
Clinical Update 2010: Chronic Liver Disease and Hepatocellular Carcinoma. Sutter
Roseville Medical Center. Roseville, CA. October 2, 2010.
One Therapy From Day One 5 year Resistance Update. Hartford, CT. October 4, 2010.
HCC Update. Hartford Hospital Grand Rounds. Hartford, CT. October 5, 2010.
VIREAD Professional Program. Kansas University Medical Center. Kansas City, KS.
October 11, 2010.
VIREAD: Examing the Clinical Studies. Kansas City, KS. October 11, 2010.
Managing HBV in the At-Risk Community. San Francisco, CA. October 12, 2010.
Chronic Hepatitis B Hypothetical Case Studies. San Jose, CA. October 18, 2010.
Chronic Hepatitis B Hypothetical Case Studies. Fremont, CA. October 19, 2010.
Viral Hepatitis Treatment and HCC. 2010 Clinical Update: New Advances in the
Management of Hepatocellular Carcinoma. Las Vegas, NV. November 13, 2010.
Curriculum Vitae
193
2011
Hepatitis C: The New Dynamic of HCV treatment, UCSD Medical, March 2011
Salix Best Practice in Advanced Liver Disease Faculty Meeting, Chicago, IL. August 2011.
Diverse Aspects of Hepatitis B, Hepatitis B Outreach Program at Hsi Fang Temple, San
Diego. September 2011
DDW 2011
Lecturer. AASLD: The Liver Meeting, San Francisco, CA, November, 2011.
Faculty: 2011 Hepatology Associates Course, San Francisco, CA. Point Counterpoint:
Complex Patient Case Management Issues. November 2011.
Panelist: 2011 Chronic Liver Disease Foundation (HCEE) HE Webcast Tapings, San
Francisco, CA. November 2011.
Curriculum Vitae
194
Vietnamese Federation of San Diego, Event- Vietnamese Elderly Association and the
Vietnamese Veterans Association on the occasion of Lunar New Year; San Diego, CA.
January 14, 2012.
Participant, Effective Teaching Skills for Faculty & Fellows, VA Hospital, Grand Rounds,
Clinical Case Conference, San Diego, CA., January 19, 2012.
Polaris Group; Investigators Meeting in conjunction with the American Society for Clinical
Oncology Gastrointestinal Cancers Symposium, San Francisco, CA. January 19, 2012.
Baldwin Park Lecture for Salix Pharmaceuticals; Los Angeles, CA. January 24, 2012.
CLDF Focus Med Event: San Diego, CA. January 25, 2012.
UCSD Annual Cancer Center Scientific Retreat, Trandisciplinary Research, San Diego,
CA. January 28, 2012.
Hepatitis Free San Diego Introductory Meeting, La Jolla, CA. January 31, 2012
HCC Web Speaker Training (Bayer/Onyx Pharmaceuticals, 2012 Nexavar Concert Series).
Conference Title: Nexavar Unresectable Heptocellular Carcinoma Web Speaker Training,
San Diego, CA. Feb.7, 2012.
Nexavar Concert Series (Bayer Healthcare and Onyx Pharmaceuticals-201 2) Title: Clinical
Consideration in Unresectable Hepatocellular Carcinoma. San Diego, CA. February 9,
2012.
Curriculum Vitae
195
2012 INCIVEK Professional Speaking Bureau Training Meeting; Santa Monica, CA.
February 11, 2012.
Asian Pacific Health Foundation Training Session: Handling, Disposal of Supplies, Barriers
and Study Surveys. San Diego, CA. February 14, 2012.
Speaker, Metabolic and Autoimmune Liver Disease: What the Primary Care Provide Needs
to Know, Scripps Mercy Hospital Grand Rounds, San Diego, CA, February 14, 2012.
Speaker, HCV Therapeutics, Brio Restaurant, Las Vegas, NV., February 23, 2012.
Speaker, HCV Therapeutics, 888 Seafood Restaurant, Rosemead, CA., February 24,
2012.
Speaker, UCSD AIDS Clinical Rounds, University of California, San Diego., San Diego, CA, March
2, 2012.
Speaker, Clinical Roundtable Discussion: Adult Patients with Chronic Hepatitis B, Ruths
Chris Steak House, Anaheim, CA, March 22, 2012.
Speaker, Variceal Bleeding, University of California, San Diego, GI Division, July 24,
2012.
2013
Understanding Hyponatremia: Treating Beyond the Primary Diagnosis, Otsuka Pharmaceutical America, Palm Springs, CA; January 28, 2013.
Managing HCV Disease, Liver Disease Support Group, Presented by Avella. Specialty
Pharmacy, Valley Hospital Medical Center, Las Vegas, NV. January 30, 2013.
Facilitator, Liver Disease Support Group, Avella Specialty Pharmaceutical Event, Las
Vegas, NV., February 20, 2013.
Speaker, HBV, Main Conference, Scripps Clinics 28th Annual New Treatments in Chronic
Liver Disease Conference, La Jolla, CA; March 23, 2013.
Curriculum Vitae
196
Speaker, Controversy: Warrehouse vs. Treat Now, HBV, Main Conference, Scripps Clinics
28th Annual New Treatments in Chronic Liver Disease Conference, La Jolla, CA; March 23,
2013.
Surveillance for Hepatocellular Carcinoma in the At-Risk Population, Bayer Onyx Oncology
Speaker Program, Phoenix, AZ; May 14, 2013.
Chronic Hepatitis C Therapy: Current and Future Perspectives, and Clinical Challenge:
Management of Chronic Hepatitis B in Special Populations, St Lukes, Manila, Philippines;
June 2, 2013
Session Chairman, Transforming Science to Clinical Practice, APASL Liver Week 2013
Singapore: Session Chairman, Singapore, June 6-10, 2013.
Speaker, Current Insights into the Management of Hepatic Encephalopathy. The Chronic
Liver Disease Foundation, 2013 Hepatology Centers of Educational Expertise Lecture Series. Ruths Chris Steak House, San Diego, CA. May 28, 2013.
Speaker, Hepatitis D and E: The Forgotten Viruses. UCSD AntiViral Research Center, San
Diego, CA. June 21, 2013.
Speaker, Hepatitis D and E: The Forgotten Viruses, AIDS Clinical Rounds San Diego
Providers, June 21, 2013. Speaker, GI Conference & HBV Management, Rady Childrens
Hospital, San Diego, CA, September 12, 2013.
Guest Educator, New and Emerging Strategies to Simplify the Cure of Chronic HCV
Infection, Ruth Chris Steakhouse, Walnut Creek, CA; Sponsored by Rush University Medical
Center & Gilead Sciences, October 24, 2013.
Speaker, Advances in HCV Treatment: The Potential for Hepatitis C Clinical Management
and Treatment in Primary Care and Other Health Care Settings, California Forum on Hepatitis C Screening and Treatment, California Endowment Conference Center, Oakland, CA,
November 8, 2013.
Curriculum Vitae
197
Speaker, Complications of Cirrhosis in the Age of Quality Health Measures, Paradise Valley,
AZ. November 14, 2013.
2014
Speaker, HCV Update CME , sponsored by Duke University School of Medicine & the
Chronic Liver Disease Foundation. Phoenix, AZ. January 20, 2014.
Speaker, NASH and Fatty Liver, Scripps Health, La Jolla, CA, March 29, 2014 - March
30, 2014
Speaker, HBV update, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014
Speaker, HEV update, Scripps Health, La Jolla, CA, March 29, 2014 - March 30, 2014
Speaker, Presenter; Hepatobiliary & Pancreas Tumor Conference, St. Johns Hospital &
Medical Center, April 2014
Speaker, EASL liver updates 2014, Digestive Disease Week (DDW) 2014 Highlights
Dinner Program, Overland Park, Kansas, May 7, 2014.
Speaker, HBV and HCC linkage, sponsored by BNS, Gilead, Onyx and Bayer, Chinese
Hospital, San Francisco, CA, May 6, 2014.
Speaker, Current Perspectives into the Management of Hepatic Encephalopathy, Presented by Hepatology Center for Educational Expertise, Ruths Chris Steak House, May
13, 2014.
Speaker, GI Tumor Conference, cCare & Associates, Fresno, CA, May 22, 2014.
Speaker, Vietnam and the growing Hepatitis problem in the Asian community, Ho Chi
Minh City Sister City Committee, Marines Memorial Hotel, San Francisco, CA, May 29,
2014.
Speaker, HCV update, UCLA Ground Rounds, University of California, Los Angeles,
Medical Center, Westwood, CA, June 11, 2014.
Ground Rounds Speaker, Liver Failure: How to Have your Patients Survive until Liver
Transplant: A Roadmap to Life, Scripps Center for Organ Transplantation, Timken Amphitheater, Scripps Green Hospital, La Jolla, CA; Friday, July 18 2014.
Speaker, Presenter; Hepatobiliary & Pancreas Tumor Conference, St. Johns Hospital &
Medical Center, June 12, 2014 Fellows Speaker, Department of Internal Medicine,
School of Medicine, University of Nevada. Las Vegas, NV; July 30, 2014.
Curriculum Vitae
198
Speaker, 3rd Annual Current Trends in Liver Disease. Symposium and Gastroenterology
Board Review, St. Josephs Hospital and Medical Center, Phoenix, AZ; September 26,
2014.
Speaker, Cirrhosis Overview, St. Josephs Hospital and Medical Center, Phoenix, AZ;
October 6, 2014.
Curriculum Vitae
199
1.
2.
3.
4.
5.
6.
7.
8.
Certificate of Attendance. 19th Conference of the Asian Pacific Association for the Study
of the Liver (APASL). February 13-16, 2009.
9.
10.
Humanitarian of the Year. San Francisco Ho Chi Minh City Sister City Committee. May
27, 2010. http://www.sfexaminer.com/local/Robert-Gish-takes-the-helm-of-hepatitis-Bprevention-94976469.html
11.
12.
13.
Alliance for CME, Outstanding CME Enduring Material, 2010 CaseLine: HCC Program
14.
San Diego County Medical Society, 2011 Top Doctors Gastroenterology. Award is
voted by peers within and outside of specialty.
15.
16.
$50,000 Grant from Gilead Foundation, Barriers to Hep B Screening. October 2011. (R.
Gish-Full Approver).
17.
$100,000 Grant (submitted) from Bristol Myers Squibb, Point of Care HVB. October
2011.
18.
2,000 HCV Kits (received) from Merck, Point of Care HCV For All At-Risk Persons.
October 2011.
Curriculum Vitae
200
$250,000 Grant (submitted) from Vertex, POC HCV + Operations Cost Savings.
October 2011
20.
21.
22.
23.
San Diegos Top Doctors Annual List, San Diego County Medical Society, 2013.
24.
National Top Doctors List, U.S. News & World Report ; 2012-2013.
25.
Diversity Pioneer Honoree & Presenter, Asian Heritage Awards, San Diego, CA,
September 14, 2013.
26.
Curriculum Vitae
201
2.
3.
4.
Lok AS, Heathcote, EJ, Hoofnagle, JH. Management of Hepatitis B: 2000- summary of a
Workshop. Gastroenterology. 2001;120:1828-1853.
5.
McHutchison J and the IHIT Study group (Gish RG). Hepatic HCV RNA before and after
treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693.
6.
7.
AASLD Expert Consensus: Managing Liver Related Challenges. Testing and vaccination
for viral hepatitis. Miami Florida 2003.
8.
Christopher Westland, Huiling Yang, William E. Delaney IV, Craig S. Gibbs, Michael D.
Miller, Michael Wulfsohn, John Fry, Carol L. Brosgart, Shelly Xiong, Week 48 Resistance
Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis
B, Acknowledgments include R. Gish.
9.
CME Monograph: Side Effect Management in HCV Infection. 2002-2003 with DVC Health
Care Communications. 1) Optimizing Treatment response in HCV Infection by Anemia
Management.
10.
11.
CME: Hot Topics in Hepatology: Updates, Strategies, and Future Trends, The Institute
for Medical Educations CME Program, September, 2004
12.
CME: Chronic Hepatitis B Infection: Re-evaluating Targets for Drug Therapy, CME
Consultants, Inc. BMS Company, September 2004
13.
CME: Building New Strategies in Chronic Hepatitis B, BMS & UAB School of Medicine,
October 2004
Curriculum Vitae
202
15.
CME: Implications & Management of Anemia in Liver Disease Impact of Side Effect
Management and Adherence in HCV-Infected Patients, CME Monograph Series, V2,
Issue 1, November 2004
2005
16.
CME: Efficacy and Safety Data on Newer Oral and Injectable Agents for Chronic
Hepatitis B Virus Infection, January 2005
17.
18.
CME: Sunrise Hospital & Medical Center, Diet, Nutrition and the Liver. January 2005
19.
CME: Treatment of Chronic Viral Hepatitis, HCA Bay Area Healthcare Network,
January 2005
20.
CME: Gastroenterology Case Conference, January 13, 2005. 1 Hour CME credit.
21.
CME: Gastroenterology Case Conference, January 27, 2005. 1 Hour CME credit.
22.
CME : UC Davis , 1st Annual Sierra Tahoe Hepatitis C Outreach Conference, February
2005
23.
CME: Sunrise Hospital and Medical Center: Heavy Metal: Wilsons Disease and
Hemochromatosis, Las Vegas, February 1, 2005
24.
CME: University of Florida College of Medicine & PVI. Efficacy and Safety Data on New
Oral and Injectable Agents for Chronic Hepatitis B Virus Infection, February 2, 2005
25.
26.
CME: Mayo Clinic College of Medicine. Update in Liver Disease & Transplantation,
Scottsdate, AZ, March 2005
27.
CME: Gastroenterology Case Conference, March 17, 2005. 1 Hour CME credit.
28.
CME: Gastroenterology Case Conference, March 24, 2005. 1 Hour CME credit.
29.
CME: Sunrise Hospital & Medical Center, Should That Patient Die? The Ethics of Liver
Transplantation, April 5, 2005
30.
CME: Gastroenterology Case Conference, April 21, 2005. 1 Hour CME credit.
Curriculum Vitae
203
31.
CME: Sunrise Hospital and Medical Center, Hepatitis C and Substance Abuse
Conference April 25, 2005, Las Vegas, NV
32.
33.
34.
35.
36.
CME: Recognition & Management of Shock: New Standard of Care, May 6, 2005.
One Hour CME credit.
37.
CME: Digestive Disease Week 2005 , Chicago, IL May 15 and 16, 2005
38.
39.
CME: Reno-Sparks Community Wide Liver Conference, May 26, 2005 Reno, Nevada
40.
41.
42.
CME: Gastroenterology Case Conference, June 23, 2005. 1 Hour CME credit.
43.
44.
45.
CME: Gastroenterology Case Conference, August 18, 2005. 1 Hour CME credit.
46.
CME: Gastroenterology Case Conference, August 25, 2005. 1 Hour CME credit.
47.
48.
Curriculum Vitae
204
CME: Emerging Treatments for Liver and Complex GI Diseases San Francisco, CA
Sept 16 to Sept 17, Omni Hotel 6hrs
50.
CME: Gastroenterology Case Conference, September 29, 2005. 1 Hour CME credit.
51.
52.
CME: Treating HVC with Ribavirin Analogues and Ribavirin-like molecules. Journal of
Antimicrobial Chemotherapy In Press.
53.
54.
CME: Gastroenterology Case Conference, October 10, 2005. 1 Hour CME credit.
55.
CME: Adult Donor Liver Transplantation, October 21, 2005. 1 Hour CME credit.
56.
CME: ACT HBV San Francisco, CA 10 20 05, San Francisco, Marriott 1.75 Units
57.
58.
59.
60.
CME: Treating HCV Maximizing Response and Minimizing Injury. November 7, 2005
1 credit toward the AMA Physicians Recognition Award.
61.
CME: 56th Annual Meeting and Postgraduate Course. American Association for the
Study of Liver Diseases, San Francisco, CA. November 11-15, 2005 26 hours.
62.
63.
CME: Hepatitis B: Identifying the Issues and Improving Patient Outcomes. University
of Wisconsin Medical School, Office of Continuing Medical Education. San Francisco,
CA. October 20, 2005.
64.
65.
66.
CME: AASLD Update. Mountain View Hospital. Las Vegas, NV. December 6, 2005.
67.
CME: A Rising Tide: The Next Wave of Treatment Options in HBV and HCV. HEP
DART. http://www.advancmed.org/807. December 2006.
Curriculum Vitae
205
2006
69.
70.
CME: Improving Outcomes for Asians and Pacific Islanders at Risk for Hepatitis B,
Washington Hospital. Fremont, CA. January 25, 2005.
CME: HOT Topics in Hepatology: Updates, Strategies and Future Trends, Hyatt
Regency Monterey, CA. February 4, 2006. 6.5 CME credits.
71.
72.
73.
74.
75.
CME: Course 2 - Natural History and Selection of Patients for Treatment of HBV,
Advanced Certificate Program in the Management of Chronic Hepatitis B. Audio
conference. 2006.
CME: Course 3 - HBV Treatment: Viral Resistance and Clinical Implications, Advanced
Certificate Program in the Management of Chronic Hepatitis B. Webcast. 2006.
76.
77.
78.
79.
80.
81.
82.
CME: Course 5.5 Natural History and Impact of Therapy, Advanced Certificate
Program in the Management of Chronic Hepatitis B. TX Reporter 5. 2006.
Curriculum Vitae
206
84.
85.
CME: Course 5.8 A Steady Advance: Latest Findings from Anti-HBV Clinical Trials,
Advanced Certificate Program in the Management of Chronic Hepatitis B. TX Reporter
8. 2006.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
CME: A Case Based Approach to the Modern Management of HCV, Meet the HCV
Masters Meeting. San Francisco. April 3, 2006.
Curriculum Vitae
207
CME: Hepatitis B, C, and Liver CA Update, Sunrise Hospital and Medical Center. Cilis
Restaurant. Las Vegas, NV. May 8, 2006. 1 AMA PRA Category 1 credit.
99.
CME: Refining the HBV Treatment Paradigm. Westin Bonaventure Hotel. Los
Angeles, CA. May 20, 2006.
100.
CME: Whats New in the Treatment of Hepatitis B & C. Double Tree Hotel. Modesto,
CA. June 7, 2006.
101.
CME: Treating HCV Maximizing Response and Minimizing Injury. Wild Ginger
Restauarant. Seattle, WA. June 12, 2006.
102.
CME: A Partnership Between Primary Care and Specialty Physicians. Syllabus. 2006.
103.
CME: Reno-Sparks Community Wide Liver Conference: Medical & Surgical Aspects of
Liver Transplantation 2006. Reno, NV. June 22, 2006.
104.
CME: The NCSCG Yosemite GI Retreat 2006. Yosemite, CA. November 3-5, 2006. 1
credit.
105.
CME: Focus on the Virus: A New Paradigm for the Management and Treatment of
HBV. Sheraton Boston Hotel, Boston , Massachusetts October 30, 2006. 1 credit
2007
106.
CME: Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV
Treatment in Asian and Other Diverse Communities. Expert Insight Intro: Provider
Knowledge and Practice Regarding Hepatitis B Screening in Chinese-Speaking
Patients. Course HBV3.03. 2007.
107.
CME: Molecular Tests for HBV: Genotype, Core and Precore Testing, Quantification
Tests. Seattle, WA. May 9, 2007
108.
109.
110.
111.
CME: Case 2 Patient FN: Management of HCV Genotype 1. CARES. August 2007.
112.
CME: Case 5 Patient KM: Psychiatric Issues in Patients Undergoing Treatment for
HCV. CARES. August 2007.
113.
CME: Case Debates with the Experts: Applying the Updated Practice Guidelines to the
Management of Hepatitis B. 2nd International Symposium. Boston, MA. November 3, 2007.
Curriculum Vitae
208
115.
CME: Expert Insight Into: Why We Should Routinely Screen Asian American Adults for
Hepatitis B: A Cross-Sectional Study of Asians in California. Bridging Cultural
Differences to Improve HBV Treatment in Asian and Other Diverse Communities.
Course HBV3.08. 2007.
116.
CME: San Francisco Hospital to Help Sick in Vietnam. Bay City News in San
Francisco. December 16, 2007.
117.
2008
118.
119.
120.
CME: Conquering Contemporary Challenges New Hope with Targeted Therapy for
Hepatocellular Carcinoma. Osake Restaurant. Santa Rosa, CA. February 5, 2008
2008
121.
122.
CME: American Association for the Study of Liver Disease Update. Saint Marys
Regional Medical Center. Reno, NV. February 28, 2008. 2 AMA Physician Recognition
Award Category 1 Credits.
123.
124.
125.
126.
CME: European Association for the Study of Liver Disease Update. Reno Sparks
Community-Wide Liver Conference. Saint Marys Continuing Medical Education. May
15, 2008. CME awarded 2 AMA Physicians Recognition Award Category 1 Credits.
127.
CME: AASLD Topic Forum. DDW-San Diego, CA. May 19, 2008.
128.
CME: AASLD Clinical Symposium. DDW-San Diego, CA. May 20, 2008.
Curriculum Vitae
209
CME: Alcoholic Hepatitis. Alameda County Medical Center. Oakland, CA. May 30,
2008.
130.
CME: American Transplant Congress 2008. Toronto, Canada. May 31, 2008 June
4, 2008. 15 AMA PRA Category 1 credits.
131.
132.
133.
CME: The Future of Hepatitis B and C. Fourth Annual Liver Update Seminar. Queens
Conference Center. Honolulu, Hawaii. July 19, 2008.
134.
135.
136.
137.
CME: 6th Annual Liver Disease Symposium, The Duke University School of Medicine.
September 5, 2008. 2.00 AMA PRA Category 1 credits.
138.
139.
CME: AASLD, October 31, 2008 to November 4, 2008. 21.5 hours of AMA PRA
Category 1 credits.
140.
141.
CME: Standard of Care for Treatment of Hepatitis B & C, Update in Gastroenterology &
Hepatology Symposium. Renaissance Hotel. Las Vegas, NV. November 15, 2008.
142.
143.
144.
CME: Screening At-Risk Individuals for Hepatitis B: What do the Guidelines Say?
Medscape, Expert Column. Novmeber 2008.
145.
Curriculum Vitae
210
147.
CME: HBV Highlights from CCOs Coverage of the 2008 AASLD Meeting, Grand Caf.
San Francisco, CA. December 2, 2008.
148.
2009
149.
CME: Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for
HCC. Gastroenterology and Hepatology. Vol 5, Issue 1, Supplement 3. January 2009.
1.0 AMA PRA Category 1 Credit.
150.
CME: Nash (Non-alcoholic Fatty Liver Disease). Reno, NV. January 8, 2009. 1 AMA
Physicians Recognition Award Category 1 Credits.
151.
CME: Hepatitis B&C Update. Grand Rounds Talk. Highland Hospital. Oakland, CA.
February 6, 2009.
152.
CME: Update New Therapies for Hepatitis B and Hepatitis C. 16th Annual Alimentary
Update. South Lake Tahoe. March 27, 2009.
153.
154.
155.
CME: Wilson Disease Symposium. California Pacific Medical Center. San Francisco,
CA. May 2, 2009. 4 CME program hours.
156.
CME: HCV and Cryoglobulinemia. Saint Marys Regional Medical Center. Reno, NV.
May 14, 2009. 1 AMA Physicians Recognition Award Category 1 Credits.
157.
158.
CME: Weekly Emergency Medicne Conference. CME talk. Alameda County Medical
Center, Highland Hospital. Oakland, CA. July 1, 2009.
159.
CME: Faculty of John Hopkins University School of Medicine CME Program. Kuleto
Trattoria Restaurant. Burlingame, CA. July 14, 2009.
Curriculum Vitae
211
CME: HCV and Cryoglobulinemia: How Cool Can You Get? Saint Marys Regional
Medical Center. Reno, NV. July 27, 2009. 1 AMA Physicians Recognition Award
Category 1 Credits.
161.
CME: Bridging Culturaly Differences to Improve HBV Treatment in Asian and Other
Diverse Communities. Projects in Knowledge. Advanced Certificate Program IV.
2009.
2010
162.
CME: Managing Hepatitis B in the Primary Care Setting. PeerView CME. February
2010.
163.
CME: Clinical Concepts in Pain and Aging: A Case-Based CME Monograph. John
Hopkins University School of Medicine. Febraury 20, 2010. 1.00 AMA PRA Category 1
credit.
164.
165.
166.
167.
168.
CME: The Clinical Implications of Manging Cirrhotics. CLDF. San Francisco, CA.
April 12, 2010.
169.
CME: Chronic Viral Hepatitis: Can we C our way to B cured? ST Lukes Grand
Rounds. San Francisco, CA. May 5, 2010.
170.
171.
CME: 2010 National Hepatitis B&C Training Program & Treatment Update. Omni
Hotel. San Francisco, CA. June 12, 2010. 7.75 AMA PRA Category 1 Credit.
172.
CME: Hepatitis C: What is the current diagnostic and treatment paradigm? Community
Hospital of Monterey. Monterey, CA. June 16, 2010.
173.
CME: Coming to your area: Case3: On the Cusp of Change: New Therapeutic
Modalities for HCV. Sienna Restaurant. El Dorado Hills, CA. June 16, 2010.
CME: Use only the A Team to beat Hepatitis B. Chinese Hospital. San Francisco,
CA. August 3, 2010.
174.
Curriculum Vitae
212
CME: Overview of INCIVEK: Phase III Clinical Trial Data and Prescribing Information,
San Diego, CA. Instructor of Program. August, 2011.
176.
CME: HBV Update. Saint Francis Hospital Grand Rounds. San Francisco, CA.
September 21, 2010.
177.
CME: Staying the Course: Patient Adherence Strategies in the Era of New Frontline
HBV Therapies Barriers to Treatment, Adherence in Asian Americans. Clinical Care
Options CME/CE Certified Treatment Update. 2010.
178.
179.
CME: Clinical Update 2010: Chronic Liver Disease and Hepatocellular Carcinoma.
Sutter Roseville Medical Center. Roseville, CA. October 2, 2010. 4 AMA PRA Category 1 credit.
180.
ME: Hepatocellular Carcinoma Current Trends in Diagnosis and Management: What all
Healthcare Providers Need to Know. Hartford Hospital Grand Rounds. Hartford, CT.
October 4, 2010. 1 AMA PRA Category 1 credit.
181.
CME: HCC Update. Hartford Hospital Grand Rounds. Hartford, CT. October 5, 2010.
182.
CME: Managing HBV in the At-Risk Community. San Francisco, CA. October 12,
2010.
183.
184.
CME: Clinical Viewpoints, Oct. 2010. Rush University Medical Center, Chicago,
Illinois.
2011
185.
CME: " 2011 American Transplant Congress Meeting -Physicians & Transplant
Coordinators April 30- May 4, 2011
186.
CME: Hepatitis C: The Expanding Role of the Physician Assistant, Teacher of this
Breakfast Symposium. CME Credit: 1.25 credits. A part of the Education Initiative in
Gastroenterology series.
187.
CME: GUTS (Gastroenterology Universal Training Symposium, June 25, 2011. CME
Credits: 8 Hour.
188.
CME: Liver Journal Club at UCSDMC, July 1, 2010-June 30, 2011. CME Credits: 6
AMA PRA Category 1 Credits.
Curriculum Vitae
213
CME: Advances in HCV: New Challenges and Hope, Hanford, CA, June 29, 2011, 2
CME Credits, AMA PRA Category 1 Credits
190.
CME: University of California San Diego Health System SPA Time Study 2011, June 29,
2011.
191.
192.
CME Roundtable Series, 2011 CME Roundtable Series Current Advances in the
Management of Cirrhotics, Palm Springs, CA. October 2011.
193.
CME: The Role of the Hepatologist, HCC Los Angeles Dinner, October 2011.
194.
195.
196.
CME: 2011 Southern California Chapters 1 & 3 Scientific Meeting. CME Credits: 4.75
AMA PRA Category 1 Credits. October, 2011.
197.
198.
199.
200.
201.
CME: Hepatology Associates Course, San Francisco. CME Credits: 1.0 hr. Teacher of
CME Course to Nephrology Physicians, November 2011.
202.
CME: Heptaology Associates Course, AASLD Certified: The Liver Meeting 2011. CME
Credits: 38.5 AMA PRA Category 1 Credits. San Francisco, November 2011.
203.
204.
CME: General Medicine Practices for Hepatitis B, CME Credits: 1 AMA PRA Category
1 Credit, November, 2011.
205.
Curriculum Vitae
214
2012
207.
CBCE (Center for Biomedical Continuing Education): Multidisciplinary Strategies for the
Management of Hepatocellular Carcinoma: Paths to Progress. January, 2012. CME
Credits: 1.0 AMA PRA Category 1 Credit. San Francisco, CA.
208.
CME, Liver Club Journal Meeting with Dr. Zarrinpar, San Diego, CA, January 10, 2012.
209.
CME, Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, January 17, 2012.
210.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; January 18, 2012.
211.
CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, January 24, 2012.
212.
CME, Liver Club Journal Meeting, Roundtable, San Diego, CA, January 31, 2012.
213.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD, and Kiarash M.,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit;
February 1, 2012.
214.
215.
CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, February 7, 2012.
216.
CME: CHB Mentorship Hub Program (CHIP), Purdue University & Asian Health
Communications, Roys Restaurant, Anaheim, CA, February 9, 2012.
217.
CME, Liver Club Journal Meeting with Dr. Zarrinpar, San Diego, CA, February 14, 2012.
218.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; February 15, 2012.
219.
CME, Liver Club Journal Meeting with Dr. Kuo, San Diego, CA, February 21, 2012.
220.
CME, Liver Club Journal Roundtable, San Diego, CA, February 28, 2012.
221.
CME, Liver Club Journal Meeting with Dr. Gish, San Diego, CA, March 6, 2012.
222.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD, and Kiarash M.,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit;
March 7, 2012.
223.
CME, Liver Club Journal Meeting with Dr. Nourredin, San Diego, CA, March 13, 2012.
Curriculum Vitae
215
CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, March 20, 2012.
225.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; March 21, 2012.
226.
CME, Liver Club Journal Meeting with Dr. Shah, San Diego, CA, March 27, 2012.
227.
CME, Liver Club Journal Meeting with Dr. Patton, San Diego, CA, April 3, 2012.
228.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit;
April 4, 2012.
229.
CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, April 10, 2012.
230.
CME, Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, April 17, 2012.
231.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit;
April 18, 2012.
232.
CME, Liver Club Journal Meeting with Dr. Philo, San Diego, CA, April 24, 2012.
233.
CME: Liver Club Journal Meeting with Dr. McTigue, San Diego, CA, May 1, 2012.
234.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; May 2, 2012.
235.
CME: Liver Club Journal Meeting with Dr. Nourredin San Diego, CA, May 8, 2012.
236.
CME, Liver Club Journal Meeting with Dr. Loomba, San Diego, CA, May 15, 2012.
237.
238.
CME: Digestive Disease Week 2012. San Diego, CA. May 19 - 22, 2012. 15 PMA
credits.
239.
CME: Liver Club Journal Meeting with Dr. Nourredin, San Diego, CA, June 5, 2012.
240.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; June 6, 2012.
241.
CME: Liver Club Journal Meeting with Dr. Kowng, San Diego, CA, June 12, 2012.
242.
CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, June 19, 2012.
Curriculum Vitae
216
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit;
June 20, 2012.
244.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; July 18, 2012.
245.
CME: Liver Club Journal Meeting with Dr. Peterson, Hep Series; Basics of Hepatopathology, San Diego, CA, July 24, 2012.
246.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; August 01, 2012.
247.
CME, Liver Club Journal Meeting with Dr. Marie Csete, Hep Series; Anesthesia for Liver
Transplantation, San Diego, CA, July 31, 2012.
248.
CME, Liver Club Journal Meeting with Dr. Misel/Kerr, Overview of Immunosuppressant
Management (Induction, Maintenance,& Acute Cellular Rejection), San Diego, CA, August 7, 2012.
249.
CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, August 14, 2012.
250.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; August 15, 2012.
251.
CME: Liver Club Journal Meeting with Dr. Kicak, Hep Series; Risk Management, San
Diego, CA, August 21, 2012.
252.
CME: Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, August 28, 2012.
253.
CME: Liver Club Journal Meeting with Dr. Gish, Hep Series; Management of Hepatitis B,
San Diego, CA, September 4, 2012.
254.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; September 5, 2012.
255.
CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, September
11, 2012.
256.
CME: Liver Club Journal Meeting with Dr. Mendler, Hep Series; Evaluation of the Liver
Transplant Candidate, San Diego, CA, September 18, 2012.
257.
CME: HCV Community TeleEcho Clinic, Project Echo., Albuquerque, NM, September
18, 2012; 6 hours.
258.
CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, September 25,
2012.
Curriculum Vitae
217
CME, Liver Club Journal Meeting with Dr. Loomba, Hep Series; Critical Assessment Of
Medical Literature, San Diego, CA, October 2, 2012.
260.
261.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; October 3, 2012.
262.
CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, October 9,
2012.
263.
CME: Liver Club Journal Meeting with Dr. Kuo, Hep Series; HCV Management in
Cirrhosis and Post-Transplant Population, San Diego, CA, October 16, 2012
264.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; October 17, 2012.
265.
CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, October 23,
2012.
266.
CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, October 30, 2012
267.
CME: Liver Club Journal Meeting with Dr. Kono, Hep Series; Screening and Management of Hepatocellular Carcinoma, San Diego, CA, November 6, 2012.
268.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh MD & K. Mirkia, MD,
Facilitators, Sunrise Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; November 7, 2012.
269.
CME: The Liver Meeting, American Association for the Study of Liver Diseases
(AASLD), Boston, MA, 38.5 AMA PRA Category 1 Credits; November 9-13, 2012.
270.
CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, November
13, 2012.
271.
CME: Liver Club Journal Meeting with Dr. Patton, Hep Series; Nutritional Assessment
and Management in Chronic Liver Disease, San Diego, CA, November 20, 2012.
272.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; November 21, 2012.
273.
CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA,
November 27, 2012.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, December 4, 2012.
274.
275.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; December 5, 2012.
Curriculum Vitae
218
CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, December
11, 2012.
277.
CME: Liver Club Journal Meeting with Dr. Abbas Fehmi, Hep Series; Overview & after
liver transplant management of biliary complications, San Diego, CA, December 18,
2012.
278.
CME: Gastrointestinal Cancer Case Discussion, Fadi Braiteh, MD, Facilitator, Sunrise
Medical Center, Las Vegas, NV, 1 AMA PRA Category 1 credit; December 19, 2012.
279.
CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, January 28,
2013.
280.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, January 15, 2013.
281.
CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, January
22, 2013.
282.
CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, January 29,
2013.
283.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, February 5, 2013.
284.
CME: Liver Club Journal Meeting with Dr. Noureddin & Mazen; San Diego, CA, February
12, 2013.
285.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, February 19, 2013.
286.
CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, February
26, 2013.
287.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, March 5, 2013.
288.
Asian Pacific Association for the Study of the Liver Conference, Singapore, March 7-10,
2013. 24 hours.
289.
CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, March 12,
2012.
290.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, March 19, 2013
291.
292.
CME: Liver Club Journal Meeting with Dr. Sohail & Muhammad, San Diego, CA, March
26, 2013.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, April 2 2013.
293.
CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, April 9, 2013.
294.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, April 16, 2013.
Curriculum Vitae
219
CME: Liver Club Journal Meeting with Dr. Desai & Shireena, San Diego, CA, April 23,
2012.
296.
EASL, The International Liver Congress 2013, 48th Annual Meeting of the European
Association for the Study of the Liver. Amsterdam, Netherlands. 24 hours. April 26,
2013.
297.
CME, Liver Club Journal Meeting Faculty Roundtable, San Diego, CA, April 30, 2013.
298.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, May 7, 2013
299.
300.
CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, May 14,
2013.
301.
CME Digestive Disease Week 2013. Orlando, FL. 1821 May 2013. 15 PMA credits.
302.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, May 21, 2013.
303.
CME: Liver Club Journal Meeting with Dr. Vodkin & Irine, San Diego, CA, May 28, 2013
304.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, June 4, 2013.
305.
CME: Liver Club Journal Meeting with Dr. Anand & Gobind, San Diego, CA, June 11,
2013.
306.
CME: Liver Club Journal Meeting, Hep Series; San Diego, CA, June 18, 2013.
307.
CME: Liver Club Journal Meeting with DrSohail & Muhammad, San Diego, CA, June 25,
2013.
308.
CME: Critical Care Summer Session, Catamaran Hotel, San Diego, CA, 3 Credits, July
25-27, 2013.
309.
CME: New and Emerging Strategies to Simplify the Cure of Chronic HCV Infection, Ruth
Chris Steakhouse, Walnut Creek, CA; Sponsored by Rush University Medical Center &
Gilead Sciences; October 24, 2013, 1 credit.
310.
CME: Guest Physician, Educator, GI Tumor Conference, Presented by cCare, St. Agnes
Medical Center, Fresno, CA; November 12, 2013. AMA PRA Category 1 credit
311.
CME: HEP DART 2013: Frontiers in Drug Development for Viral Hepatitis 6, sponsored
by Emory University School of Medicine. Kailua-Kona, Hawaii, December 8-12, 2013.
312.
Curriculum Vitae
220
314.
CME: State of the Art Therapy for HCV, University of Washington, University of Alabama
Birmingham, IAS-USA online training module, Funded by a grant from the Centers for
Disease Control and Prevention. March 15, 2014
315.
CME: New Treatments in Chronic Liver Disease 2014, Scripps Health, La Jolla, CA
March 29, 2014 - March 30, 2014; 8.00 AMA PRA Category 1 credits.
316.
CME: International Liver Congress 2014, European Association for the Study of the
Liver, London. United Kingdom, April 9-13, 2014; 20 hours CME accredited credits.
317.
CME: Gastro Cancer Case Conference, Sunrise Medical Center, Las Vegas, NV, 1 hour,
1 AMA PRA Category 1 Credit, March 5, 2014.
318.
CME: Gastro Cancer Case Conference, Sunrise Medical Center, Las Vegas, NV, 1 hour,
PRA 1 credit, March 19, 2014.
319.
CME: Digestive Disease Week (DDW) 2014 Highlights, University of Kansas Medical
Center, Overland Park, Kansas, 2.5 hours, 2.5 AMA PRA Category 1 Credits, May 7,
2014.
320.
CME: WFA-20 Wilderness First Aid, 20 hours, Wilderness Medicine Outfitters, June 7,
2014. CME: The American Society of Transplant Surgeons & World Transplant Congress, Moscone West Convention Center, San Francisco, CA; July 26 - 31, 2014, 31.25
AMA PRA Category 1 Credit(s)
321.
322.
CME: Public Forum on Redesigning Liver Distribution ", Attendee, Webinar presented by
United Network for Organ Sharing (UNOS.org); September 16, 2014.
323.
CME: 3rd Annual Current Trends in Liver Disease. Symposium and Gastroenterology
Board Review, St. Josephs Hospital and Medical Center, Phoenix, AZ; September 26,
2014, 6.25 AMA PRA Category 1 Credits.
324.
Curriculum Vitae
221
CALIFORNIA
Community Physician's Center
Fresno Liver Clinic
Clovis, California
Enloe Hospital
W. 5th & The Esplanade
Chico, California 95926
Gould Medical Group
6000 Coffee Road
Modesto, CA 95355
Highland Clinic
1411 E. 31st St.
Oakland, California 94602
Liver Clinic
2900 Harris Street
Eureka, California 95501
McHenry Medical Group
1541 Florida Ave. #200
Modesto, California 95355
Merced Liver Clinic
3605 Hospital Rd.
Atwater, California 95301-5173
Oakland East Bay Liver Clinic
Doctors Medical Building
400 - 30th Street, Suite 200
Oakland, California 94609-3305
Redding Liver Clinic
2225 Court St
Redding, California 96001
Curriculum Vitae
NEVADA
Desert Gastroenterology
3150 N. Tenaya, Ste. 630
Las Vegas, NV 89128
Digestive Health Associates
5250 Kietzke Lane
Reno, NV 89511
Gastroenterology Consultants
880 Ryland
Reno, NV 89502
Sunrise Liver Clinic
3006 S Maryland Parkway
Las Vegas, Nevada
222
Curriculum Vitae
223
RESEARCH SUMMARY
In his historical roles as Co-Director of the Center for Hepatobiliary Disease and Abdominal
Transplantation and Chief of Clinical Hepatology, Dr. Gish was both overseeing and personally
participating in cutting edge research on viral hepatitis, liver transplant, bio-artificial liver, and
liver cancer. He is currently working to expand clinical trials for a variety of antiviral therapies
(including the latest-generation therapies for hepatitis B and for hepatitis C), end-stage liver
disease, autoimmune hepatitis, and new bio-artificial liver systems. He was also directing the
development of a state-of-the-art biorepository to support future scientific investigation. Under
his direction, UCSD researchers are using databases to help uncover associations between
liver cancer and certain cancer biomarkers that may ultimately help to guide treatment decisions
and choice of therapies. He is currently working toward building a multidisciplinary liver cancer
program that will include models of HCC signaling. Dr. Gish has an extensive background in
viral hepatitis clinical trials and liver cancer trials, with a quarter century of experience as a
clinical investigator on many aspects of liver disease, liver transplant and liver cancer.
In addition, Dr. Gish is actively involved, both nationally and internationally, in shaping public
policy that relates to liver transplantation and viral hepatitis screening, vaccination, and
treatment that should ultimately have an impact on liver cancer rates in the region, nationally
and internationally. He recently developed and published a five-year plan for a comprehensive
approach to liver disease in Viet Nam, a country that has a very high prevalence of liver disease
due to the high prevalence of chronic infection with hepatitis B (12%) and C (at least 2%) along
with heavy alcohol consumption by men, but which to date has had no nationwide approach to
the disease and no systematic screening of at-risk individuals. The program that Dr. Gish
developed in collaboration with colleagues in Viet Nam, Australia, and the United States
includes nationwide education for healthcare providers, health educators, and the public;
expansion of nationwide screening for hepatitis B and C followed by HBV vaccination or
treatment of chronic HBV and/or HCV; education about alcoholic liver disease; long-term
surveillance for liver cancer; and reduction of infection transmission related to medical,
commercial, and personal re-use of contaminated needles, syringes, sharp instruments, razors,
and inadequately sterilized medical equipment. The program has already received the full
support of the Vietnamese government and several other countries have now expressed
interest in working with Dr. Gish to develop similar programs. He is currently working on
development of a liver program for Armenia. Dr. Gish has lectured in China, Viet Nam, and a
dozen other countries, and has ongoing long-term research collaborations with colleagues in
Australia, Japan, Viet Nam and China.
In addition, Dr. Gish is currently working in collaboration with the Asian Pacific Health Foundation on development of a major hepatitis B and C screening program in the greater San Diego
area with the goal of ultimately screening at least 10,000 individuals, followed by provision of
vaccination and linkage to care, as appropriate. As part of this program, cutting edge research
on the use of point-of-care rapid results testing for both hepatitis B and C will be carried out. A
unique aspect of this program will be the integration of viral hepatitis screening with broadbased healthcare screening for other disease states such as metabolic syndrome both of which
are leading causes of liver cancer.
Curriculum Vitae
224
Curriculum Vitae
225
Role as Director of California Pacifics Liver Disease Management & Transplant Program
Clinic sites established during my tenure at CPMC 1988 to 2010
Reddi ng
Chi co
Uki ah
Reno
Sant a Rosa
Modest o
Sant a Cr uz
Mer ced
Fr esno
Curriculum Vitae
226
Disclosures
(Updated March 2013)
PHARMACEUTICAL COMPANY RELATIONSHIPS
Dr. Robert Gish: Financial Disclosure relative to the pharmaceutical industry up to current for the last 2 years. Robert Gish, MD, has a financial interest/relationship or affiliation in the form of:
Grants/Research Support, Bristol-Myers Squibb Company, Gilead, Polairs.
Payments from selected companies are directed to an institutional fund under contract to
UCSD research program. Dr. Gish has performed as Consultant and/or Advisor to (in
the last two years):
Bayer AG, Bristol-Myers Squibb Company, Hoffmann-LaRoche Ltd., Genentech, Gilead Sciences, Onyx, Janssen.
Consultant Payments are made directly to Dr Gish:
Abbott, Hepahope, Merck, Vertex, Arrowhead, Celula, Isis Pharmaceuticals, Benitec,
Tekmira,
Advisory Board: Applied ImmunoGenetics, Arrowhead
Chair Clinical Advisory Board: Arrowhead: Chair of CAB
SPEAKERS BUREAU
These speaker bureau activities focus on HBV, HCV, and liver cancer; specifically, epidemiology, diagnosis, and treatment. In addition, program presentations on vaccination
for HBV and management of complications of cirrhosis.
Dr. Gish has an active speakers contract to do promotional talks for BMS, Roche,
Bayer, Bristol-Myers Squibb Company, F. Hoffman-LaRoche Ltd., Gilead Sciences Inc.,
GlaxoSmithKline, Onyx, Merck, Genentech Pharmaceuticals, Salix,
Major Stock Shareholder Hepahope
Minor Stock Shareholder Kinex, Arrowhead (options)
Other Financial Support or Material Support None
Full details of all Research Grant Support See CV
Leadership Position, Other than Employment other than at UCSD None
Expert Testimony for Pharma BMS, ICN
Other Remuneration from Pharma None
DSMB: Tekmira 2011 2013